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During the recent decades, life expectancy of elderly human increased drastically (OECD, 2009).
The average life expectancy of 60 years old OECD citizens in 1971 was estimated to 14 years
(15.6 in women, 12.7 in men). Less than 40 years later, people of the same age can ex-
pect to live for 5 more years in average. The progression of life expectancy during the re-
cent decades follows an almost linear trend with no plateau in sight yet (see figure 1.1).





























Figure 1.1 – Life expectancy in 65 and 80 years old OECD
citizens from 1971 to 2007:
The graphic was adapted from the OECD report ”Health at
a glance” (OECD, 2009)
While a longer life is in principle an el-
igible privilege for most people, an in-
creasing life expectancy does bear some
negative aspects. With increasingly ag-
ing societies, the prevalence of age re-
lated diseases is unfortunately rising as
well. Alzheimer’s disease (AD) is only
one example for these age-related dis-
eases in human. According to the World
Alzheimer’s Report 2015 from the ADI
(Alzheimer’s Disease International), the
average incidence for AD at an age of 60-64 years is 0.39%, however, this number drastically
increases with increasing age (see figure 1.2A, p.2) (Prince et al., 2015). Approximately 1% of all
humans between an age of 70 and 74 are suffering from AD and in countries with a high income,
this number rises to 12.5% for people older than 90. Concordantly, more than 46 million people
worldwide are suffering from the disease and the ADI estimated that the incidence will triplicate
within the next 35 years (see figure 1.2B, p.2). This drastic increase of AD cases is a rising bur-
den for our societies, both socially and economically. During the past five years, the worldwide
costs of AD increased by more than 35% from 604 to 818 billion US$ and were even estimated to
triplicate within the next fifteen years, highlighting the need for further knowledge on how to
counteract or prevent the disease.
Michael Gertig 1


























Age group (in years)
































High income countries Low & middle income countries
Figure 1.2 – Age dependent incidence and predicted increase of AD cases:
A) Number of AD patients of a certain age ranging from 60 to 90 and above, grouped for different world
regions and their economic wealth.
B) Estimated progression of incidence during the next 35 years in countries with high income and those
with middle and low income. Graphics were adapted from the ADI’s World Alzheimer’s Report (Prince
et al., 2015).
Due to the correlation of AD incidence and life expectancy, the awareness of AD is constantly
rising since its discovery in the early 20th century. In 1901, the psychiatrist and neuropathologist
Alois Alzheimer examined new patients at the Frankfurt Asylum (Germany) and was intrigued
by the symptoms of the 51 years old Auguste Deter (A.D.) (Maurer andMaurer, 1998). According
to her husband, who brought her to the asylum, the behavior and habits of A.D. were changing
severely. In his publication in 1907, Alois Alzheimer described that the patient A.D. had suddenly
become jealous of her husband, was disoriented, delirious, experienced hallucinations and de-
veloped a rapid loss of memory (Alzheimer et al., 1995). She often seemed unable to perceive
the actual situation and when she was interviewed during her examinations, she could not un-
derstand the questions, responded incoherently or seemed devoid of thoughts. Additionally, she
had troubles in reading, writing and speaking. Alzheimer found the majority of symptoms to
oscillate in strength with one exception that was progressively aggravating until her death: ”im-
becility”. Even though he himself interpreted these symptoms not to be severe, the entire loss of
cognitive abilities described developed in a rather short period of time.
A.D. died in 1906 from a sepsis caused by bedsores, only 41/2 years after entering the asylum.
When dissecting the brain of A.D., Alzheimer found the two major characteristics for that par-
ticular disease later on named Alzheimer’s disease: A massive degeneration of neurons driven
or at least coinciding with fibrillary tangles that led to the loss of 25% to 30% of all cortical
neurons; and additionally, deposits of an unknown substance throughout the cortex that were
2 Michael Gertig
1.1. ALZHEIMER’S DISEASE 1. INTRODUCTION
visible without dyeing (Alzheimer et al., 1995). It took 70 to 80 years until tau and APP, the pro-
teins involved in these pathologies and their corresponding genes were described in more detail
(Masters et al., 1985; Weingarten et al., 1975). Based on his findings, Alois Alzheimer concluded,
that the case of A.D. describes an - until then - special illness and he found an increasing number
of patients with similar symptoms throughout the subsequent years. Furthermore, he suggested
to reevaluate the classical clinical distinction of known pathologies to enable a more detailed
definition of illnesses in general. Notably, researches today mostly agree that AD itself is a het-
erogeneous disease with distinct subtypes regarding symptoms, disease progression and origin
(Bredesen, 2015; Lam et al., 2013).
1.1.1 Symptoms, diagnosis, progression and treatment of Alzheimer’s dis-
ease
The differentiation of AD from other mental diseases is, due to its heterogeneity and the lack
of binary biomarkers, not trivial. In 1985, a joint work group from the National Institute of
Neurological and Communicative Disorders and Stroke (NINCD) and the Alzheimer’s Disease
and Related Disorders Association (ADRDA) tried to redefine the clinical diagnosis of AD, since
approximately 20% of all diagnosed AD cases were found to be false-positive after autopsy (McK-
hann et al., 1984). Together with diagnostics for AD described in the text revision of the fourth
edition of the ”Diagnostic and Statistical Manual for Mental Disorders” (DSM-IV-TR), published
by the American Psychiatric Association, the NINCDS-ADRDA criteria were the standard for di-
agnosing AD for the recent decades (Dubois et al., 2007). Even though these diagnostic criteria
were revised multiple times, a recent study on the accuracy of diagnosing AD estimated a sensi-
tivity of 70 to 87% and a specificity of 44% to 71% (Beach et al., 2012). Thus, almost 30 years after
the first definition of the NINCDS-ADRDA criteria, approximately one fourth of all AD cases are
still not identified as such and a third to half of all diagnosed patients do actually not suffer from
AD according to the gold standard: amyloid plaques and neurofibrillary tangles (NFT).
In 2007, Dubois et al. proposed a new diagnostic approach based on the classical criteria and
novel, recently developed techniques. This approach combined core diagnostic criteria with
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supportive features and exclusion criteria to determine the probability for AD in a human pa-
tient. These core criteria describe a gradual progressive decline of memory function reported
by patients or informants and a loss of episodic memory evaluated by psychological tests. AD
is considered as a probable diagnosis when these core criteria coincide with either one of the
following supportive feature: medial temporal lobe atrophy, thus a loss of volume in the hip-
pocampus, entorhinal cortex and amygdala; abnormal cerebrospinal fluid biomarkers like low
concentrations of neurotoxic Aβ1−42; a high concentration of tau and/or increased concentra-
tions of phosphorylated tau along with other biomarkers that might be developed in the future.
Non-coding RNAs are only one example of molecules considered as promising biomarkers (Rao
et al., 2013). Other proposed supportive features are a reduced glucose metabolism in tempo-
ral parietal regions and other well validated ligands detected by positron emission tomography
and autosomal dominant mutations in known genetic risk factors for AD (see section 1.1.4, p.12)
(Dubois et al., 2007).
In addition to these features, Dubois et al. proposed certain exclusion criteria that would contra-
dict the diagnosis of AD, including a sudden disease onset, early gait abnormalities and seizures,
sensory loss, major depression or cerebrovascular disease. Other psychological symptoms that
were not included in Dubois’ diagnostic strategy, though can frequently be found in AD pa-
tients are hallucinations (Holroyd et al., 2000), delusions (Forstl et al., 1994), apathy (Tunnard
et al., 2011), anxiety (Teri et al., 1999), sleep disturbances (Cole and Richards, 2005), agitation
(Bruen et al., 2008), and aggression (Poulin et al., 2011). While the intensity of some psycholog-
ical symptoms might slightly decrease during disease progression, the decline of memory func-
tion and neuroanatomical symptoms, including amyloid plaques and NFT, deteriorate gradually
(Alzheimer et al., 1995; Holtzer et al., 2003). The progression of these anatomical symptoms was
described in detail and categorized by Braak and Braak in 1991. These ”Braak and Braak stages”
are commonly used for the post-mortem evaluation of disease stage and will subsequently be
described in more detail.
Unfortunately, even though a number of drugs against AD were developed during the recent
decades, no cure is available yet and the efficacy of treatments are debated (Mangialasche et al.,
2010). Four FDA-approved therapeutic drugs are currently in use for treating AD patients (on Ag-
ing, 2015). Donepezil, rivastigmine, and galantamine are all acting as cholinesterase inhibitors
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and are used for treating mild to severe AD cases (Burns et al., 1999; Rösler et al., 1998; Wilcock
et al., 2000). Acetylcholine was shown to be severely decreased in AD patients but also dur-
ing healthy aging (Bartus et al., 1982). The importance of acetylcholine for neuronal functioning
was already discovered in the early 20th century by Henry Hallett Dale and Otto Loewi who were
later awarded the Nobel Prize for Medicine (”for their discoveries relating to chemical transmis-
sion of nerve impulses”). Nowadays, the function of acetylcholine as a neurotransmitter and its
importance in cognitive processes is well accepted since disruptions in neuronal acetylcholine
levels can cause cognitive impairments (Sarter and Bruno, 1997). The only non-cholinesterase
inhibitor among the approved AD-drugs is memantine.
Memantine was shown to improve memory function and induce anti-depressant like effects by
antagonizing NMDA-receptors and thus re-establishing a homeostatic level of glutamatergic sig-
naling (Barnes et al., 1996; Kos and Popik, 2005; Parsons et al., 2007). However, targeting NMDA-
receptors is not a trivial approach since both hyper- and hypoactivity of glutamatergic signaling
were shown to cause neuronal dysfunction (Parsons et al., 2007). Concordantly, even though
memantine is considered a well tolerated drug, a variety of milder side effects is relatively com-
mon (≥ 2% of all recipients) including headaches, back pain, vomiting, incontinence, bronchitis,
anxiety, and anorexia (Thomas and Grossberg, 2009). Interestingly, depression is a common side
effect of memantine as well, highlighting the difficulty of reinstating a healthy glutamatergic sig-
naling. In addition to the adverse side effects, all available medications for AD are limited in
their efficacy indicating the need for novel therapeutic approaches (Godyn et al., 2016).
1.1.2 Amyloid pathology: Aβ plaques
When dissecting the brain of A.D., Alois Alzheimer discovered plaques of an unknown substance
throughout the cortex. Eighty years after his discovery, Masters et al. (1985) purified and de-
scribed the ”amyloid plaque core protein” that is nowadays known as Aβ (amyloid β) for the
first time. This plaque forming Aβ is the cleavage product of the amyloid precursor protein
(APP), whose gene is localized on human chromosome 21 and was identified by 4 groups indi-
vidually in 1987 (Goldgaber et al., 1987; Kang et al., 1987; Masters et al., 1985; Robakis et al., 1987;
Tanzi et al., 1987). APP is intensively studied ever since its discovery, however, little is known
about its role in a healthy, physiological context even though APP can be implicated in a variety
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of cellular processes. Studies on APP deficient mice suggest that it might function in glutamater-
gic synapse formation and transmission and thus in the acquisition of aversive memory (Priller
et al., 2006; Senechal et al., 2008). Studies on neuronal cell cultures further indicate a role of APP
in proliferation, differentiation, and survival of neurons (Araki et al., 1991; Hayashi et al., 1994;
Milward et al., 1992; Perez et al., 1997).
Many studies regarding APP focus on its enzymatic cleavage and the neurotoxic effect of re-
sulting amyloid fragments, in particular Aβ1−42. APP is a transmembrane protein and con-
sists of three extracellular domains (E1, KPI, and E2), a transmembrane domain and the in-
tracellular C-terminal domain of relatively unknown functional significance (see figure 1.3)
(Dawkins and Small, 2014). The transmembrane domain, however, contains cleavage sites











Figure 1.3 – Estimated 3-
dimensional structure of APP:
Extracellular domains E1, KPI,
and E2, transmembrane do-
main (TMD) and C-terminal
domain (CTD) of APP. Arrows
point at the α- to ǫ-cleavage
sites. Graphic was adapted
from Dawkins and Small (2014).
Initially, APP can be cleaved by α- and β-secretases, producing
soluble APPα and -β peptides (Haass et al., 2012). Cleavage by
α-secretases is considered as the anti-amyloidogenic pathway as
it prevents the formation of neurotoxic Aβ species (Haass et al.,
2012). In contrast, cleavage by the β-secretase BACE1 (β-site
APP cleaving enzyme 1) produces larger residual fragments that
can further be cleaved by the γ-secretase generating Aβ and an
APP intracellular domain (see figure 1.4, p.7). The γ-secretase
is a protein complex that consists of four integral membrane
proteins with presenilin (PS/PSEN) as the catalytic component
(De Strooper et al., 2012). The amyloid peptide isoform Aβ1−42
resulting from enzymatic cleavage though β- and γ-secretases
was initially considered the neurotoxic species as it is likely to
form oligomers which can further aggregate to amyloid plaques.
Interestingly, a second isomer, Aβ1−40, was shown to inhibit
this oligomerization and might thereby ameliorate the amyloid
plaque burden (Murray et al., 2009). In AD patients, a significant
increase of Aβ1−42 in relation to Aβ1−40 can be detected. Aβ1−40
and Aβ1−42 are by far the most studied amyloid peptides, though
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a variety of Aβ isoforms were recently isolated from human tissue and implicated with AD as


















Figure 1.4 – Amyloidogenic cleavage of APP and formation of plaques:
Cleavage of APP by β- and γ-secretases lead to the production of monomeric Aβ which can aggregate to
oligomers, subsequently forming plaques. The graphic was adapted from Götz and Ittner (2008).
Based on the gradual increase of amyloid plaques in size and number, Braak and Braak (1991)
defined three stages of amyloid pathology in AD patients (see figure 1.5, p.8). In ”stage A”, the
first amyloid deposits with low density can be found in the ventral parts of the frontal, temporal,
and occipital lobes. These deposits become denser during disease progression and spread across
the entire isocortex except from primary sensory areas and the motor cortex in ”stage B”. Most
plaques can be found in cortical layers Va and VI and in thewhitematter underlying these layers.
The hippocampus is only mildly affected at this stage with the highest number of deposits found
in the CA1. In the end-stage of AD (amyloid ”stage C”), amyloid plaques are spread across the
entire brain with a slightly milder impact on the hippocampus, thalamus, and hypothalamus
compared to other forebrain regions.
Though the level of amyloid deposits is drastically increased in AD patients, synthesis of neuro-
toxic amyloid species and subsequent oligomerization is not exclusive for AD but can be found in
other diseases and even cognitive healthy elderly as well (Iwatsubo et al., 1995; Price and Mor-
ris, 1999). Thus, the more commonly used categorization of AD pathology follows the burden
fromNFT. How amyloid plaques impact physiological processes is rather unknown and some re-
searches even debate the effect of amyloid deposits on neurodegeneration and cognitive decline
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(Wirth et al., 2013). However, cell culture experiments and studies on transgenic mice express-
ing mutated forms of APP strongly suggest a role of amyloid plaques in disturbing homeostasis,
impairing immune functions and driving neurodegeneration, thus cognitive decline. Soluble
oligomeric Aβ produced by human neuronal cell cultures and injected into the lateral ventricle
of rats was shown to specifically impair cognitive functions independently of neurodegeneration
(Cleary et al., 2005). Bittner et al. (2012) found that amyloid plaques in mice led to a significant
loss of dendritic spines in proximate neurons. On the molecular level, these neuroanatomical
and psychological effects might partially be driven by disturbances of JAK/STAT signaling caused
by an induction of Aβ1−42 (Chiba et al., 2009; Hsu et al., 2013). This JAK/STAT signaling pathway
functions in synaptic plasticity and might be a direct link between neuronal functions and glial
immune response that is induced but impaired by the presence of amyloid deposits (Meda et al.,
1995; Nicolas et al., 2012).
A B
Figure 1.5 – Braak and Braak stages for amyloid deposition:
A) Amyloid deposits in ”stage A” (a), ”stage B” (b-c), and ”stage C” (d-f) inside the occipital isocortex.
B)Hippocampal formation in ”stage C”. Dashed lines represent the boundaries between the subiculum and
CA regions, the arrow highlights ”fluffy material” at the border of the dentate gyrus. Unedited graphics
from Braak and Braak (1991).
Phagocytosis and thus clearance of disturbing protein aggregates within the CNS (central ner-
vous system) is mainly achieved by microglia. Amyloid peptides might be recognized by the
TREM2/DAP12 receptor complex expressed in microglia, thereby inducing phagocytotic activity
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(Jones et al., 2014). In an AD context however, microglia cannot cope with the increased levels of
Aβ oligomers and are functionally impaired (Krabbe et al., 2013). While this impairment might
be reversed by reducing the plaque burden, it might induce cytotoxic autoimmunity and thus
promote neurodegeneration (Butovsky et al., 2005). Interestingly, upregulation of TREM2 was
found to reinstate microglial function thereby reducing plaque burden and rescuing cognitive
functions in mice (Jiang et al., 2014). Alongwithmicroglia, astrocytes were shown to induce com-
pensatorymechanisms in response to amyloid deposits. Astrocytes bear anti-oxidative functions
and show an increased activity near amyloid plaques. Increased levels of Aβ1−42 coincide with
an induction of oxidative stress which can lead to the activation of caspases driving cell death
and thereby promote neurodegeneration (Butterfield et al., 2013; Garćıa-Matas et al., 2010).
One potential therapeutic approachmight be to prevent the formation of amyloid plaques. While
this can be achieved by immunizing individuals with Aβ1−42, clinical trials were aborted due to
a pathological induction of CNS inflammatory response upon vaccination (Bard et al., 2000; De-
Mattos et al., 2001; Hardy, 2002; Schenk et al., 1999). Leinenga and Götz (2015) recently published
a non-invasive approach to clear the CNS from amyloid plaques and could successfully reinstate
memory function in a transgenic mouse model for AD. Still, further knowledge is needed to un-
derstand the molecular processes underlying amyloid pathology in AD patients.
1.1.3 tau pathology: neurofibrillary tangles
The tau protein responsible for the formation of the fibrillary tangles identified by Alois
Alzheimer was first described in 1975 (Weingarten et al., 1975). However, it took nine more
years until increased protein levels of tau were found in the cerebrospinal fluid of AD patients,
given the first implication of that particular protein in the disease (Chapel et al., 1984). Two years
later, several research groups identified tau in NFT simultaneously (Grundke-Iqbal et al., 1986;
Ihara et al., 1986; Kosik et al., 1986; Wood et al., 1986). The knowledge on tau structure and the
function of the respective protein domains is rather little as classical structure analysis are not
suitable for proteins like tau (Mukrasch et al., 2009). Probably the most important parts of the
tau proteins are the tubulin binding domains and proline-rich domains. In a healthy context,
tau stabilizes microtubules thereby promoting their assembly (Brandt and Lee, 1993). Thus, it
functions in proliferation and differentiation of cells as well as antero- and retrograde transport
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in neurons (Rodŕıguez-Mart́ın et al., 2013; Sennvik et al., 2007). The binding towards micro-
tubules is regulated by phosphorylation through cAMP dependent kinases, most likely acting on
the proline-rich domains of tau (Landrieu et al., 2006; Mukrasch et al., 2009). Phosphorylation
of tau hereby leads to a dissociation of tau from microtubules and thus their destabilization. In
human, multiple splice variants of tau are expressed by the MAPT gene (microtubule-associated
protein tau) located on chromosome 17 in different developmental stages or cellular compart-
ments (Goedert et al., 1988; Kempf et al., 1996; Wang et al., 1993b). Alternative splicing of MAPT
exon 10 results in two isoforms of tau with three (3R) or four repeats (4R) of microtubule-binding
domains leading to a significant increase of microtubule polymerization through 4R-tau that is 3
times higher compared to 3R-tau (Goedert et al., 1989).
In AD patients, levels of tau phosphorylation show an up to 4-fold increase (Köpke et al., 1993).
This hyperphosphorylation induces a variety of pathological changes. First, hyperphosphory-
lated tau is unable to bind microtubules and thus to promote their stability and assembly. The
resulting disintegration of microtubules is likely to cause axonal degradation and synapse loss
which then leads to neuronal cell death and induction of microglia activity (Alonso et al., 1996;
Yoshiyama et al., 2007). Second, excessive phosphorylation of tau causes tau proteins to form
NFT preceeded by soluble aggregates of tau (see figure 1.6, p.11) (Götz and Ittner, 2008; Ihara
et al., 1986). Interestingly, approximately 40% of all hyperphosphorylated tau proteins remain
soluble and do not form fibrils in the brains of AD patients (Köpke et al., 1993). As for amyloid
plaques, the mode of action of NFT and soluble tau aggregates is still debated. The classical view
on protein aggregates and deposits assumes a pathogenic function and in fact, both soluble tau
aggregates and NFT were shown to cause neurodegeneration (Fox et al., 2011; Rohn et al., 2001).
Interestingly, the ratio of 3R:4R tau isoforms was found to be shifted towards 4R in AD patients
(Ginsberg et al., 2006). The increase of 4R tau might resemble a compensatory response towards
hyperphosphorylation of tau, since 4R tau has a higher microtubule-stabilizing activity (Goedert
et al., 1989). However, Chen et al. (2010) found a decrease of neuronal survival and an induction
of apoptosis on a gene expression level upon upregulation of 4R tau isoforms rather indicating a
cytotoxic activity.
In contrast to the described implications of tau in neurodegeneration, some researchers question
the ”tau-hypothesis” of AD pathology since neurodegeneration in AD exceeds NFT burden and
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Figure 1.6 – Hyperphosphorylated tau aggregates and forms neurofibrillary tangles:
Microtubuli (MT) are degrading upon dissocation of tau following hyperphosphorylation (P). Graphic was
adapted from Götz and Ittner (2008).
neurons containing those fibrils can survive for years and rather propose neuroprotective func-
tions of tau (Gómez-Isla et al., 1997; Lee et al., 2005; Morsch et al., 1999). In general though, the
significant function of tau in AD is well accepted and the post-mortem evaluation of AD pathol-
ogy is commonly based on NFT burden. Braak and Braak defined six stages for tau pathology
(see figure 1.7, p.12). In stage I, only a modest number of NFT can be found in few brain regions
including the transentorhinal region, the CA1 region, the deeper layers of the entorhinal cortex,
and parts of the thalamus and basal forebrain. These modest changes are aggravated during
stage II and additional plaques can be found in the subiculum and the association areas of the
cerebral cortex.
Stage III is characterized by a severe NFT burden including the first occurrence of ”ghost tan-
gles”, extracellular NFT, in the transentorhinal and entorhinal cortex. The hippocampal forma-
tion remains rather mildly affected and the isocortex does only rarely show any NFT during that
stage. Notably, most AD cases are not diagnosed earlier than Braak and Braak stage III. In stage
IV, all previously affected regions do now show severe NFT while the isocortex remains mildly
affected. As soon as the isocortex is significantly affected by tau deposits, the tissue is categorized
as stage V. The transentorhinal and entorhinal cortex are floodedwith ghost tangles and NFT can
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A
B
Figure 1.7 – Braak and Braak stages for neurofibrillary tangles:
A) NFT in the different layers of the entorhinal cortex in stage III, IV, V, and VI.
B) Tau pathology in the CA1 in stage II, III, V, and VI. Arrows depict particular dense NFT at the boundaries
of the CA1. Unedited graphics were taken from Braak and Braak (1991).
be found all over the hippocampus. Stage VI describes an even more pronounced pathology as
found in stage V brains with a significant loss of neurons and even degradation of ghost tangles
within the entorhinal cortex and the hippocampus. NFT are found in all areas of the isocortex
including the motor and sensory cortex.
1.1.4 Risk factors for Alzheimer’s disease
Treatment of AD patients so far only delays cognitive decline and bears a variety of adverse
side effects. Though a number of molecules were proposed as potential drugs for AD, meman-
tine was the last component approved by the FDA for treating AD patients in 2003 (Godyn et al.,
2016). The heterogeneity of AD and the relatively low accuracy of diagnosis prove the discovery
of novel drugs to be difficult and, in fact, the number of clinical trials regarding AD is relatively
low (Beach et al., 2012; Cummings et al., 2014; Mangialasche et al., 2010). Another approach to
counteract AD besides the treatment of AD patients is the prevention of its development. This
prevention requires a broad knowledge of factors that either increase or decrease the risk for
sustaining AD. During the recent decades, knowledge on these risk factors drastically increased
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through epidemiological analysis, supporting pre-clinical studies and potentially reducing fu-
ture incidence of AD (Barnes and Yaffe, 2011). These risk factors include intrinsic and extrinsic
parameters and, unfortunately thus, not all of them can be actively avoided.
One example for these intrinsic factors is the genetic background of an individual. Mutations in
a variety of genes were shown to increase the risk for developing AD or even cause a heritable,
early-onset form of Alzheimer’s disease (Tilley et al., 1998). The first genetic risk factors caus-
ing this familial AD were point mutations at APP codons 670/671 (called ”Swedish” mutation),
692 (”Flemish”), 693 (”Dutch”), and 717 (”London”) (Goate et al., 1991; Hendriks et al., 1992; Levy
et al., 1990; Mullan et al., 1992). During the recent decades, more than 20 additional pathogenic
mutations were discovered within the APP gene, a bit less in PS2 and, remarkably, over 200
mutations in PS1 (ALZFORUM, 2016). Interestingly, some mutations of APP might also have neu-
roprotective functions (Jonsson et al., 2012). While mutations in MAPT can cause a familial form
of frontotemporal dementia, there is no evidence yet for a role of genetic tau variants in familial
AD (Wolfe, 2009). Familial AD, however, resembles less than 5% of all AD cases and apart from
mutations in APP, PS1 and PS2, more than 20 genetic predispositions were identified increasing
the risk for sporadic, late-onset AD (Association, 2015; Van Cauwenberghe et al., 2015). These
predispositions include mutations in apolipoprotein E, Trem2, or protein tyrosine kinase 2 beta
(Ptk2b) (Jonsson et al., 2013; Strittmatter et al., 1993). Other intrinsic risk factors for AD are
female gender and, most importantly, aging (see figure 1.2A, p.2) (Launer et al., 1999).
Apart of the intrinsic risk factors, epidemiological studies identified a broad variety of external
impacts on the risk of sustaining AD. In general, researchers found clear correlations between
a ”healthy lifestyle” and a reduced disease risk. Both physical and cognitive activity, thus edu-
cation, have protective effects in regard to AD (Barnes and Yaffe, 2011; Sando et al., 2008; Tyas
et al., 2001). In contrast, obesity can increase the probability to develop the disease by up to
60% while regular smoking might even double the risk for AD (Cataldo et al., 2010; Ott et al.,
1998; Profenno et al., 2010). In accordance with findings on obesity, patients with diabetes also
face an increased probability to develop AD in their later life (Profenno et al., 2010; Tyas et al.,
2001). A drastic increase of relative risk was found in individuals that were regularly exposed
to defoliants and fumigants or other toxins. Interestingly, any kind of vaccination was shown to
coincide with a 2.5 fold reduction of risk which is most likely coherent with a generally healthier
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way of life (Tyas et al., 2001). Besides metabolic diseases like diabetes, other medical conditions
are implicated in the development of AD as well. Patients with migraine or antecedent suffering
from post-traumatic stress disorder are more likely to suffer from AD in their later life (Tyas
et al., 2001; Yaffe et al., 2010). Altogether, a ”healthy lifestyle” together with a good education
and avoidance of danger can be considered a promising strategy to reduce one’s own individual
risk for sustaining AD significantly.
1.1.5 The APP/PS1 mice and other mouse models for Alzheimer’s disease
Compared to diseases acting on the peripheral nervous system or other human organs than the
brain, researchers face a substantial issue when studying CNS diseases. While it is possible for
most organs to directly study fresh tissue from living patients by taking biopsies, research on
the human brain almost completely depends on indirect sampling (i.e. cerebrospinal fluid) or
post-mortem tissue. To circumvent these limitations, researchers commonly use animal mod-
els for studying basal functions of the brain or CNS diseases. A variety of genetically modified
mouse models for AD were generated during the past 25 years. In 1991, the first transgenic
mouse model for AD overexpressing a C-terminal fragment of APP was described 4 years after
the discovery of the APP gene (Kang et al., 1987; Kawabata et al., 1991). The first mouse model
for tauopathy followed in 1995 (Götz et al., 1995). Nowadays, the most frequently used mouse
models for AD either express native or mutated human tau, human APP or APP-fragments, or
coexpress human APP and human PS1 driven by PDGF-B-, Thy1-, or Prp-promoters (Hall and
Roberson, 2012). Another interesting ADmodel is the Ck-p25 mouse which features an inducible
overexpression of p25 (a truncated form of cyclin-dependent kinase 5 activator) and subsequent
inactivation of the cyclin-dependent kinase 5 (CDK5) leading to the formation of tauopathology,
neurodegeneration, and cognitive decline (Cruz et al., 2003; Fischer et al., 2005).
The transgenic mouse strain B6-Tg(Thy1-APPswe; Thy1-PS1 L166P) (subsequently called ”AP-
P/PS1 mice”) was generated by Radde et al. in 2006. Those mice coexpress human APP carry-
ing the ”Swedish mutation” and human PS1 with a single point mutation at codon 166 (CTT to
CCT) leading to an exchange of leucine with proline. The ”Swedish mutation” of APP describes
a double point mutation of codons 670 and 671 (AAGATG to AATCTG) leading to an exchange of
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lysine-methionine with asparagine-leucine (Mullan et al., 1992). The human APP shows a three-
fold overexpression compared to the endogenousmurine APP and as a result, Aβ levels gradually
increase drastically during aging (Radde et al., 2006). The first amyloid plaques can be observed
at an age of 2 months in the frontal cortex and at 3 months within the hippocampus inducing
immune response. Radde et al. evaluated the spatial memory performance of this transgenic
mouse line and detected memory impairments at an age of 8 months. Preliminary data from
our lab, however, indicate that the memory in APP/PS1 mice is already impaired at an age of 4
months, nicely correlating with increasing plaque burden.
1.2 Learning and memory
Probably one of the most important traits in higher animals is learning and memory. The ability
to cognitively store information is essential for an individual’s survival. Dudai (2002) defined
learning as an induced lasting alteration in behavior upon an individual’s experience. With the
ability to gain knowledge, individuals are able to remember feeding grounds, shelter or avoid
adverse situations, i.e. encountering a predator, thereby drastically improve their chance to
survive. Besides the ability to communicate with other individuals, memory can be considered
as crucial for the regular social interactions and thus cultural evolution. It is a conventional
belief that the remarkable human memory is what differentiates us from other animals. This
highlights the strong impact of neurodegenerative disease encompassing cognitive decline on
patients and their respective families. Understanding the molecular basics underlying learning
and memory is thus also crucial for our knowledge of neurodegenerative diseases.
1.2.1 Categories of memory
Memory can classically be classified as explicit (declarative) and implicit (procedural) memory
(Tulving et al., 1972). Implicit memory functions rather unconsciously and includes priming,
procedural memory (habits and skills), associative and non-associative memory (Kandel, 2013).
Priming is a process determining how a certain stimulus is perceived based upon previously
achieved knowledge regarding both explicit and implicit memory. As an example, the second
word of a pair of words is significantly faster processed when it can be associated to the first one
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(Meyer and Schvaneveldt, 1971). Non-associative memory describes learning processes regard-
ing single stimuli including habituation and sensitization (Kandel, 2013). Habituation leads to
a decrease in response upon a continuously reappearing stimulus while sensitization describes
a general induction of perception upon receiving an intense stimulus (Kandel and Tauc, 1965;
Thompson and Spencer, 1966).
Associative memory describes the theoretical linkage between two initially unrelated events
(Dudai, 2002). The principles of associative learning were already studied by Ivan Pavlov who
was one of the first Novel laureates for Medicine, which he received in 1904. When repeat-
edly pairing a so called ”unconditioned stimulus” naturally evoking a certain behavior with a
”conditioned stimulus” that would not cause similar behavior in time, the conditioned stimulus
becomes capable of inducing the behavioral response of the unconditioned stimulus. In the clas-
sical conditioning performed by Pavlov himself, a bell (conditioned stimulus) was rung to a dog
who received a portion of meat powder (unconditioned stimulus), immediately after making the
dog salivate. After repeating this procedure a certain time, Pavlov was able to trigger the dog’s
salivation simply by ringing that particular bell. Another form of associative behavior is op-
erant (or instrumental) conditioning, where an individual’s behavior itself becomes associated
with an unconditioned stimulus. This form of memory was first described in 1898 by Edward
L. Thorndike. When putting cats into a small, closed box with a door opening upon pulling on a
string inside of the box, he observed that with increasing number of trials, cats performed better
and better in regard to escaping this box (Thorndike, 1898).
Explicit memory can be described as a conscious form of memory and includes acquired knowl-
edge on personal experiences and autobiographic information (episodic memory), and knowl-
edge on facts (semantic memory). For instance, episodic memory helps us to remember a certain
moment we listened to a song while semantic memory stores information on the actual musical
notes of that particular song. In contrast, playing that respective song on an instrument upon
practice involves procedural, thus implicit memory. Interestingly, episodic memory is not ”set in
stone” and was shown to be remodeled frequently during remembering (Bartlett, 1995).
Memory is further distinguished by its continuance and capacity limits into short-term mem-
ory (STM) and long-term memory (LTM). Even though the exact duration of STM is unknown,
it is generally believed to last several seconds to minutes in average while there is no temporal
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limitation for LTM (Kandel, 2013). However, researchers claim that the decay of STM does not
depend on time but on a limit of memory capacity (Cowan, 2008; Lewandowsky et al., 2004).
This capacity can be described as a limited number of theoretical items that can be stored in
STM (Miller, 1956). This limitation was initially estimated to 7 ± 2 items, though later studies
proposed a STM capacity of only 4-6 items maximally (Miller, 1956; Tulving and Patkau, 1962).
Importantly, these items might not only resemble a single stimulus but a combination of stimuli
into a larger unit (Cowan et al., 2004). In contrast to the debate in STM limitations, LTM is con-
sidered not to have any temporal or quantitative limitations and resembles the whole acquired
knowledge of an individual’s life-time (Cowan, 2008; Kandel, 2013).
1.2.2 Brain areas involved in different modes of memory
A healthy and stablememory function consists of three distinct stages: acquisition, consolidation
and retrieval. Acquisition describes the perception of short-term storage of novel information
therefore includes sensory processes and STM. The transformation of this novelty, thus STM,
into stable knowledge, thus LTM, is termed consolidation while memory retrieval is commonly
known as ”remembering”. Memory can also be classified into subtypes. This classification is
in general well accepted and evidence from patients with different neuroanatomical symptoms
indicate that distinct brain areas are involved in the respective forms and stages of memory. The
most commonly known case is patient H.M. who was suffering from a severe epilepsy in the mid
1950s. In order to ameliorate the epileptic seizures, the hippocampus and adjacent regions of
the temporal lobe were bilaterally removed via surgery (Scoville and Milner, 1957). Although
this particular treatment did reduce the pathology, it led to a significant loss of memory func-
tions in H.M. Interestingly, H.M. had a relatively stable episodic memory for events before his
surgery and could remember new information for several seconds and even minutes, though he
completely lacked the ability to store these information for a longer period of time. Despite this
anterograde amnesia, H.M. was fully capable of learning new tasks though could not recall doing
that certain task ever before. Thus, while implicit memory worked fine as well as the acquisition
and retrieval of explicit memory, H.M. specifically lacked the ability to consolidate explicit mem-
ory. Findings from H.M. indicated that the hippocampus and temporal lobe are crucial for the
formation of new explicit memory. Data from other patients with neuroanatomical disturbances
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and more recent data using novel approaches for real-life imaging in vertebrates could confirm
these findings and in addition led to the identification of a number of brain regions involved in











Figure 1.8 – Location of the ACC and hippocampus in human and mouse brains:
A) Sagittal section of a human brain showing the ACC (blue, left) in the frontal lobe below the pre-frontal
cortex and frontal sections displaying the hippocampus (red, right) in the medial temporal lobe. Graphics
were modified from Kandel (2013).
B) Sagittal sections of a mouse brain showing the cingulate cortex (yellow) and the hippocampus (red). The
anterior part of the cingulate cortex (dashed red lines) is considered as the mouse ACC. Graphic modified
from Franklin and Paxinos (1997).
The anterior cingulate cortex (ACC) is a part of the frontal lobe located below the pre-frontal cor-
tex and is partially surrounding the corpus callosum in the human and mouse brain alike (see
figure 1.8). In human, the ACC shows extensive connections with the hippocampus, amygdala,
prefrontal cortex, anterior insula, and the nucleus accumbens indicating its broad impact on
cognition but also autonomic functions (Bush et al., 2000; Kandel, 2013). Based on neuroimaging
studies and data from patients with lesions inside the ACC, this brain region is most commonly
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linked to error detection and evaluation, reward prediction, decision making, empathy, impul-
sity and emotion such as aggression (Bubenzer-Busch et al., 2015; Carter et al., 1999; Ende et al.,
2016; Lockwood et al., 2015; Nelson et al., 2015; Olié et al., 2015). The anatomical linkage between
the ACC and regions involved in memory function like the hippocampus and the pre-frontal cor-
tex, however, indicate its role in memory as well. In fact, several studies could confirm a role
of the ACC in learning and memory including the formation of episodic and spatial memory
or retrieval of semantic memory (Cazalis et al., 2011; Giannakopoulos et al., 2000; Seo et al.,
2015). Further evidence for a role of the ACC in memory function was found by Frankland et al.,
since gene expression analysis upon contextual fear conditioning and behavior tests following
a specific anesthetic inactivation of the ACC clearly demonstrated its importance for associative
memory. Disruptions within the ACC were implicated in depression, schizophrenia and bipo-
lar disorder but also in mild cognitive impairment and AD (Giannakopoulos et al., 2000; Kandel,















Figure 1.9 – Scheme of the hippocampal for-
mation:
The hippocampal regions (DG, CA3, CA2, CA1)
receive their input from the entorhinal cor-
tex (EC) via the perforant pathway. Signal-
ing within the hippocampus is mainly unidirec-
tional through mossy fibers and Schaffer collat-
erals. Sub: Subiculum; PaS: Parasubiculum; PrS:
Presubiculum. Graphic adapted from Kandel
(2013).
The hippocampal formation, one of the brain regions removed in patient H.M., is located within
the medial temporal lobe and reminds of the shape of a seahorse when dissected (see figure 1.8,
p.18) (Andersen et al., 2007). It consists of the hippocampal regions cornu ammonis (CA) and
dentate gyrus (DG), and the subiculum connecting the hippocampus with the entorhinal cortex
via the perforant pathway (see figure 1.9). While the developing hippocampus signals bidirec-
tionally, the adult hippocampus mainly functions unidirectional, signaling from the DG through
the different CA regions (Shi et al., 2014). Themajor input is thereby received by the DG from the
entorhinal cortex. The important role of the hippocampus in learning and memory is nowadays
well accepted with the respective subregions acting in distinct modes of memory (Battaglia et al.,
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2011; Kandel, 2013). The DG is one of the rare sites in the mammal brain where neurogenesis
occurs throughout maturity (Gage, 2000). Thereby, neuronal progenitor cells within the sub-
granular zone of the DG proliferate andmainly differentiate into dentate granule cells (Cameron
et al., 1993). This synthesis of new neurons plays an important role in DG-dependent memory,
including pattern recognition, temporal separation of acquired memory, or memory remodeling
(Aimone et al., 2009; Cao et al., 2004; Deng et al., 2009). This effect on memory function seems
to be specific for certain modalities as inhibition of adult neurogenesis impairs some but not all
hippocampus related memories (Shors et al., 2002). These memory functions also include spatial
memory, associative memory, and explicit sequential learning, strongly depending on the CA1
and CA3 region which are required for both acquisition and retrieval of learned information
(Farovik et al., 2010; Montgomery and Buzsáki, 2007; Sakaguchi et al., 2015).
1.2.3 Cellular mechanisms of learning and memory
Different forms of memory can be related to certain areas of the brain and thus different neu-
ronal sub-types and networks. It can thus be assumed, that these different forms depend on
distinct cellular mechanisms and it is well accepted that STM is in principle regulated through
temporal modifications within synapses while LTM depends on alterations in gene expression
and resulting long-lasting cellular changes (Abel and Lattal, 2001; Cowan, 2008; Kandel, 2013). As
previously described, STM is limited in its duration and capacity, thus requiring cellular mech-
anisms which can immediately be activated upon request. Implicit STM is considered to act by
changing the pre-synaptic strength.
One of the first studies regarding synaptic strength and habituation were done by Spencer et al.
(1966). Following a repetitive stimulus, the input from excitatory interneurons on motor neu-
rons in the spinal cord of cats was decreased while the preceding signaling from sensory neurons
was unaffected. After a certain time without that repetitive stimulus, Spencer et al. observed
restoration of the excitatory signal, nowadays termed dishabituation. Studies in the seaslug
Aplysia californica confirmed that habituation relies on reduced pre-synaptic signaling and thus
a decrease of neurotransmitter release (Castellucci and Kandel, 1974). Aplysia has a relatively
simple nervous system and large neurons thus enabling locally well defined electrophysiologi-
cal measurements. Besides habituation and dishabituation, the cellular basics of sensitization
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were also studied in the seaslug already in 1965 (Kandel and Tauc, 1965). When transmitting a
short electric shock to an animal, it showed an increased pre-synaptic current in interneurons
as a response for other - harmless - stimuli as well. Depending on the strength or frequency of
the priming stimulus, this sensitization effect lasted for minutes or even weeks and are thus not
restricted to STM. More recent studies indicate that the pre-synaptic induction during sensitiza-
tion depends on a higher rate of exocytosis following each single action potential (Stevens and
Wesseling, 1999).
No limits were discovered yet in regard to duration and capacity of LTM and, conclusively, the
cellular mechanisms of LTM can not solely rely on an induced neurotransmitter release (Kan-
del, 2013). Even though there is evidence for a quantitative change in the readily releasable
vesicle pool during long-term potentiation and long-term depression, these changes - includ-
ing an increased number of available neurotransmitter vesicles - depend on upstream mecha-
nisms and most likely changes in gene expression (Goda and Stevens, 1998; Stanton et al., 2003).
Thereby, gene expression changes are indirectly caused by neurotransmitters. For instance,
the pre-synaptic release of serotonin, which in Aplysia is relevant for long-term potentiation,
leads to an activation of serotonin-receptors and the initiation of a protein cascade (Bailey et al.,
1996; Varrault et al., 1991). Binding of serotonin to its receptor leads to an increased level of
cAMP which can activate the protein kinase A. Upon activation, protein kinase A can be translo-
cated into the nucleus where it can phosphorylate transcription factors (TFs) like CREB (cAMP-
responsive element binding protein) thereby regulating gene expression. The resulting changes
of de-novo protein synthesis can then lead to a strengthening or dampening of synapses, i.e. by
changes in neurotransmitter availability or receptor density (Goda and Stevens, 1998; Stanton
et al., 2003; Stecher et al., 1997), a change in synapse number as a result of synaptogenesis or
synaptic turnover (Shen and Ganetzky, 2009; Waites et al., 2005), and neurite outgrowth (Modar-
resi et al., 2012; Tolwani et al., 2002). During the early 21st century, researchers were able to
show that these changes in gene expression upon stimulation of neurons does not depend on
TFs alone but on an interaction between TFs and epigenetic processes (Guan et al., 2002).
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1.3 Epigenetics and its impact on gene expression
Since the discovery of the DNA structure in the early 1950s and preliminary studies on trans-
formation in bacteria, the concept of the DNA as a carrier for hereditary information is well ac-
cepted (Avery et al., 1944; Watson and Crick, 1953) The first estimations concerning the number
of genes in the human genome were in the range of millions (Vogel, 1964). However, more re-
cent studies suggest approximately 20,000 protein coding genes, highlighting the misconception
of the DNA as a blue-print for invariant gene expression in former times (Clamp et al., 2007). Ev-
ery somatic cell within the human body does in principle contain the same nucleotide sequence,
thus requiring a differential expression of genes to enable the broad variety of cells. In 1972, two
separate groups identified proteins in Escherichia coli and Bacillus phage SPO1 which are able
to specifically modulate gene expression (Ghosh and Echols, 1972; Wilhelm et al., 1972). These
proteins, termed transcription factors, can promote or repress gene expression by directly or
indirectly binding DNA. Studies from the past decade strongly suggest, that the function of these
TFs at least partially depends on epigenetic mechanisms.
Figure 1.10 –Waddington’s ”epigenetic landscape”:
Hypothesis on the modulation of cellular develop-
ment based on epigenetic regulation of genes. The
marble on top of the depicted hill can in principle
follow each distinct descent, describing the full ge-
netic potential of each somatic cell. However, epi-
genetic mechanisms are determining the marble’s
route, thus the gene expression program. Adapted
from Waddington (2014).
The term ”epigenetics” originally described causal mechanisms of the development connecting
an individual’s genotype with its actual phenotype (Waddington, 2012). These mechanisms were
later identified as covalent modifications of DNA binding proteins or the DNA itself, but also
inhibitory functions of non-coding RNAs on mRNA and are not only happening during develop-
ment but also in response to several endogenous and exogenous stimuli (Castel andMartienssen,
2013; Jenuwein and Allis, 2001; Robertson et al., 2000). Researchers thus hypothesize that while
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every somatic cell has the full genetic potential, it is the epigenetic machinery that is determin-
ing cell state (see figure 1.10, p.22). The methylation of DNA and modifications on histones, DNA
binding proteins, is subsequently described in more detail.
1.3.1 DNAmethylation
DNA methylation was already described in the 1960s and changes in methylation levels were
regularly proposed as symptoms of several diseases, including AD, or potential therapeutic ap-
proaches for these ever since (Dover et al., 1983; Gold et al., 1963; Pfeifer et al., 1988; West et al.,
1995). Methylation of DNA acts mainly within CpG islands of the genome (Robertson et al., 2000).
These CpG sites are DNA sequences with a relative frequency of cytosine-guanine dinucleotides
higher than 55%. DNA methylation in human is catalyzed by three distinct DNA methyltrans-
ferases (DNMT) by transferring a methyl residue from S-adenosyl methionine to the 5’ position
of the cytosine pyrimidine ring (Day and Sweatt, 2010) (see figure 1.11, p.24). DNMT1 identi-
fies hemi-methylated CpG-sites and methylates the complementary strand’s cytosine (Berkyurek
et al., 2014). This process is also called ”maintenance methylation”. In contrast, DNMT3A and
DNMT3B are also able to catalyze a de-novo methylation of CpG sites (Okano et al., 1999). DNA
can be demethylated by 5-methylcytosine demethylases (also termed TET proteins) or DNA gly-
cosylases (Cervoni et al., 1999; Kohli and Zhang, 2013). However, scientists claim that demethy-
lation of cytosine is rather energy-consuming and DNA methylation represents a rather stable
epigenetic mechanism (Wolffe et al., 1999).
The development of Next-generation sequencing (NGS) in the past decade allows scientists to
sequence DNA in a genome-wide approach, allowing analysis of gene expression via comple-
mentary DNA (RNA sequencing), DNA bound by specific proteins (ChIP sequencing) or modified
DNA, e.g. methylated DNA (MeDIP sequencing) (Metzker, 2010). In contrast to more classical ap-
proaches like gene microarrays, NGS has several advantages which were frequently described
in the past years (Marioni et al., 2008; Wang et al., 2014; Zhao et al., 2014). Microarrays are de-
signed to study a pre-defined set of nucleotide sequences and are thus strongly biased while NGS
unbiasedly reads sample DNA regardless of the actual sequence, enabling a genome-wide analy-
sis and the identification of novel or exogenous sequences. Additionally, NGS is considered more
accurate and replicable than microarray studies. Using this genome-wide approach in regard
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Figure 1.11 – De novo and maintenance
methylation of cytosine by DNTMs:
Top: Methylation of cytosine to methylated cy-
tosine (MeCytosine) happens at the 5’ position
of the pyrimidine ring. DNMTs use S-adenosyl
methionine (SAM) as a methyl donor gener-
ating methylated cytosine (MeCytosine) and S-
adenosyl homocystein (SAH).
Bottom: DNTMs 3A and 3B catalyze de-novo
methylation of cystein while DNMT1 methylates
the complementary CpG site. Graphic was mod-
ified from Day and Sweatt (2010).
to DNA methylation increased our understanding on the function of DNA methylation and its
distribution along the genome. DNA methylation in fungi or invertebrates was shown to repre-
sent a mosaic pattern where stable methylated regions are interspersed (Suzuki and Bird, 2008).
In contrast, MeDIP sequencing of vertebrates revealed a global pattern of large methylation do-
mains primarily in intergenic regions.
In 1981, Mohandas et al. suggested that the suppression of the inactivated x-chromosome in fe-
males is driven by DNA methylation as the two x-chromosomes had opposite DNA-methylation
patterns. This led to the general understanding of DNA methylation as a mechanism for gene
silencing. Recently, Wagner et al. (2014) investigated the correlation between gene expression
and DNA methylation state in a non-genome-wide approach. They identified a negative corre-
lation between DNA methylation state at the promoter or gene body and gene expression levels
in only 20% to 30% of all genes while up to 35% of genes even showed a positive correlation
between DNA methylation and their respective expression level. This was clearly contradictory
to the common consensus of DNA methylation causing silencing of genes (Newell-Price et al.,
2000). A number of recent genome-wide analysis might indicate, that the negative correlation
between DNA methylation and gene expression most likely only accounts for long-term stabi-
lization of gene silencing (Jones, 2012). In addition to gene expression per se, DNA methylation
was shown to function in differential splicing as well. Interestingly, alternatively spliced exons
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included during transcription tend to have a higher methylation level than excluded exons and
pharmaceutical inhibition of DNA methylation led to an aberrant exclusion of exons (Maunakea
et al., 2013). These findings indicate that DNA methylation is not a uniform, binary mechanism
but rather variable and multi-functional.
1.3.2 Histone modifications
Another epigenetic mechanism is the modification of histones at specific amino acids. Five dif-
ferent histone families are described, namely H1, H2A, H2B, H3, and H4, which mainly function
in octamers consisting of two H2A/H2B and two H3/H4 dimers respectively (Bhasin et al., 2006;
Luger et al., 1997). The DNA of eukaryotic cells is wrapped around these histone octamers form-
ing a nucleosome, which describes the first magnitude of DNA compaction. Sequences of nucleo-
somes are condensed once more, forming a structure termed ”chromatin” (Allis et al., 2007). Hi-
stone 1 acts as a linker protein that strengthens the binding of the histone octamer towards the
DNA, maintaining its position inside the nucleosome and regulating a higher-order chromatin
structure (Bednar et al., 1998). Modifications on specific residues of these histones were shown
to impact the DNA binding properties and promote or repress gene expression (Allis et al., 2007).
In addition, some histones within a nucleosomemight also be exchanged by an isoform affecting
the binding properties as well (Gaume and Torres-Padilla, 2015). These changes on DNA binding
and therefore the chromatin structure are one aspect of a process called chromatin remodeling
and are considered important mechanisms for regulating gene expression (Allis et al., 2007).
The structure of histones, which consist of a globular and a flexible domain, the ”histone tail”, is
highly conserved among species (Bhasin et al., 2006; Luger et al., 1997). Various covalent mod-
ifications on the histone tails were discovered during the past 50 years including acetylation,
methylation, phosphorylation, and ubiquitination (Portela and Esteller, 2010). The most preva-
lent and probably best studied modifications are acetylation (ac) and methylation (me) (see fig-
ure 1.12, p.26). For convenience, a terminology for histone modifications was established giving
information about the modified Histone, the affected amino acid, and the respective modifica-
tion. H3K4me3, for instance, resembles tri-methylation of the lysine-residue at the N-terminal
position 4 in histone 3 (Allis et al., 2007).
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Figure 1.12 –Major modifications of histones H1, H2A, H2B, H3, and H4:
Excerpts of the histone tails’ amino acid sequence (single-letter abbreviations) and the major covalent mod-
ifications, including acetylation (blue), methylation (red), phosphorylation (yellow), and ubiquitiniation
(green). Numbers underneath the respective amino acids resemble their positions within the histone tail.
Graphic was modified from Portela and Esteller (2010).
The effects of distinct histone modifications on gene expression are quite diverse and depend on
the modified amino acid, respective kind of modification and the position of the modified his-
tone and thus nucleosome within the gene. H3K4me3 for instance is in general implicated with
active or poised gene promoters and H3K4me1 with gene enhancers, thus supporting gene ex-
pression (Heintzman et al., 2007). In contrast, H3K9me3 mainly occurs within the gene body of
repressed genes (Gu et al., 2012; Lachner et al., 2001). Methylation of histone tails is regulated by
histone methyltransferases and histone demethylases while acetylation is regulated by histone
acetyltransferases and histone deacetylases (HDAC). Interestingly, some of these histone modi-
fying proteins are acting together in protein complexes which usually also contain DNA-binding
proteins, ATP-ases and linker-proteins (Hayakawa and Nakayama, 2011). One example is the
Mi-2/NuRD complex, containing HDAC1 or HDAC2 along with the lysine-specific demethylase 1
(LSD1) and Mi-2 which functions in nucleosome positioning (Zhang et al., 1997, 1999). Notably,
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histone modifying complexes and histone modifying enzymes themselves were shown to inter-
act with DNA methylation but also TFs. Some histone modifying complexes are able to specifi-
cally bind to methylated CpG-sites where they are likely to cause a repression of gene expression
(Denslow andWade, 2007; Hendrich and Bird, 1998).
1.3.3 DNAmethylation and histone modification in age and disease
Memory impairments are one of the most striking symptoms of AD patients. However, this facet
of cognitive decline does also happen during healthy aging, though at milder level (Deary et al.,
2009). One potential mechanism driving this progressive decline is the disruption of the nu-
clear lamina during senescence which was shown to disrupt the three-dimensional organization
of chromatin thereby histone modifications and DNA methylation (Berman et al., 2011; Righolt
et al., 2011; Shumaker et al., 2006). This pathological effect on epigenetic modifications is thought
to trigger severe changes in gene expression observed in AD patients. Another reason for poten-
tial disruptions in gene expression is the deregulation of proteins involved in epigenetic mech-
anisms themselves (Fraga and Esteller, 2007; Kyrylenko et al., 2000). In fact, different patterns
of these epigenetic processes can be found in adolescent individuals compared to younger ones
and experiments onmice could confirm a linkage between age-dependent memory impairments
and altered histone modifications (Fraga and Esteller, 2007; Lubin et al., 2011; Peleg et al., 2010).
The epigenetic profile and, concordantly, gene expression in AD patients is strikingly different
than the one from age-matched cognitively healthy human and distinct from changes occurring
during healthy aging (Mills et al., 2013; Twine et al., 2011). RNAseq studies on post-mortem tissue
from AD patients revealed that approximately 20% of all transcripts are differentially expressed
in the frontal lobe and parietal cortex compared to samples from healthy controls. The majority
of genes were upregulated in their expression in AD patients. Both up- and downregulated genes
could be linked with neuronal functions, cellular metabolsim, and homeostasis. Interestingly,
DNA methylation in AD patients also shows a global increase which might resemble a global dis-
ruption of the transcription machinery (Bakulski et al., 2012; Coppieters et al., 2014). The APP-
and MAPT-genes are, in contrast, hypomethylated in some brain areas which is likely to cause
a specific induction of APP and MAPT expression (Bakulski et al., 2012; Iwata et al., 2014; West
et al., 1995). Some studies performed in mice regarding the specific effect of amyloid-pathology
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on DNA methylation were published recently though their results are rather inconsistent (Cong
et al., 2014; Sung et al., 2011). Unfortunately, data concerning histone modifications in AD pa-
tients are rather sparse while a considerable amount of studies were conducted in AD mouse
models (Fischer, 2014). Results from animal experiments, however, strongly suggest a disrup-
tion of histone modifications following amyloid plaque formation (Francis et al., 2009).
Targeting enzymes involved in epigenetic mechanisms is considered a promising approach for
counteracting and reinstating memory functions in AD patients (Adwan and Zawia, 2013; Fischer
et al., 2010). In fact, a variety of molecules are available targeting DNMTs or histone modifying
enzymes like HDACs. The synthetic nucleoside 5-acacytidin is able to inhibit DNMTs, thus DNA
methylation (Tanaka et al., 1980). It was approved by the FDA in 2004 for treating myelodysplas-
tic syndromes, though pre-clinical trials in mouse models indicate a beneficial role in reinstating
a healthy gene expression in context of AD as well (Sung et al., 2011). One histone modification,
namely acetylation, is of particular interest due to the availability of different HDAC-inhibitors,
including SAHA (suberoylanilide hydroxamic acid), trichostatin-A, or valproic acid. By inhibit-
ing HDACs Peleg et al. (2010) were able to normalize histone acetylation which is significantly
decreased in adolescent mice, thereby reinstating memory functions. Additionally, all three pre-
viously mentioned HDAC-inhibitors were able to augment cognitive processes in an APP-mouse




The incidence of Alzheimer’s disease is prospected to increase dramatically during the next
years. However, the possibilities to treat AD patients is strongly limited due to the weak effec-
tiveness of approved drugs and our current inability to actually cure AD. The drug development
for AD is considered problematic due to the heterogeneity of the disease and our relatively little
knowledge on the molecular basics involved in its progression and development. In addition,
studies to discover novel drugs are often targeting single proteins known to be directly involved
in the pathology, i.e. γ-secretases generating neurotoxic Aβ, and are thus strongly biased and
restricted to these already known effectors. Recently, HDAC-inhibitors that were initially tested
successfully in regard to different types of cancer showed beneficial effects in mouse models for
AD and might be promising treatments for AD patients as well.
I hypothesized that this ”pan”-disease efficacy is not exclusive for HDAC-inhibitors thus other,
even commonly used drugs might be efficient for AD as well, and that these drugs can be identi-
fied by amolecular-symptomatic (i.e. gene expression or epigenetic changes) approach. In order
to test this hypothesis, I aimed to
1. investigate transcriptional and epigenetic genome wide changes specifically caused by
amyloid deposition in a longitudinal approach using a mouse mouse model for AD to ad-
vance the knwoledge on molecular changes during disease development and progression,
2. identify upstream core modulators - proteins which disruption might cause the deregula-
tion of a variety of downstream cellular processes - so far not linked to AD, and
3. screen public databases to discover and potentially validate new drugs for AD in the given
mouse model, which were not yet considered as promising treatments.
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3.1 Animals
All wildtype and transgenic mice used for this study were from the APP/PS1 mouse strain B6-
Tg(Thy1-APPswe; Thy1-PS1 L166P) (Radde et al., 2006), initially received from Mathias Jucker
(German Center for Neurodegenerative Diseases; Tübingen, Germany). Transgenic mice were
heterozygously positive for both human APP carrying the swedish mutation (Mullan et al., 1992)
and human PS1 with a point mutation at position 166 (leucine to proline) (Moehlmann et al.,
2002). Mice from three age groups were chosen for experiments: 1.5 (healthy; young), 4 (early
AD pathology; mid-age) and 8 months old (late AD pathology; old)
All mice were bred in groups with their respective littermates, kept in individually ventilated
cages (365x207x140mm) unless otherwise stated. Animals were exposed to a 12 hour light/dark-
cycle, a stable room temperature (RT) of 22oC and air humidity of 58%. Food and water were
provided ad libitum.
Housing, breeding and animal experiments were planned and conducted in full compliancewith
the German Federal Act on the Protection of Animals andwere approved by the responsible min-
istry of Lower Saxony (”Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittel-
sicherheit”).
3.1.1 Genotyping
Mouse tail biopsies were lysed by incubation in 200µl DirectPCR tail-lysis buffer (Viagen Biotech;
Los Angeles, USA) and 40µg Proteinase K (7528.2 from Carl Roth GmbH + Co. KG; Karlsruhe,
Germany) in a thermoshaker at 1400rpm and 55oC for 3hr following 85oC for 45min.
The PCR was done with primers for both human APP (3’: GAATTCCGACATGACTCAGG, 5’: GTTCT-
GCTGCATCTTGGACA, amplicon size: 264bp) and human PS1 (5’: AATAGAGAACGGCAGGAGCA,
3’:GCCATGAGGGCACTAATCAT, amplicon size: 608bp) using DreamTaq polymerase (Thermo
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Fisher Scientific; Waltham, USA) according to table 3.1. Samples were evaluated via gel elec-
trophoresis on a 1.5 agarose gel containing 0.1% ethidiumbromide.
Table 3.1 – Standard protocol for a genotyping PCR using DreamTaq polymerase
Component Volume
10x DreamTaq Green Buffer 2.5µl
dNTP Mix, 2.5mM each 2µl











final elongation 72oC 5min
cooling 4oC ∞
3.1.2 Brain dissection
To dissect brains, mice were sacrificed by cervical dislocation and decapitated. The scalp was
carefully cut open to expose the skull. The posterior and lateral muscles were cut through to ease
isolating the brain. The occipital, temporal, and parietal bones were removed after fracturing
the interparietal bone by a precise but thorough cut. A transversal incision of the frontal bone
allowed removing the brain, which was immediately placed on an ice cold, sterile metal plate
for further isolation of brain regions.
3.1.2.1 Dissection of the anterior cingulate cortex
The olfactory bulbs and the most anterior 0.5mm of the forebrain were removed using a scalpel.
A second coronal cut 3mm posterior to the latter onewas done to receive a brain slice containing
the ACC which is usually visible as a darker triangular region dorsal of the corpus callosum.
3.1.2.2 Dissection of the hippocampus
A superficial cut along the midline of the forebrain was done. The forebrain hemispheres were
dissected and freed from the thalamus using a surgical scoop. The hippocampus was now freed
from vessels and meninges. The DG was then dissected from the hippocampus by performing
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two orthogonal cuts along its border using a cannula (1.2x50mm, 18G). The remaining hippocam-
pal parts were pulled off the cortex using a surgical scoop and split into CA1 and CA3. All steps
starting from the dissected hemispheres were done in ice cold PBS using a stereoscope.
3.1.3 Intracardial perfusion
Animals were anesthetized with 30µl/g avertin and fixed by pinning their limbs once they did
not respond to external stimuli anymore. The abdominal cavity was opened with a transversal
cut following a careful medial cut to the throat without damaging the rips. The liver was gently
pushed aside before removing the thoracic diaphragm. Afterwards, the rips were disjointed
laterally without penetrating the lungs.
The heart was freed from the pericardium, a butterfly cannula (Venofix A G21, B.Braun; Melsun-
gen, Germany) connected to a perfusion pumpwas inserted into the left ventricle and its position
was fixed. A precise cut into the right atrium was done to open the circuitry system which was
immediately rinsed with 5ml/min PBS afterwards. Once the circuitry system was cleared from
blood, the tissue was fixated using a total volume of 25ml ice cold fixation buffer (PBS containing
4% PFA).
The brain was carefully dissected as previously described (see section 3.1.2, p.31) and incubated
in fixation buffer for 6 hours. Afterwards it was transferred to 30% sucrose in water and incu-
bated for one day before it was dried, sealed in aluminum foil and frozen in liquid nitrogen.
The used anesthetic Avertin was produced by slowly adding 71ml distilled water to a mixture of
1g 2,2,2-tribromoethanol and 1ml 98% isoamylalcohol.
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3.2 Molecular analysis
3.2.1 Immunohistochemistry
For immunohistochemistry, mouse brains were cut into slices using a cryostat (Leica; Wetzlar,
Germany) set to -20oC. Brains were allowed to acclimate for at least 25min before sectioning and
fixation. For hippocampal slices, brainswere sectioned by cutting coronally≈ 0.5mm and 3.3mm
posterior to the Bregma. Sections were placed on a specimen stage covered with Jung tissue
freezing medium (Leica; Wetzlar, Germany) with the posterior plane facing down. They were
then sealed with the freezing medium. After letting themedium dry for 20min, the sections were
cut into 40µm thick slices which were transferred to 24well plates. Each well was previously
filled with 500µl PBS containing Penicillin and Streptomycin. Up to 3 slices were stored in a
single well.
Table 3.2 – Primary (top) and secondary (bottom) antibodies for immunohistochemistry
Target protein Host species Concentration vendor & product ID
NeuN guinea pig 1:1000 Synaptic Systems (Göttingen, Germany) - 266-004
GFAP rabbit 1:1000 Abcam (Cambridge, UK) ab7260
IBA1 rabbit 1:1000 Wako Chemicals (Neuss, Germany) 019-19741
human Aβ rabbit 1:1000 Tecan (Männedorf, Switzerland) JP18584
Target protein Dye Host species Concentration vendor & product ID
rabbit IgG AlexaFluor 488 goat 1:1000 Life technologies (Carlsbad, USA)
A11034
guinea pig IgG AlexaFluor 633 goat 1:1000 Life technologies (Carlsbad, USA)
A21105
Brain slices of the same anteroposterior region were selected for each sample and transferred
to a fresh 24 well plate. The slices were incubated twice in PBS containing 0.2% Triton-X to per-
meabilize cell membranes. Samples were blocked afterwards with 5% normal goat serum in
PBS containing 0.3% Triton-X for 1.5hr. The blocking medium was removed and primary anti-
bodies dissolved in 300µl PBS containing 1% normal goat serum and 0.3% Triton-X were added
and incubated at 4oC over night (see table 3.2 top panel). Next, samples were washed thrice for
10 minutes with PBS containing 1% normal goat serum. Afterwards, secondary antibodies were
Michael Gertig 33
3. MATERIALS AND METHODS 3.2. MOLECULAR ANALYSIS
added dissolved in 300µl PBS containing 1% normal goat serum and 0.3% Triton-X and incubated
for 2hr (see table 3.2 bottom panel, p.33). Samples were washed twice with PBS for 5min before
incubating with DAPI (6335.1 from Carl Roth GmbH + Co. KG; Karlsruhe, Germany) (1:10,000) in
PBS for 20min. The samples were finally washed once more with PBS for 5min and mounted on
objective slides using mowiol (Sigma Aldrich; St. Louis, USA). Mounted slides were dried briefly
at 37oC for 20min or over night at 4oC.
3.2.2 Confocal imaging
Confocal imaging was done with a ZEISS LSM 710 (Carl Zeiss AG; Oberkochen, Germany)
equipped with a 20x objective. Images were acquired using the ZEN lite software from ZEISS
with a resolution of 2048x2048 pixel at 1.58µs/pixel, bit depth of 12 Bit and 8 times line averag-
ing. Laser and software settings for image acquisitionwere set up once prior to image acquisition
and remained unchanged during the experiment.
3.2.3 RNA isolation
RNA isolation was performed in a sterile fume hood and all technical equipment used was previ-
ously washed with 70% ethanol and RNAseZap to avoid contamination and degradation of RNA.
Brain samples were kept on dry ice until they were processed and all steps were performed on
ice unless otherwise stated to reduce degradation. The RNA isolation protocol was adapted from
the TRIzol reagent protocol from Thermo Fisher Scientific (Waltham, USA).
Each sample was supplied with 500µl TRIzol-reagent and 10 ceramic beads before homogenizing
in an Omni Bead-Ruptor 24 (Omni International; Kennesaw, USA) for 10s at a relative speed of
2.6. Afterwards, the samples were incubated at RT for 5 minutes to ensure a proper lysis of the
tissue. 100µl chloroformwas added, samplesweremixedmanually for 15 seconds and incubated
for another 5 minutes at RT. After centrifuging at 12,000g for 15 minutes at 4oC, the transparent
upper phase was transferred to a fresh tube. 250µl isopropanol and 1µl GlycoBlue (Thermo
Fisher Scientific; Waltham, USA) were added to each sample before they were incubated at -20oC
over night to precipitate the RNA.
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Then, the samples were centrifuged at 12,000g for 30 minutes at 4oC and the supernatant was
discarded carefully. For washing, the RNA pellets were mixed with 300µl 75% ethanol, vortexed
and centrifuged at 12,000g for 5 minutes at 4oC before removing the supernatant. This washing
step was repeated once. Before redissolving the RNA, the tubes were briefly spinned and freed
from remaining liquid. Samples were air-dried for 2 minutes to clean the RNA from ethanol.
Finally, RNA pellets were redissolved in sequencing graded water (W4502 from Sigma Aldrich;
St. Louis, USA) and incubated for 10 minutes at 42oC before proceeding with DNAse treatment.
3.2.3.1 DNAse treatment
To ensure a high quality of RNA, samples were treated with DNAse I (EN0525, from Thermo
Fisher Scientific; Waltham, USA) to remove any contamination with DNA. Therefore, samples
were mixed with reaction solution prepared according to the DNAse I standard protocol from
Thermo Fisher Scientific (Waltham, USA), described in table 3.3. After incubating at 37oC for
20 minutes, 150µl sequencing graded water was added to each sample and phenol-chloroform
extraction was performed.
Table 3.3 – DNAse I reaction solution.
Component Volume
10x Incubation Buffer 5µl
DNAse I (10U/µl) 1µl
RNAse OUT (40U/µl) 0.5µl
RNA in sequencing graded H2O x µl
Sequencing graded H2O 43.5-x µl
3.2.3.2 Phenol-chloroform extraction
To retrieve the RNA from the DNAse reaction solution, a phenol-chloroformextraction was done.
Each sample was mixed with 200µl phenol/chloroform/isoamyl alcohol (25:24:1) and centrifuged
at 13,000g for 2 minutes at 4oC. The aqueous phase was transferred to a fresh tube and mixed
with 1µl GlycoBlue (Thermo Fisher Scientific; Waltham, USA), 20µl 3M sodium-acetate (pH 4.8),
and 200µl isopropanol. Samples were incubated over night to precipitate the RNA and processed
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further as previously described (see section 3.2.3, p.34). RNA content was quantified using a
Nanodrop 2000 (Thermo Fisher Scientific; Waltham, USA) and purity was validated using an
Agilent 2100 Bioanalyzer (Agilent Technologies; Santa Clara, USA). Samples with a RNA integrity
number below 8.0 were re-purified as described.
3.2.4 cDNA synthesis
To quantify specific transcripts via quantitative PCR, the RNA first has to be rewritten into cDNA
(complementary DNA). To do so, the Transcriptor First Strand cDNA Synthesis Kit (Roche; Basel,
Switzerland) was used following the standard protocol. Samples and reagents were kept on ice
during the whole procedure unless otherwise stated.
An equal amount of RNA templates was mixed with primers and RNAse-free water according
to table 3.4 (top left panel) and denatured by incubating at 65oC for 10 minutes in a PCR cycler.
Afterwards, the reaction mixture was set up according to table 3.4 (bottom left panel), added to
each template-primer mix and incubated as described below (see table 3.4 right panel) in a PCR
cycler.
Table 3.4 – Standard protocol for Transcriptor First Strand cDNA Synthesis
Component Volume
Random hexamer primer (0.6mM) 2µl
RNA template (500ng) x µl
RNAse-free H2O 11-x µl
Component Volume
5x Reaction buffer 4µl
RNAse Inhibitor (40U/µl) 0.5µl
dNTP Mix (10mM each) 2µl







Upper left: template primer mix. Bottom Left: cDNA synthesis reaction solution. Right: cDNA synthesis
reaction protocol.
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3.2.5 Quantitative real time PCR
Quantitative real time PCR (qPCR) was used to quantify specific mRNA levels. Primers for qPCR
were designed using the ”UPL Assay Design Center” (http://www.universalprobelibrary.com)
from Roche and ordered from Sigma Aldrich (St. Louis, USA). Samples were mixed with Primers,
LightCycler480 MasterMix and a universal probe library and run in a LightCycler 480 (Roche;
Basel, Switzerland) as described in table 3.5.
Table 3.5 – Protocol for qPCR of mRNA samples with LightCycler 480
Component Volume
PCR-graded H2O 4.05µl
Primer Mix (10mM each) 0.3µl
LightCycler480 Master Mix 7.50µl
Universial probe library 0.15µl









Left: qPCR reaction solution. Right: Light cycler program.
3.2.6 RNA sequencing
Messenger RNA from the ACC, CA1 and DG of 1.5, 4 and 8months old APP/PS1 wildtype and trans-
genic mice (n=6) was sequenced for genomewide gene expression analysis using a HighSeq 2000
sequencing system (Illumina; San Diego, USA). Paired-end RNA libraries were prepared from the
CA1 and single-end libraries from ACC and DG using the TruSeq RNA Library Preparation Kit
v2 and subsequently the TruSeq PE Cluster Kit v3-cBot-HS or TruSeq SR Cluster Kit v3-cBot-HS
respectively following the standard protocols from Illumina. Quality of RNA libraries was vali-
dated using a Nanodrop 8000 (Thermo Fisher Scientific; Waltham, USA), Qubit 2.0 fluorometer
(Life technologies; Carlsbad, USA) and RNA 6000 Nano Kit on a Agilent 2100 Bioanalyzer (Agilent
Technologies; Santa Clara, USA).
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3.2.7 Fluorescence-activated cell sorting (FACS) of nuclei
To perform celltype-specific Chromatin immunoprecipitation (ChIP) and methylated DNA im-
munoprecipitation, nuclei from the ACC, CA1 and DG of 1.5, 4 and 8months old APP/PS1 wildtype
and transgenic mice were isolated and sorted using fluorescence-activated cell sorting (FACS) as
previously described (Bonn et al., 2012). Samples from 3 animals (6 for 1.5 months old mice) per
group were pooled to retrieve a feasible amount of chromatin.
The pooled tissue was homogenized in 100µl low sucrose buffer using motorized micro-pestles.
The pestle was washed in 400µl of the same buffer which was then added to the homogenate. For
cross-linking, a final concentration of 1% formaldehyde was added and incubated for 5min at RT
on a rotation wheel. The sample was quenched by adding 51.4µl 1.25M glycine for another 5min
at RT. 500µl low sucrose buffer was added. The samples were washed by centrifuging at 2000g
for 3min at 4oC and the resulting supernatant was removed carefully. The pellet was dissolved
in 1ml low sucrose buffer and homogenized a second time using a T10 basic Ultra-Turrax (IKA;
Staufen im Breisgau, Germany) for 30s at a relative force of 3.5.
Nuclei were isolated using a sucrose gradient. The homogenate was carefully layered onto 6ml
high sucrose buffer in oak ridge tubes and centrifuged at 3200g for 10min at 4oC. The buffer
was carefully removed without disturbing the nuclei pellet. The pellet was resuspended in 1ml
PBTB and washed by centrifuging at 2000g to remove any residual sucrose buffer. The oak ridge
tube was rinsed with 750µl PBTB to retrieve any remaining nuclei. The nuclei were collected by
centrifuging at 4000g for 5min at 4oC and stained by resuspending the pellet in 300µl PBTB con-
taining 3% normal goat serum and conjugated anti-NeuN antibody frommouse (1:500) (MAB377
from Merck Millipore; Darmstadt, Germany) for 30min at 4oC on a rotation wheel. The staining
was stopped by washing the nuclei four times as described above.
Before loading a sample into the FACS machine, the samples were pathed through a 26G nee-
dle and syringe to detach nuclei and avoid nuclei cluster. Sorting was done in a FACSARIA III
(BD Biosciences; Franklin Lakes, USA) and sorted cells were collected in 1.5ml Eppendorf tubes.
Tubes for nuclei collection were coated with bovine serum albumin by rinsing them with 300µl
PBTB for 1 hour at RT prior to sorting to prevent the nuclei from attaching to the tube’s wall.
Sorted nuclei were pelleted by centrifugation at 20,000g for 5min at 4oC, redissolved in 100µl
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RIPA buffer and transferred to 600µl Bioruptor tubes.
3.2.8 Chromatin preparation from sorted nuclei
Sorted nuclei in RIPA buffer were sheared 4 times for 5 cycles (30s on/off) in a Bioruptor Plus
(Diagenode; Liège, Belgium)with high power. After each shearing cycle, the samples were briefly
spun down. Afterwards, the samples were centrifuged at 16,000g for 5min at 4oC to separate the
sheared chromatin containing supernatant from residual nuclear compartments. All following
steps were conducted in DNA LoBind tubes (Eppendorf; Hamburg, Germany).
A proper shearing of chromatin was validated for every single sample by isolating the DNA.
Therefore, 2µl of each sample was mixed with 8µl elution buffer containing 0.1µg/µl RNAse A
and incubated for 45min at 37oC to reduce the concentration of SDS, elute the DNA and digest
residual RNA. 10µl Wienmann shearing buffer containing 2µg/µl proteinase K was added and
samples were incubated over night at 65oC in a thermoshaker at 800rpm. 20µl SureClean along
with 3µl LPA as a co-precipitant were added to precipitate the DNA. Samples were rigorously
vortexed and centrifuged at 15,000g for 20min after incubating for 10min at RT. The DNA pellets
were washed twice with 200µl 70% ethanol by centrifuging at 15,000g for 5min. Afterwards,
the ethanol was removed and possible remainings were allowed to evaporate. The pellets were
dissolved in 15µl elution buffer.
DNA content was measured with a Qubit 2.0 fluorometer (Life technologies; Carlsbad, USA) and
fragmentation of DNA was quantified using a DNA High Sensitivity Kit on a Agilent 2100 Bioan-
alyzer (Agilent Technologies; Santa Clara, USA). The desired fragmentation reached from 100-
500bp with an average fragment size of 300bp. In case the DNA fragments did exceed the given
sizes, respective samples were re-sheared and fragmentation as well as DNA content were vali-
dated again.
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3.2.9 Chromatin immunoprecipitation (ChIP)
ChIP sequencing was performed to investigate potential changes of H3K4 methylation state.
Chromatin from neuronal and non-neuronal nuclei retrieved from the ACC and DG of 1.5, 4 and
8 months old APP/PS1 wiltype and transgenic mice (n=2 each) was immunoprecipitated using
an H3K4me3 antibody (ab8580 from Abcam; Cambridge, UK). Each processed sample equaled a
pool of at least 3 animals. All steps were done using DNA LoBind tubes (Eppendorf; Hamburg,
Germany) to reduce loss of DNA to a minimum.
From each sample, 250µg DNA were diluted 1:10 in IP buffer without SDS to reduce the con-
centration of SDS and, thus, ensure a proper antibody-binding. Magnetic beads were blocked
to reduce unspecific binding. Therefore, 50µl Dynabeads Protein A (Life technologies; Carls-
bad, USA) per ChIP sample were washed once with IP buffer and afterwards incubated in IP
buffer containing 0.5% bovine serum albumine for 2hr. The beads were washed twice with 1ml
IP buffer and resuspended in 50µl IP buffer per ChIP sample. Diluted samples were then pre-
cleared by adding 30µl blocked magnetic beads for 1hr at 4oC to reduce unspecific precipitation
of chromatin. Samples were cleaned from beads and 2% of each sample was taken as an input.
The H3K4me3 antibody was added to each sample and incubated over night at 4oC on a rota-
tion wheel. 20µl of blocked magnetic beads were added and the samples were incubated for
another 1.5hr at 4oC. Samples were washed twice with a sequence of three different buffers (2x
IP buffer, 3x LiCl buffer, 2x IP buffer, 2x TE buffer) to isolate specifically precipitated chromatin.
Afterwards, the DNA of ChIPed and input samples was isolated as described in section 3.2.8 (see
p.39).
3.2.10 Library preparation for Multiplex Illumina ChIP-sequencing
DNA libraries for ChIP samples were generated using the NEBNext Ultra DNA Library Prep Kit for
Illumina, NEBNext Multiplex Oilgos for Illumina (NewEngland Biolabs; Ipswich, USA) and AM-
Pure XP beads (Beckman Coulter; Breas, USA) for end repair and adaptor ligation, amplification
and clean-up respectively.
As fragmentation of DNA might lead to blunt ends or 3’- and 5’-overhangs of different size, both
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ends of the fragments need to be converted into blunt ends and tagged by a single adenine nu-
cleotide to avoid fragment-oligomerization. For end repair, DNA samples were mixed with 1.5µl
End Prep Enzyme Mix and 1.5µl End Repair Reaction Buffer following incubation for 30min at
20oC and 65oC respectively. Adapter ligation was done by adding 7.5µl Blunt/TA Ligase Master
Mix, 2µl NEBNext Adapter and 0.5µl NEBNext Ligation Enhancer to each sample followed by
incubation for 30min at 20oC. Adapters are specific sequences for 5’ and 3’ ends organized in a
stem-loop and separated by a central uracil. This structure forces adapters to bind a single DNA
fragment exclusively. Uracil is afterwards excised by adding 1.5µl USER enzyme to each sample
and incubating for 30min at 37oC.
DNA fragments are then isolated using AMPure XP beads which selectively bind to DNA with a
preference for fragments longer than 100bp and, thus, allow size selection of fragments. 26.5µl
AMPure XP beads were added to a sample and incubated for 5min at RT before removing the
supernatant. Beads were washed twice with 200µl 80% ethanol and air-dried for 2minutes. DNA
was eluted from the beads by adding 17µl elution buffer, vortexing and incubating for 2min at
RT.
The number of amplification cycles needed for each single ChIP samplewas determined via qPCR
according to the protocol in table 3.6 (see p.42). The ct value was computed using the LightCycler
480 Software (release 1.5.0, Roche; Basel, Switzerland). Samples were mixed with 0.6µl NEBNext
Index Primer, 0.6µl NEBNext Universal Primer and 15µl NEBNext Q5 Hot Start HiFi PCR Master
Mix. For multiplex sequencing, samples that were run on the same lane need to be amplified
with different indices. Six samples were run per lane, thus, index primes 2, 4, 5, 6, 7 and 12
were used for amplification as those share the least similarity among each other. Samples were
amplified for ct-2 PCR cycles according to table 3.6 (see p.42).
The DNA was isolated as described and transferred to a DNA LoBind tube (Eppendorf; Hamburg,
Germany). DNA content was measured with Qubit 2.0 fluorometer (Life technologies; Carlsbad,
USA) and quality control was done using a DNA High Sensitivity Kit on a Agilent 2100 Biooana-
lyzer (Agilent Technologies; Santa Clara, USA). Amplification of DNA was repeated with the same
Index primers for low concentrated samples (¡1.5nmol) and clean-up of DNA was repeated in
case of residual adapters and/or primers.
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Table 3.6 – Protocol for qPCR of ChIP samples using NEBNext Q5 polymerase
Component Volume
NEBNext Q5 Hot Start HiFi PCR
Master Mix
2.5µl
NEBNext Index Primer 0.1µl
NEBNext Universal Primer 0.1µl











Left: qPCR reaction solution. Right: Light cycler program.
3.2.11 Methylated DNA immunoprecipitation (MeDIP)
Methylated DNA immunoprecipitation (MeDIP) is a technique to unravel potential changes in
DNA methylation and was performed as described in (Halder et al., 2015). Sheared chromatin
can serve as starting material for MeDIP, however, one first has to isolate the DNA as described
above (see section 3.2.8, p.39ff.). 200ng of sheared chromatin were used for each sample and
DNA pellets were resuspended in 55µl elution buffer. Then, DNA fragments underwent end
repair and adapter ligation as described in section 3.2.10 (see p.40) using the NEBNext Ultra
DNA Library Prep Kit (NewEngland Biolabs; Ipswich, USA). 41.25µl AMPure XP beads (Beckman
Coulter; Breas, USA) were added to each sample to clean the ligated DNA from adapters and to
perform size selection. After vortexing, the samples were incubated for 7min at RT and placed
on a magnetic rack afterwards for 5 minutes. The clear supernatant was removed without dis-
turbing the magnetic beads, bound to the DNA. Beads were washed and incubated with 200µl
80% ethanol for 30s at RT twice. The ethanol was carefully removed, and the beads were dried
for 10min before eluting the DNA into 22µl elution buffer. The clear supernatant was separated
from the beads and againmixed with 20µl AMPure XP beads. DNAwas isolated once again. After
a final resuspension of beads in 27µl elution buffer, samples were incubated for 2 minutes at RT
and the DNA containing clear buffer was extracted from the beads.
0.1µg of size selected DNAwere mixed with 2µl blocking DNA and 38µl TE buffer. These blocking
DNA resembles 20bp sequences complementary to the used adaptors. Samples were denatured
at 99oC for 10min and immediately placed on ice for another 10min. TheDNAwasmixedwith 5µl
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of 10x IP buffer, 1µl of 1:5 diluted 5mc antibody (BI-MECY-0500 from Eurogentec; Liège, Belgium)
and 2µl Dynabeads Protein G (Life technologies; Carlsbad, USA) and incubated for 6hr at 4oC on
a rotation wheel. Afterwards, the beads were isolated and washed thrice with 700µl IP buffer
by incubating the tubes for 10min at 4oC on a rotation wheel. The beads were isolated again,
mixed with 30µl Proteinase K digestion buffer containing 70µg proteinase K. DNA was isolated
as described in section 3.2.8 (see p.39).
The number of cycles needed for amplification of DNA were estimated by qPCR using the TruSeq
PCR Primer Cocktail (Illumina; San Diego, USA) and Phusion HF PCR Master Mix (NewEngland
Biolabs; Ipswich, USA) according to table 3.7. Samples were amplified for ct-2 cycles using 9µl
DNAmixed with 0.5µl TruSeq PCR Primer cocktail and 9.5µl Phusion HF PCRMaster Mix and the
same PCR protocol as used for qPCR. Afterwards, the DNA was isolated as described above (see
section 3.2.10, p.40).
Table 3.7 – Protocol for qPCR of MeDIP samples using Phusion HF polymerase
Component Volume
PCR-graded H2O 3.4µl
TruSeq PCR Primer Cocktail
(25µM)
0.4µl
Phusion HF PCR Master Mix (2x) 5.0µl













Left: qPCR reaction solution. Right: Light cycler program.
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3.3 NGS data analysis
Raw data from Next-Generation Sequencing were quality controlled using FastQC (Andrews,
2010). Handling of raw data including generation of BAM files and RNAseq count files as well as
differential expression analysis were done in collaboration with the lab of Stefan Bonn (German
Center for Neurodegenerative Diseases; Göttingen, Germany).
3.3.1 Differential gene expression
Alignment of RNAseq data was done using the Musmusculusmm10 reference genome and STAR
aligner (Dobin et al., 2013) for generating BAM files. RNA count files were created with Fea-
turesCount (Liao et al., 2013) and differential expression analysis was done using DESeq2 (Love
et al., 2014).
Genes with an adjusted p-value ≤ 0.05 were considered as significantly differentially expressed.
Additionally, a cutoff for log2fold-changes of ±0.5 was applied on gene expression data unless
otherwise stated and only those transcripts that code for actual proteins were considered.
Distance heatmaps showing the euclidean distance between samples and plots for principle
compnent analysis were generated using the R packages DESeq, DESeq2, gplots and RColor-
Brewer (Anders and Huber, 2010; Love et al., 2014; Neuwirth, 2014; R Core Team, 2015; Warnes
et al., 2015) to visualize clustering of samples (see code 3.1, p.51). Heatmaps for fold changes
of significantly differentially expressed genes were generated using the R packages Biobase and
DESeq2 (Huber et al., 2015; Love et al., 2014) along with the previously used packges gplots and
RColorBrewer (see code 3.2, p.52).
To visualize a longitudinal pattern of differential gene expression, all genes which were differen-
tially expressed in at least one of the respective comparisons were clustered using the Partition
AroundMedoids technique and plotted in a heatmap using R (see code 3.4, p.52) (Maechler et al.,
2015). The number of clusters was set to 7 to enable clustering of all possible intersects of genes.
Functional pathway analysis of differential gene expression data was done with the commercial,
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Java based tool Ingenuity Pathway Analysis (http://www.ingenuity.com, Qiagen; Venlo, Nether-
lands) and DAVID Bioinformatics Resources (https://david.ncifcrf.gov) regarding KEGG (Kyoto
Enzyclopedia of Genes and Genomes) pathways. Only the top 10 ”Ingenuity pathways” of one
comparison were plotted for visual clarity purposes. P-values were computed using fisher’s ex-
act t-test. Heatmaps for functional pathways were generated using the R-packages gplots and
RColorBrewer (Neuwirth, 2014; R Core Team, 2015; Warnes et al., 2015).
3.3.2 Transcription factor binding site prediction
To identify potential core regulators of differential gene expression, Pscan (vers.1.3) was used
to screen for overrepresented TFs (Zambelli et al., 2009). All differentially expressed genes (see
section 3.3.1, p.44) of a comparison were taken as input and Pscan was run with the following
preferences: Mus musculus (organism), -200bp to +50bp (region around TSS), Jaspar 2014 (de-
scriptor). EnsemblIDs from the differential expression tables were converted to RefSeqIDs using
BioMart (http://www.ensembl.org/biomart/) and R (R Core Team, 2015).
Adjusted p-values for the whole set of TFs were computed with R (see code 3.3, p.52). Only those
TFs with an adjusted p-value of 0.05 or less and a motif length of at least 8bp were used for
further analysis. Differentially expressed genes with a score of 0.95 or higher for a respective TF
were considered as likely target genes. The top 20 motifs were plotted for visual clarity.
3.3.3 Differential splicing
Raw count files from RNAseq were analyzed for differential exon usage using the R-package
”DEXSeq” (see code 3.6, p.53) (Anders et al., 2012; R Core Team, 2015). Exons with an adjusted
p-value of 0.1 and a log2foldchange of ±0.15 were considered as significantly differentially ex-
pressed. Functional (KEGG-)pathway analysis of genes containing significantly differentially
expressed exons was done using DAVID Bioinformatics Resources (https://david.ncifcrf.gov)
(Huang et al., 2008, 2009). Correlation analysis between gene expression and alternative splicing
was done using R (see code 3.5, p.52).
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3.3.4 MeDIP- and ChIPseq data analysis
Differential DNA methylation was analyzed using the R package MEDIPS (Lienhard et al., 2014)
as described in source code 3.7 (see p.54). MACS was used for calling significant peaks of ChIP-
sequencing (Zhang et al., 2008) and differential binding was analyzed using the R package Diff-
Bind with default parameters (Stark and Brown, 2011). ChIPSeeker was used for annotating
identified peaks to the reference genome Mus Musculus mm10 (Carlson and Maintainer, 2015;
Yu et al., 2015).
NGS plots showing the average DNA- and H3K4-methylation along gene bodies of low, mid and
high expressed genes and the NGS pie charts showing the relative distribution of peaks within
the genome were generated with the standalone software ngs.plot (Shen et al., 2014). Low and
High expressed genes resemble the bottom and top 0.1 quantiles of normalized read counts re-
spectively. Mid expressed genes resemble quantile 0.25 to 0.35. Functional pathway analysis
was done using DAVID Bioinformatics Resources (https://david.ncifcrf.gov) (Huang et al., 2008,
2009). Correlation studies were done with R as described (see code 3.5, p.52).
Identification of long distance interactions was done based on published Hi-C data from the
mouse cortex (Dixon et al., 2012). Hot-spots of gene expression were defined as long distance
interaction domains in which at least 20% of the included genes are differentially expressed.
3.3.5 Drug screening
The Java based and freely available Drug Pair Seeker (Zhong et al., 2013) was used for a direct
approach to uncover potential therapeutic drugs based on the set of differentially expressed
genes. The Drug Pair Seeker compares an input set of deregulated genes with published data
from the CMAP database (Lamb et al., 2006) where approximately 1300 drugs were tested on
human cancer cell-lines. The top 10 pairs of drugs for each comparison (wildtype vs transgenic;
aging in transgenic mice) and brain region were collected and individually evaluated for their
bioavaiablity, mechanism of action, potential side effects and published data considering the
drugs.
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3.4 Behavioral experiments
3.4.1 Drug administration
Four months old male and female APP/PS1 transgenic mice were treated with either vehicle
(n♂=5, n♀=5), 125mg/l SAHA (n♂=6, n♀=5), 50mg/l memantine (n♂=7, n♀=3) (both from Cayman
Chemicals; Ann Arbor, USA) or a combination of both medications (n♂=8, n♀=5) in potable wa-
ter containing 18g/l (2-Hydroxypropyl)-β-cyclodextrin (Sigma Aldrich; St. Louis, USA). To find a
potential beneficial effect of the two drugs when given in combination, dosages were arbitrary
chosen where the individual drugs were not suspected to cause their full therapeutic potential
previously described (Barnes et al., 1996; Benito et al., 2015; Guan et al., 2009; Minkeviciene et al.,
2004). Assuming an average body weight of 30g and drinking volume of 3ml per day, the given
concentrations resemble 12.5mg/kg SAHA and 5mg/kg memantine per day respectively.
The cyclodextrin was added to increase solubility and bioavailability as well as to cover any
potential flavor caused by the respective therapeutic drugs (Jambhekar and Breen, 2015). Treat-
ment of mice started four weeks before animal experiments and lasted until the last day of be-
havioral experiments.
3.4.2 Open field
Mice were tested in the open field test to study explorative behavior and locomotion (n=9 for
vehicle, memantine or SAHA, n=13 for combinatory treatment). A mouse was placed into the
center of an open quadratic arena (50x50cm, 20cm high walls) and recorded for 5 minutes using
the VideoMot2 system (TSE Systems; Bad Homburg, Germany). The overall traveled distance
and the proportion of time the mice spent within the arena’s center (more than 10cm distance
to the walls) are conventionally quantified for indicating locomotive and explorative behavior
respectively (Carola et al., 2002).
Michael Gertig 47
3. MATERIALS AND METHODS 3.4. BEHAVIORAL EXPERIMENTS
3.4.3 Elevated plus maze
For analyzing basal anxiety levels, mice were tested in the elevated plus maze (n=9 for vehicle,
memantine or SAHA, n=13 for combinatory treatment). Themaze consisted of two open and two
enclosed arms (l x w: 30x9cm, 20cm high walls) without ceiling which were connected by a 9cm2
large center area. It was placed on a metal stand at a height of 75cm. A mouse was placed into
the center of the maze and recorded for 5 minutes using the VideoMot2 tracking system. The
relative time a mouse spent in open and enclosed arms was quantified, whereby a pronounced
preference for enclosed arms indicated a higher basal anxiety (Carola et al., 2002).
3.4.4 Morris water maze
The morris water maze is a behavioral experiment to investigate spatial memory in mice (Mor-
ris, 1981). A mouse was placed into a round basin (1.2m in diameter) filled with opaque water,
unable to escape the basin by itself. A quadratic platform (10x10cm) was placed right under-
neath the water surface, thus hidden from the mice’s view. The basin was sectioned in 4 equal
quadrants, each with an optic cue attached to the basin’s wall. The platform was placed in the
center of one random section and remained in the same position for the entire experiment.
During the training days, a mouse was placed in each of the four quadrants once and was al-
lowed to explore the basin until finding the platform and remaining on it for 10 seconds. Mice
that did not find the platform within 60s were placed onto the platform afterwards to ensure
memory formation. Training was done for 10 consecutive days. One the sixth and eleventh day,
a probe test was performed. The platform was removed prior to the test and each mouse was
allowed to explore the basin for 1 minute starting at the quadrant opposite to the initial plat-
form’s position (n=9 for vehicle, memantine or SAHA, n=13 for combinatory treatment). Three
days after the second probe test, mice underwent a reversal learning test to investigate memory
plasticity (nvehicle=5, nSAHA=5, nMemantine=9, ncombi=9) (Vorhees and Williams, 2006). Therefore,
the platform was placed in the opposite quadrant of its initial position and mice were trained
for another three days as previously described. A final probe test was done at the fourth day of
reversal learning.
48 Michael Gertig
3.4. BEHAVIORAL EXPERIMENTS 3. MATERIALS AND METHODS
The latency to discover the platform during each learning trial was quantified to assess infor-
mation on spatial memory formation. The percentage of time spent in the target quadrant and
the number of visits to the initial platform’s position during the probe test were measured as
indicators for spatial memory retrieval.
3.4.5 Contextual fear conditioning
To analyze contextual fear memory, mice underwent Pavlovian contextual fear conditioning
using an automated fear conditioning setup for mice (Med Associates; St. Albans, USA). Similar
to previous studies, a mouse was placed into a conditioning chamber (30.5 x 24.1 x 21.0cm, l
x w x h) with controlled visual and auditory stimuli (Agis-Balboa et al., 2011). The floor of the
chamber was a metal grid used to transmit electric shocks to the test subjects.
For training, mice were allowed to explore the chamber for 3 minutes until they received a foot-
shock (0.7mA) for 2 seconds. 24 hours later, they were reintroduced to the very same context
and their locomotive behavior was assessed. The relative amount of freezing behavior indicated
contextual fear memory, whereby freezing in mice describes the absent of significant motion.
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3.5 Statistics and graphical output
Simple calculations and table handlingwas donewithMicrosoft Excel 2010 (Microsoft; Redmond,
USA). Statistical analyses, data mining and batch processing of data was done in R (R Core Team,
2015). Correlation analyses and linear regressions were generated as described in code 3.5 (see
p.52). A list of all used R packages is displayed in table 3.8 (see p.51). Statistical evaluation of
behavioral experiments was done in Prism 6 (GraphPad Software; La Jolla, USA). Significance
for whole data sets were tested with one-way and two-way ANOVA. Tukey’s multiple comparison
test was used for one-to-one comparisons within groups. A potential significant difference from
chance level in the Morris Water Maze was tested via two-tailed t-test. Potential effects of gender
or batch affiliation onmice behavior was tested by two-way ANOVA. Behavioral differences with
a p-value ≤ 0.05 were considered as significant and were highlighted in plots by an asterisk.
Adobe Illustrator CS5.1 (Adobe Systems Inc.; San José, USA) was used to generate Venn diagrams
and pie charts, and to reformat graphical outputs fromGraphPad Prism and R. In full compliance
with the general terms on good scientific practice, adjustments on data plots were exclusively
made on fonts, colors, and global scaling without affecting the actual data.
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3.6 R source codes
Table 3.8 – List of R packages
Package citation
Biobase Huber et al. (2015)
BSgenome Pages (2016)
BSgenome.Mmusculus.UCSC.mm10 The-Bioconductor-Dev-Team
ChIPseeker Yu et al. (2015)
cluster Maechler et al. (2015)
DESeq Anders and Huber (2010)
DESeq2 Love et al. (2014)
DEXSeq Anders et al. (2012)
DiffBind Stark and Brown (2011)
GenomicFeatures Lawrence et al. (2013a)
GenomicRanges Lawrence et al. (2013b)
gplots Warnes et al. (2015)




FeaturesCount Liao et al. (2013)
TxDb.Mmusculus.UCSC.mm10.ensGene Carlson and Maintainer (2015)






plot_distance_heatmap = function(dataset, control=’control’,
treated=’treated’, breaks_custom=breaks)
{
dataSet <- read.delim(as.character(dataset), sep=’\t’, header=TRUE, row.names=1)
condition <- c(rep(as.character(control), length(grep(as.character(control),
colnames(dataSet)))), rep(as.character(treated), length(grep(as.character(treated),
colnames(dataSet)))))
cds <- newCountDataSet(dataSet, condition)
sizeFac <- estimateSizeFactors(cds)
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rownames(mat) = colnames(mat) = colnames(dataSet)
















#input = table of normalized read counts for all significant genes
#normal = identifier for columns which serve as control group
color_scheme <- colorRampPalette(brewer.pal(10, "RdBu"))(200)
carpet <- heatmap.2(data.matrix(input), dendrogram=’column’, col=rev(color_scheme),
trace=’none’, density.info=’none’, scale=’row’, labRow=’’)
sorted <- names(sort(colMeans(carpet$carpet[grep(normal, colnames(input)),])))
heatmap.2(data.matrix(input[sorted,]), Rowv=F, col=rev(color_scheme), trace=’none’,
density.info=’none’, scale=’row’, labRow=’’, dendrogram=’column’)
Code 3.3 – Computing adjusted p-values in R
padj <- p.adjust(pvalue, "fdr", length(pvalue))






#geneset = table of genes and corresponding log2FoldChange of each analysed comparison
pclust <- pam(geneset, k=7)
#Generate graphical output
breaks <- c(seq(min(pclust), -0.5-0.0001, length.out=80), seq(-0.5, 0.5+0.0001,
length.out=41), seq(0.5, max[pclust], length.out=80))
heatmap.2(pclust, cellnote=round(pclust, 3), col=rev(colorRampPalette(brewer.pal(9,
"RdBu"))(200)), breaks=breaks, Rowv=FALSE)
Code 3.5 – Correlation and linear regression in R
#input = dataframe of values of choice from a single comparison (i.e.
wildtype vs transgenic mice, or gene expression vs splicing).
plot(input$A, input$B)
abline(lm(input$A˜input$B))
r_square <- cor(input$A, input$B)ˆ2
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Code 3.6 – Differential Splicing analysis using DEXSeq in R
#Read-in library
library(DEXSeq)
#countFiles = list of countfiles to be analysed
#sampleTable = list of sample names and corresponding condition (i.e. 4mo transgenic ACC)
#flattenedFile = .gff file
#set number of CPU cores to work on
BPPARAM = MulticoreParam(workers = cores)
#execute DEXSeq
dxd = DEXSeqDataSetFromHTSeq(countFiles, sampleData=sampleTable, design= ˜ sample + exon +
condition:exon, flattenedfile=flattenedFile)
dxd = estimateSizeFactors(dxd)
dxd = estimateDispersions(dxd, BPPARAM=BPPARAM)
dxd = testForDEU(dxd, BPPARAM=BPPARAM)
dxd = estimateExonFoldChanges(dxd, fitExpToVar="condition", BPPARAM=BPPARAM)
dxr1 = DEXSeqResults(dxd)
#create output files
DEXSeqHTML(dxr1, file, FDR=0.1, color=c("#FF000080", "#0000FF80"), BPPARAM=BPPARAM )
write.csv(as.data.frame(dxr1), file)
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chr=c(paste("chr", 1:19, sep=""), "chrX", "chrY")
#parse all bam files related to control and test
controlFiles = .BAM-files for control samples
testFiles = .BAM-files for test samples
#Create control and test set
controlSet <- c()
for (k in 1:length(controlFiles))
{
controlSet=c(controlSet,MEDIPS.createSet(file=controlFiles[k], BSgenome=BSgenome,
extend=250, shift=0, uniq=1, window_size=700, chr.select=chr))
}
testSet <- c()
for (k in 1:length(testFiles))
{
testSet=c(testSet,MEDIPS.createSet(file=testFiles[k], BSgenome=BSgenome, extend=250,
shift=0, uniq=1, window_size=700, chr.select=chr))
}
CS = MEDIPS.couplingVector(pattern = "CG", refObj = controlSet[[1]])
mr.edgeR = MEDIPS.meth(MSet2 = controlSet, MSet1 = testSet, ISet1 = NULL, ISet2 = NULL,
CSet = CS, p.adj = "BH", diff.method = "edgeR", MeDIP = T, CNV = F, type = "rpkm",
minRowSum = mincov)
sigdata = MEDIPS.selectSig(results=mr.edgeR, p.value=pval, adj=T, ratio=NULL, bg.counts=NULL,
CNV=F)
write.table(sigdata, "temp.txt", sep="\t", quote=F, col.names=T, row.names=F)
peakAnno=annotatePeak("temp.txt", tssRegion=c(-5000,0), TxDb=txdb,level="transcript",
assignGenomicAnnotation=TRUE, genomicAnnotationPriority=c("Promoter", "5UTR", "3UTR",




merged = MEDIPS.mergeFrames(frames=sigdata, distance=1)
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3.7 Buffers and solutions
Elution buffer (pH 8) 10mM Tris
High sucrose buffer (ph 8) 1M Sucrose, 3mM MgAc2, 50mM HEPES, 1mM
DTT
IP buffer (pH 8) 150mMNaCl, 50mM Tris, 20mM EDTA, 1% NP-40,
0.5% Sodium deoxycholate, 1% SDS
LiCl wash buffer (ph 8) 100mMTris, 500mMLiCl, 20mM EDTA, 1% NP-40,
1% Sodium deoxycholate
Low sucrose buffer (pH 8) 0.32M Sucrose, 5mM CaCl2, 5mM MgAc2, 50mM
HEPES, 0.1mM EDTA, 1mM DTT, 0.1% Triton-X
PBTB 1x PBS, 0.1% Tween, 50mg/ml BSA
RIPA buffer (pH 8) 140mM NaCl, 1mM EDTA, 10mM Tris, 1% Triton-
X, 1% SDS, 0.1% Sodium deoxycholate
TE buffer (pH 8) 10mM Tris, 1mM EDTA
Wienmann shearing buffer (pH 7.4) 10mM Tris, 20mM EDTA, 2% SDS
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4. Results
4.1 Transcriptional differences among brain regions
For studying the molecular processes underlying the age-related cognitive decline in APP/PS1
mice, I chose three different areas of the murine brain involved in memory functioning and
affected by amyloid depositions in AD patients. The ACC as a part of the frontal lobe is involved
in consolidation and retrieval of LTM, the two hippocampal sub-regions CA1 and DG in encoding
spatial and associative memory. To study longitudinal effects of the amyloid pathology on gene
expression and epigenetic modifications, I selected three age groups resembling a healthy (1.5
months; young), early (4 months; mid-aged) and late-state (8 months; old) of the disease based
on preliminary data regarding amyloidosis and mice behavior.
To highlight the importance of tissue-specific approaches, I analyzed interregional gene expres-
sion differences for the given brain areas. A useful statistical technique for clustering data is
the Principal component analysis (PCA). In this technique, an orthogonal transformation of each
variable of a dataset is made based on the actual values of this respective set of data (Jolliffe,
2002). Starting with a linear regression of the data that results in a maximal variance (PC1), an
orthogonal vector is computed which by itself again shows the highest variance possible (PC2).
By plotting principal component values (i.e. PC1 over PC2) for each sample, separate clusters can
be identified. PCA was done for all age groups and revealed a clear separation of samples from
the respective brain areas as it is exemplarily shown in figure 4.1A (see p.57) for young mice.
Figure 4.1B (see p.57) shows the relative euclidean distance among all samples where RNA was
sequenced for. The euclidean distance as a measure for similarity or dissimilarity of measure-
ments also enables clustering of samples. Three major clusters can be identified resembling the
given brain regions. Clusters for the ACC and CA1 are relatively consistent, while samples from
the DG seem to be more diverse. Two subclusters for the DG can be identified from the heatmap,
whereby the samples inside these clusters cannot be separated by either age or genotype. Clus-
ters resembling age groups or genotypes are in general overshadowed by the big dissimilarity of
samples from the distinct brain regions.
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Figure 4.1 – Transcriptional differences among brain regions
A) PCA plots for interregional comparisons of ACC vs CA1 (left), ACC vs DG (center), and CA1 vs DG (right).
Samples from different brain regions can clearly be separated by a straight line and thus belong to distinct
clusters.
B) Euclidean distance between all sequenced RNA samples and clustering of these. The color key is ranging
from 100% similarity (white) to dissimilarity (red) with increasing value (arbitrary unit). Three major clus-
ters can be identified, namely samples from the different brain regions: ACC, CA1 and DG. No clusters can
be observed resembling age groups or genotypes. A detailed listing of samples is shown in supplemental
figure 7.1 (see p.129).
C) Number of differentially expressed genes between the given brain regions of 1.5 months old wildtype
and transgenic mice. Up- and downregulation of genes is comparable in both genotypes.
The total number of significant genes differentially expressed among the brain regions ranges
from 3861 (ACC vs CA1) to 5430 (ACC vs DG) in 1.5 months old wildtype mice (see figure 4.1C).
Similar numbers of genes were observed in transgenic mice of the same age (ACC vs CA1: 3718;
ACC vs DG: 5574). Within the hippocampal sub-regions CA1 and DG, 4328 genes were differen-
tially expressed in young wildtype mice and 3920 in transgenic mice. Across all brain regions,
protein coding RNA from 15,234 genes was detected by Illumina sequencing. Thus, the differen-
tially expressed genes resemble approximately 25-35% of the whole transcriptome, emphasizing
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the difference between the tested brain areas. Functional pathways analysis was performed to
discover cellular functions enriched by the set of differentially expressed genes. Identified path-
ways mainly resemble neuronal signaling, i.e. ”Axon guidance” or ”Neuroactive ligand-receptor
interaction”, and functions involved in cell survival and regulation of gene expression, i.e. ”p53
signaling” or ”Wnt signaling pathway” (see table 7.1, p.130).
1.5 months 4 months 8 months





































































































































































Figure 4.2 – Interregional differences: Percentage of upregulated genes:
A) Normalized ratio of up- and downregulated gene expression among brain regions for both genotypes
and all given age groups. Values > 0 resemble upregulation and vice versa.
B) Venn diagrams showing interregional differentially expressed genes common and uncommon between
1.5, 4, and 8 months old wildtype (top) and APP/PS1 transgenic (bottom) mice. The majority of genes is
common between the age groups.
Transcriptional differences between brain regions remained relatively stable across all age
groups and genotypes (see figure 4.2A). Compared to the ACC, genes are in average higher ex-
pressed in the CA1 in all age groups. Up- and downregulation of gene expression in the DG is
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rather evenly distributed compared to the ACC or CA1. Figure 4.2B (see p.58) shows the number
of differentially expressed genes that are common or specific for the three age groups in each re-
spective interregional comparison and genotype. When comparing the ACC to the CA1, the vast
majority of genes is shared between all age groups. In contrast, comparisons of either the ACC or
the CA1 with the DG revealed quite a high number of differentially expressed genes specific for
a respective brain region in 8 months old mice. For instance, 2321 genes are exclusively differ-
entially expressed when comparing the ACC to the DG in 8 months old wildtype mice compared
to 3674 that are shared with other age groups in the same brain regions. Similar findings were
made for APP/PS1 transgenic mice.
4.2 Wildtype-like gene expression in young APP/PS1 mice
Preliminary data from our lab showed, that no differences in cognitive performance can be ob-
served in young APP/PS1 mice compared to wildtype littermates. Nevertheless, molecular pro-
cesses might already be affected by the transgene driving the age related cognitive decline in
those mice that can already be observed at an age of 4 months. I thus analyzed the gene ex-
pression profiles of the ACC, CA1, and DG from 1.5 months old APP/PS1 wildtype and transgenic
mice and performed a cluster analysis as previously described (see section 4.1, p.56ff.). Distance
heatmaps and PCA for all three brain regions of young wildtype and transgenic mice are shown
in figure 4.3 (see p.60). The distance heatmaps clearly show that no distinct separation can be
observed for either brain region. Samples fromwildtype and transgenic mice can neither be sep-
arated by a single straight line in the PCA plots for either region further indicating their relative
likeness. Samples can thus not be clustered on the basis of the whole transcriptome.
Despite there being no major differences between genotypes at 1.5 months of age, I was able to
detect some amyloid-associated transcriptional changes. Figure 4.4 (see p.61) shows heatmaps
only for the significantly differentially expressed genes in the given brain regions of youngmice.
Values represent relative foldchanges of deregulated genes in arbitrary units. Considering only
the significant genes, samples from 1.5 months old wildtype and transgenic mice can nicely be
separated as shown by the respective dendrograms. Forty-one genes are differentially expressed
in the ACC of 1.5 months old mice, 28 of which are upregulated. In the CA1, 12 genes are up-
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Figure 4.3 – Clustering of 1.5 months old mice:
A) Distance heatmaps showing euclidean distance of samples from all three brain regions of 1.5 month old
mice. The color key is ranging from 100% similarity (red) to dissimilarity (blue) with increasing value (arbi-
trary unit). Dendrograms displayed above each heatmap show no distinct clustering of the two genotypes,
highlighted by green (wildtype) and yellow (transgenic) bars respectively.
B) PCA plots for comparison of wildtype (green) and APP/PS1 transgenic (yellow) 1.5 months old mice.
Samples from different genotypes cannot be separated by a straight line and thus cannot be clustered.
and 9 genes downregulated and in the DG, 17 genes are up- and 15 genes are downregulated.
To discover potentially overrepresented pathways based on these genes, I screened for KEGG
pathways enriched in the given datasets (see table 4.1, p.61). This analysis was done without
a foldchange cutoff, increasing the number of input genes fore analysis to 348 in the ACC. The
number of genes in the CA1 and DG remained relatively stable with or without a foldchange
cutoff (CA1: 49, DG: 32).
Pathway analysis for the ACC revealed four significant pathways, namely ”Endocytosis”
(p=0.0017), ”Notch signaling pathway” (p=0.0091), ”Axon guidance” (p=0.0209), and ”Calcium
signaling pathway” (p=0.0382). Only one pathway was significant for the CA1 (”Axon guidance”,
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p=0.0043) and none for the DG. Though only a slight tendency towards upregulation of gene ex-
pression can be observed in all three brain areas, the genes involved in the significant functional
pathways are almost exclusively upregulated, with the exception of Vps37d, Lrrc4c, CD38, and
Srgap1.
ACC CA1 DG
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Figure 4.4 – Transcriptional differences in 1.5 months old mice:
Heatmaps for differentially expressed genes in the ACC, CA1, and DG of 1.5 months wildtype and APP/PS1
transgenic mice. Upregulation of gene expression is resembled by positive values and red boxes, downreg-
ulation by negative values and blue boxes.
Table 4.1 – Functional pathways in the ACC (top) and CA1 (bottom) of 1.5 months old mice. Downregulated
genes are labeled in red.
ACC KEGG pathway p-value genes
Endocytosis 0.0017 AGAP3, HGS, ACAP3, LDLR, EPN1, RAB11FIP3, PSD,
VPS37D, HSPA2, AP2A1, VPS37B
Notch signaling pathway 0.0090 JAG2, DVL1, NCOR2, DTX1, NUMBL
Axon guidance 0.0209 SEMA6B, SLIT1, UNC5A, LIMK1, EPHB6, EFNB1, LRRC4C
Calcium signaling pathway 0.0382 GRIN2D, CACNA1H, GRIN1, HTR6, CD38, SLC8A2, GNA11,
PTK2B
CA1 KEGG pathway p-value genes
Axon Guidance 0.0043 LRRC4C, SRGAP1, ABLIM3, MAPK3
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4.3 Differential gene expression in APP/PS1 mice with mild
and severe amyloidosis
RNA from the ACC, CA1, and DG of APP/PS1 wildtype and transgenic mice was sequenced and
compared to discover putative molecular mechanisms that might affect and partially drive the
previously described cognitive decline in this mouse model for AD via gene expression profiles.
Figure 4.5A (see p.63) shows the fold change and p-value of all protein coding transcripts identi-
fied by Illumina RNA sequencing in 1.5, 4, and 8 months old mice. A strong shift towards upreg-
ulation of gene expression can be observed in all three tested brain regions. This shift becomes
more intense during aging and the number of significant genes rises with increasing age. The
majority of genes with a p-value less than 0.05 is only mildly differentially expressed, meaning a
log2foldchangeweaker than±0.5. As previously described, the gene expression profile of the DG
is quite different from the ones observed for the ACC and CA1 (see section 4.1, p.56). Compared
to the other brain regions, gene expression is only mildly affected in the DG of 4 months old mice
and in general shows a broader and weaker distribution.
While samples from 1.5 months old mice were not yet separating significantly in the respective
brain regions, wildtype and transgenic mice are becomingmore diverse during aging. Compared
to 41 genes that were differentially expressed in the ACC of young mice, 390 (363 up, 27 down)
are already significantly affected in mid-aged and 839 (764 up, 75) in old mice (see figure 4.5B,
p.63). In the CA1, 21 genes (12 up, 9 down) were differentially expressed at an age of 1.5 months,
326 (302 up, 24 down) at 4 months, and 856 (812 up, 44 down) at 8 months. In the DG of 8 months
old mice, the number of significant genes rouse to 890 (542 up, 348 down) in older mice while
the number of genes remained relatively stable in 4 months old mice compared to 1.5 months
old mice (50 and 22 respectively).
To analyze the consistency of transcriptional changes during progressing age, I performed a
partition around medoid (PAM) analysis. PAM is an advanced version of k-means clustering
and can identify clusters of data-points that behave similar under different conditions - like age.
PAM clustering was chosen as it is less susceptible to noise and outliers compared to its primitive
technique of classical k-means clustering.
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Figure 4.5 – Differential gene expression in APP/PS1 transgenic mice:
A) Volcano plots of all coding genes detected by Illumina RNA sequencing for the ACC, CA1 and DG of 1.5
(yellow), 4 (red), and 8 (blue) months old transgenic mice. Vertical dashed lines resemble the cutoff for
log2foldchange (±0.5) and horizontal dashed lines resemble the cutoff for the adjusted p-value (≤0.05).
Note that differential gene expression in APP/PS1 transgenic mice is prone to upregulation rather than
downregulation of genes.
B) Number of up- and downregulated genes for the given age groups and brain regions.
C,E,G) Results from partition around medoids clustering of log2foldchanges for 7 clusters. Values depicted
in each cell represent the respective cluster’s medoid of foldchanges for each age group. Downregulation
of genes is resembled by blue, upregulation by red boxes.
D,F,H) Venn diagrams showing the number of common and exclusive differentially expressed genes in the
ACC, CA1 and DG of 1.5, 4, and 8 months old wildtype and APP/PS1 transgenic mice.
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PAM analysis was done for 7 clusters to enable one cluster for each possible intersection of
shared genes and group-exclusive genes. Figure 4.5C, E, and G (see p.63) shows heatmaps for
the medoids retrieved for each respective clustering. With only one exception in the CA1, the
deregulation of gene expression is changing in a unidirectional manner. A gene that is deregu-
lated in 4months oldmice is thus likely to be deregulated in the same direction in a later stage as
well. Only a single cluster in ACC was identified, were genes are upregulated in 1.5 months old
APP/PS1 transgenic mice and not deregulated anymore in older mice. The DG is the only brain
regions with more than one cluster of downregulated genes identified.
The findings from the PAM analysis also becomes visible in the Venn diagrams shown in figure
4.5D, F, and H (see p.63). The vast majority of deregulated genes is shared between 4 and 8
months old mice, while those genes deregulated during early life are almost exclusive to young
mice (ACC: 33 out of 41, CA1: 18/21, DG: 19/22). Only few genes are shared among all age groups
due to that exclusivity of genes affected in early life, namely Thy1 (all brain areas), Nipal4 (ACC),
Mrc2, and Capn3 (both CA1). Only 22 genes differentially expressed in the ACC of 4 months old
mice were not expressed in the ACC of 8 months old mice as well. In the CA1, 78 out of 326
deregulated genes in 4 months old mice were exclusive for 4 months old mice and 7 out of 50 in
the DG. These data suggest that the general pattern of molecular deregulation is already set at
an age of 4 months and becomes more intense during aging.





























Figure 4.6 – Differentially expressed genes in APP/PS1mice shared among brain regions:
Venn diagrams for common and brain region selective differentially expressed genes in 1.5 (yellew), 4 (red),
and 8 months old (blue) APP/PS1 transgenic vs wildtype mice.
Figure 4.6 shows the number of differentially expressed genes in APP/PS1 transgenic mice that
are shared among the three tested brain regions. While only a single gene, namely Thy1, is
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shared among the regions in 1.5 months old mice, the majority of genes is shared in the older
mice. Only 5 genes from the DG are selective for that brain region in 4 months old mice while
the majority of differentially expressed genes are shared among all three brain regions. In total,
the ACC and CA1 of 4 months old mice shared approximately 52-62% of significant genes respec-
tively. In 8 months old mice, the majority of genes is shared among the ACC, CA1, and DG as well
(all: 414, ACC&DG: 25, ACC&CA1: 216, CA1&24: 24). However, the DG only shares approximately
half of its differentially expressed genes with the other brain regions. 427 out of 890 genes are
exclusive for the DG and the majority of these 427 genes (318) is downregulated. Together with
data from the regional comparisons in section 4.1 (see p.56), these data confirm that the DG as
a hippocampal sub-region shares less similarity with the CA1 than the two anatomical distant
regions CA1 and ACC share among each other.
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Figure 4.7 – Overrepresented functional pathways in APP/PS1 transgenic mice:
A) Enriched functional pathways in 1.5 (yellow), 4 (red), and 8 (blue) months old APP/PS1 transgenic mice
compared to wildtype mice identified by Ingenuity Pathway Analysis. The top 10 pathways identified for 8
months old mice were chosen for plotting. Dotted lines resemble the threshold for significance (=0.01).
B)Number of common and region exclusive significant functional pathways for 4 (red) and 8months (blue)
old mice respectively.
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To bring the deregulation of gene expression during aging in a functional context, I performed
functional pathway analysis using Ingenuity. The top 10 significant pathways (p<0.01) identified
for the ACC, CA1, and DG of 8 months old APP/PS1 transgenic mice compared to wildtype mice
are displayed in figure 4.7 (see p.65). From the top10 pathways of a brain region, the majority
(8) is also among the top 10 in the other regions and can be related to immune response, i.e.
”Dendritic Cell Maturation”, ”Role of Pattern Recognition” (innate immune system related), or
”TREM1 (Triggering receptor expressed on myeloid cells) Signaling”. By comparing all signifi-
cant functional pathways in the given set of deregulated genes, the majority of pathways is still
shared among all three regions (see figure 4.7B, p.65). While few pathways can be related to
metabolism (i.e. ”cholesterol biosynthesis”, ”Type I Diabetes Mellitus Signaling”), the vast major-
ity of pathways can be linked with immune response mainly resembling upregulation of gene
































































Figure 4.8 – Functional pathways frommildly downregulated genes:
Three functional pathways related to immune response (red) identified for all upregulated genes also in-
cluding those with a |log2foldchange| < 0.5 and pathways related to neuronal plasticity (blue) identified
for all downregulated genes without foldchange cutoff. Values represent the respective -lg(p-value) of each
pathway and comparison. With few exceptions, deregulation of pathways becomesmore significant during
aging.
Recently published data for another AD mouse model (Gjoneska et al., 2015) suggests a bulk
downregulation of genes related to neuronal plasticity upon amyloid pathology. Additionally,
since cognitive decline can already be observed at an age of 4 months in APP/PS1 mice as well,
some functional pathways were expected to resemble neuronal functioning. Thus, I also an-
alyzed mildly affected genes (|log2foldchange| < 0.5) for overrepresented functional pathways
(see section 7.2, p.131ff.). Seventeen pathways with a p-value ≤ 0.01 were found, shared among
the ACC, CA1, and DG in 8 months old mice regarding downregulated genes. Some of those path-
ways can clearly be related to neuronal plasticity, i.e. ”Axonal Guidance Signaling”, ”Dopamine-
DARPP32 Feedback in cAMP Signaling”, and ”Glutamate Receptor Signaling”. Figure 4.8 shows
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the -lg(p-value) for the previously mentioned plasticity related pathways and three arbitrary
chosen immune response related pathways (”Complement System”, ”Dendritic Cell Maturation”,
”TREM1 Signaling”) for each given age group and brain region. As it was previously shown for
progression of gene expression per se (see figure 4.5, p.63), these pathways also behave in a uni-
directional manner. Overrepresented pathways in 4 months old mice become more significant
during aging. Among the set of pathways identified for mildly upregulated genes, only a single
plasticity-related pathway was found common for all three regions, namely ”Reelin Signaling in
Neurons”. However, more neuronal signaling pathways were found common for the ACC and
the CA1, i.e. ”Synaptic Long Term Depression”. These data suggest that the neurons in APP/PS1
transgenic mice are only mildly affected in their gene expression by amyloid pathology and that
the major effect on gene expression is acting on glial cells functioning in immune response upon
amyloid deposition.
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Besides quality control of Illumina sequencing itself, data from RNAseq are usually validated
via qPCR to ensure trustful data. Figure 4.9 shows the validation via qPCR for two highly dereg-
ulated genes, namely MPEG1 and RUNX1. A similar pattern of deregulation found by RNAseq
can be identified for qPCR data as well. Significance analysis with ANOVA and Tukey’s multiple
comparisons test confirms the findings from RNAseq for both MPEG1 (pgenotype < 0.0001; p4vs8 =
0.0092) and RUNX1 (pgenotype = 0.0001; p4vs8 = 0.0112).







































































































Figure 4.9 – Validation of RNA sequencing via qPCR:
Data fromRNAseq (top) and qPCR (bottom) forMPEG1 (left) and RUNX1 (right). The very same RNA samples
of 1.5, 4, and 8 months old wildtype and transgenic mice were used for both RNAseq and qPCR. Data from
qPCR was tested for significance using 2-way ANOVA for group effects and Tukey’s multiple comparison
test for time point comparisons. Significant differences from RNAseq could be validated for both MPEG1
(pgenotype < 0.0001; p4vs8 = 0.0092) and RUNX1 (pgenotype = 0.0001; p4vs8 = 0.0112). Error bars resemble the
standard error of means.
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4.4 Differential gene expression during aging
4.4.1 Healthy aging in wildtype mice
Gene expression analysis from APP transgenic mice suggest that the effect of the transgene on
gene expression is already severe at 4 months of age. It is mainly driven by immune response
related mechanisms and deteriorate during aging. By analyzing transcriptional changes during
aging in both APP transgenic and wildtype mice, I aimed to shed some more light on the molec-
ular mechanisms underlying the cognitive decline in those mice. To do so, I first investigated
aging in wildtype mice to see how gene expression develops during healthy aging. These data
were analyzed similarly to the previously described ones.
Figure 4.10A (see p.70) shows volcano plots of early-life- (1.5 vs 4 months, green) and mid-life-
aging (4 vs 8 months, purple) in wildtype mice. For the ACC and CA1, the majority of genes with
an adjusted p-value below the given threshold of 0.05 is only mildly differentially expressed.
The DG shows a broader pattern of differential gene expression as it could already be observed
when comparing the different genotypes. In general, gene expression in wildtype mice across
different ages does not show a universal trend towards either up- or downregulation in all age
comparisons and brain regions.
While almost an equal number of genes is up- and downregulated in the ACC of 1.5 vs 4 months
old mice (155 up, 153 down), 582 genes are downregulated in 4 vs 8 months old mice compared
222 that are upregulated (see figure 4.10B, p.70). In the CA1, only 15% of the significant genes
are upregulated in early-life aging. The number of differentially expressed genes during aging
is going down to 267 (67 up, 200 down) in the CA1. Compared to the ACC and CA1, the DG is
only mildly affected in regard to gene expression and without any tendency for up- or downreg-
ulation. In 1.5 vs 4 months old mice, 153 genes were up- and 179 genes downregulated and the
number of significant as well as their ratio of up- vs downregulation remains stable.
Michael Gertig 69
4. RESULTS 4.4. DIFFERENTIAL GENE EXPRESSION DURING AGING















































































































































1.5 vs 4 months



























4 vs 8 months
Figure 4.10 – Differential gene expression in aging wildtype mice:
A) Volcano plots of all coding genes detected by Illumina RNA sequencing for the ACC, CA1 and DG of 1.5
vs 4 (green) and 4 vs 8 (purple) months old wildtype mice. Vertical dashed lines resemble the cutoff for
log2foldchange (±0.5) and horizontal dashed lines resemble the cutoff for the adjusted p-value (≤0.05).
Note that differential gene expression in wildtype mice is slightly tended towards downregulation during
aging.
B) Number of up and downregulated genes for the given age groups and brain regions.
C,E,G) Results from partition around medoids clustering of log2foldchanges for 7 clusters. Values depicted
in each cell represent the respective cluster’s medoid of fold changes for each age comparison. Downregu-
lation of genes is resembled by blue, upregulation by red boxes.
D,F,H) Venn diagrams showing the number of common and exclusive differentially expressed genes in the
ACC, CA1 and DG of 1.5 vs 4 and 4 vs 8 months old wildtype mice.
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PAM analysis of aging-related differential gene expression in wildtype mice revealed that gene
expression is not following a unidirectional pattern as it was observed for the comparison of
wildtype vs transgenic mice (see figure 4.10C, E, and G, p.70). Three different kinds of clusters
were identified: genes that are not yet affected in early-life aging but in mid-life aging or vice
versa; genes that are downregulated in 4 months old mice compared to 1.5 months old mice
but upregulated in 8 months old mice or vice versa; and genes that are downregulated in both
aging comparisons. The only cluster of the latter kind was observed in the DG. The majority of
genes differentially expressed in the CA1 reverse their direction of deregulation during aging,
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Figure 4.11 – Common up- and downregulated genes during aging in wildtype mice:
Venn diagrams for up- (top) and downregulated (bottom) genes shared between early-life andmid-life aging
in wildtype mice. Only genes deregulated in the same direction are plotted.
The findings from PAM analysis are also reflected by the Venn diagrams for 1.5 vs 4 and 4 vs 8
months old mice showing that only a small fraction of genes is shared among the aging compar-
isons in the ACC (80 from 308 in early-life and 804 in mid-life aging) (see figure 4.10D, F, and H,
p.70). This effect is even stronger in the DG, where only 9 genes out of 186 and 297 respectively
are shared, partially resembling the cluster of unidirectional downregulated genes. Almost half
of the genes differentially expressed in the CA1 of 4 vs 8 months old mice (129 out of 267) is also
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differentially expressed in early-life aging. However, data from PAM analysis already suggested
thatmost genes are likely to develop in opposite directions during aging progression. Figure 4.11
(see p.71) confirms these findings. Out of the 80 genes shared between the aging groups in the
ACC of wildtype mice, only 4 are upregulated and 6 downregulated in both comparisons. Only 3
genes from both age comparisons are developing in the same direction in the CA1 (2 down, 1 up)
and in the DG, only 9 genes were shared among the aging groups to begin with. 4 of those are
upregulated during aging and 2 are downregulated.
1.5 vs 4 months 4 vs 8 months
ACC CA1 DG
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Figure 4.12 – Overrepresented functional pathways in aging wildtype mice:
Overrepresented functional pathways in aging wildtype mice identified by Ingenuity Pathway Analysis.
The top 10 pathways identified for 4 vs 8 months old mice were chosen for plotting. Dotted lines resemble
the threshold for significance (=0.01).
To identify functional pathways involved in healthy aging, I performed a functional pathway
analysis using Ingenuity (see figure 4.12). Only few pathways were significant (p ≤ 0.01) and
due to the relatively low coverage of genes between the two age comparisons in the respective
brain regions, the pathways are exclusive for one of the aging comparisons with few exceptions.
Not a single pathway was found to be significant in the DG of 4 vs 8 months old mice. The
categories of the few significant functional pathways detected for the other tested brain regions
include immune response (i.e. ”Antigen Presentation Pathway”) and homeostasis or anti-cancer
pathways (i.e. ”p53 signaling”, ”Cell Cycle: G2/M DNA Damage Checkpoint Regulation”).
As mice from 1.5 to 8 months of age are not expected to develop severe cognitive impairments,
these data are fitting to the phenotype of wildtype aging. Still, due to the low number of overrep-
resented pathways, I ran a pathway analysis on all up- and downregulated genes respectively,
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regardless of the foldchange (see figure 4.13). Due to the relatively weak effect of aging on gene
expression in the DG of aging wildtype mice, only few functional pathways were identified even
without a cutoff for expression foldchanges. Pathways identified for the DG can be linked to
immune response, however, less than 4 genes were matched for each pathway. The ACC and
CA1 both show a higher number of differentially expressed genes compared to the DG. Though
the categories of functional pathways are quite diverse, the majority of them can be related to
neuronal functions (i.e. ”Synaptic Long Term Potentiation”, ”CDK5 Signaling”, ”Axonal Guidance
Signaling”).
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Figure 4.13 – Functional pathways frommildly deregulated genes in aging wildtype mice:
Overrepresented functional pathways in aging wildtype mice identified by Ingenuity Pathway Analysis
for up- and downregulated genes separately. All genes with an adjusted p-value ≤ 0.05 were considered,
regardless of their respective foldchange. The top 10 pathways identified for 4 vs 8 months old mice were
chosen for plotting. Dotted lines resemble the threshold for significance (=0.01).
Figure 4.14 (see p.74) shows the number of significant pathways that are shared between the
brain regions. Approximately 35-60% of all pathways identified for the CA1 of up- or downregu-
lated genes in early- or mid-life aging were also identified for the ACC of the same comparison.
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No clear separation of pathway categories regarding up- and downregulation of genes can be
observed, suggesting that the differential gene expression resembles a shift from post-natal de-
velopmental to mature neuronal pathways rather than a deregulation of these.























































Figure 4.14 – Common functional pathways frommildly deregulated genes in aging wildtype mice:
Number of overrepresented functional pathways identified for 1.5 vs 4 (left) and 4 vs 8 (right) months old
wildtypemice, common for the ACC, CA1, and DG. Pathway analysis was based on all genes with an adjusted
p-value ≤ 0.05, regardless of the respective foldchange.
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4.4.2 Pathological aging in APP/PS1 transgenic mice
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Figure 4.15 – Differential gene expression in aging APP/PS1 mice:
A) Volcano plots of all coding genes detected by Illumina RNA sequencing for the ACC, CA1 and DG of 1.5
vs 4 (green) and 4 vs 8 (purple) months old APP/PS1 transgenic mice. Vertical dashed lines resemble the
cutoff for log2foldchange (±0.5) and horizontal dashed lines resemble the cutoff for the adjusted p-value
(≤0.05). Note that differential gene expression in transgenic mice is slightly tended towards upregulation
during aging.
B) Number of up and downregulated genes for the given age groups and brain regions.
C,E,G) Results from partition around medoids clustering of log2foldchanges for 7 clusters. Values depicted
in each cell represent the respective cluster’s medoid of fold changes for each age comparison. Downregu-
lation of genes is resembled by blue, upregulation by red boxes.
D,F,H) Venn diagrams showing the number of common and exclusive differentially expressed genes in the
ACC, CA1 and DG of 1.5 vs 4 and 4 vs 8 months old transgenic mice.
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Gene expression profiles from aging APP/PS1 transgenic mice are similar to the comparisons of
wildtype and transgenic mice (see figure 4.15A, p.75). Genes tend towards upregulation of their
expression and the DG shows the mildest deregulation of gene expression of all three regions.
During early-life aging (1.5 vs 4 months), 482 genes are upregulated in the ACC compared to 115
downregulated ones and the number of downregulated genes is increasing to 296 in mid-life ag-
ing (4 vs 8 months) (see figure 4.15B, p.75). In the CA1 of 1.5 vs 4 months old mice, 509 genes
are upregulated and 375 downregulated compared to 563 upregulated and 169 downregulated
genes in 4 vs 8 months old transgenic mice. With 463 significant genes in total, the number of
deregulated genes in the DG is relatively small and is decreasing further during aging. The num-
ber of differentially expressed genes during aging in transgenic mice is only slightly different
than those observed for wildtype aging, though the expression profile with its tendency towards
upregulation highlights the diverse effect of aging in those mice.
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Figure 4.16 – Common up- and downregulated genes during aging in transgenic mice:
Venn diagrams for up- (top) and downregulated (bottom) genes shared between early-life andmid-life aging
in transgenic mice. Only genes deregulated in the same direction are plotted.
Figure 4.15C, E, and G (see p.75) shows PAM cluster analysis for aging APP/PS1 transgenic mice.
Similar to aging in wildtype mice, genes are not only developing in a unidirectional pattern,
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though gene expression changes in aging transgenic mice seem to be more consistent. The ACC
and DG show themost consistent gene expression changes, as most of the genes are either dereg-
ulated in the same direction during aging or are affected in either early or late aging only. In con-
trast, PAM analysis of genes deregulated in the CA1 revealed 4 clusters of genes that are changing
the direction of deregulation, thus are downregulated in early-life aging and upregulated in mid-
life aging or vice versa. Only a single cluster was found for the DG where genes in both early-
and mid-life aging are significantly downregulated.
A substantial number of genes is commonly differentially expressed in both aging groups for the
respective brain regions (see figure 4.15D, F, and H, p.75). Approximately 35% of the deregulated
genes for either age comparison and brain region were shared with the respective other aging
comparison. As it is shown in figure 4.16 (see p.76), the majority of those shared genes are
actually deregulated in a unidirectional pattern, except from genes in the CA1. From all 293
genes that are commonly differentially expressed during early-life and mid-life aging, only 163
(162 up, 1 down) are developing in the same direction. This relatively low coverage in the CA1
confirms the findings from PAM clustering (see figure 4.15C, E, and G, p.75). In the ACC and DG,
236 out of 251 and 124 out of 130 genes are unidirectionaly expressed respectively.
As it was already shown for transgenic vs wildtype mice, functional pathway analysis for aging
transgenic mice results almost exclusively in immune response related pathways, i.e. ”Dendritic
Cell Maturation” or ”TREM1 Signaling” (see figure 4.17A, p.78). All top10 significant pathways (p
≤ 0.1) identified for the given brain regions are overrepresented in both mid-age and early-life
aging. The majority of significant pathways is shared among the ACC, CA1, and DG (see figure
4.17B, p.78). While the most significant pathways in 1.5 vs 4 months old mice were found in
the ACC (64 compared to 21 in the CA1 and 30 in the DG), the ACC is the region with the least
overrepresented pathways in 4 vs 8 months old mice (ACC: 43, CA1: 67, DG: 71), though it is the
region with the highest number of differentially expressed genes (see figure 4.15B, p.75).
In healthy aging, both mildly up- and downregulated genes during aging were involved in neu-
ronal plasticity related pathways (see figure 4.13, p.73). Here, I performed a similar pathway
analysis based on mildly differentially expressed genes of both directions separately (see figure
4.18, p.79). The top 10 pathways revealed for upregulated genes are again exclusively related to
immune response. From all significant pathways common between the brain regions, the only
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Figure 4.17 – Overrepresented functional pathways in aging transgenic mice:
A)Overrepresented functional pathways in aging APP/PS1 transgenic mice identified by Ingenuity Pathway
Analysis. The top 10 pathways identified for 4 vs 8 months old mice were chosen for plotting. Dotted lines
resemble the threshold for significance (=0.01).
B) Venn diagrams showing the number of common and region exclusive significant functional pathways
for 1.5 vs 4 (green) and 4 vs 8 (purple) months old transgenic mice respectively.
pathway related to neuronal functioning is ”Reelin Signaling in Neurons” (see figure 4.19, p.79),
while quite a number of neuronal function related pathways were found for all brain regions
in healthy animals. Additionally, a single neuronal function related pathways can be found re-
stricted to the ACC namely ”Synaptic Long Term Potentiation”. In contrast to upregulated gene
expression, analysis for downregulated genes revealed some neuronal functioning related path-
ways for both age comparisons and all brain regions, i.e. ”Axonal Guidance Signaling”, ”Synaptic
Long Term Potentiation” or ”Synaptic Long Term Depression”. Consequently, genes from trans-
genic and wildtype mice do only partially overlap in all aging comparisons and tested brain
regions (see figure 4.20, p.80). The majority of genes is uniquely significant in either transgenic
or wildtype mice during aging.
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Figure 4.18 – Functional pathways frommildly deregulated genes in aging transgenic mice:
Overrepresented functional pathways in aging transgenic mice identified by Ingenuity Pathway Analysis
for up- and downregulated genes separately. All genes with an adjusted p-value ≤ 0.05 were considered,
regardless of their respective foldchange. The top 10 pathways identified for 4 vs 8 months old mice were
chosen for plotting. Dotted lines resemble the threshold for significance (=0.01).
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Figure 4.19 – Functional pathways frommildly downregulated genes in transgenic mice:
Three functional pathways related to immune response (red) identified for all upregulated genes also in-
cluding those with a |log2foldchange| < 0.5 and pathways related to neuronal plasticity (blue) identified
for all downregulated genes without foldchange cutoff. Values represent the respective -lg(p-value) of each
pathway and comparison. With few exceptions, pathways become more significant during aging.
Michael Gertig 79
4. RESULTS 4.4. DIFFERENTIAL GENE EXPRESSION DURING AGING

































































































































































































Figure 4.20 – Overlaps in gene expression among wildtype and transgenic aging mice:
A) Venn diagrams for common differentially expressed genes of 1.5 vs 4 (green) and 4 vs 8 (purple) months
old wildtype and transgenic mice.
B) Correlation between the foldchange of all significant genes in wildtype mice and the respective fold-
change in transgenic mice. All genes with an adjusted p-value ≤ 0.05 were considered regardless of fold-
change. Black lines resemble an ideal correlation of r=1. A linear regression is shown for each single
comparison by a dashed red line and the computed r2 is depicted ontop of each plot. A global trend can
be observed where expression of genes differentially expressed during wildtype aging is less plastic in
transgenic mice.
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When calculating the adjusted p-value using multiple comparison algorithms, the output de-
pends on the total number of bins and their respective values. Thus, non-adjusted p-values of
a certain magnitude might lead to a significant adjusted p-value in one comparison but to an
insignificant one in another. To rule out that genes which are differentially expressed in healthy
aging are notmasked artificially by the effect of multiple comparison, I compared the foldchange
of all genes that were significant in wildtype mice (including mildly deregulated ones) with the
foldchange from transgenic aging (see figure 4.20, p.80). A global trend in gene expression be-
comes visible as the majority of genes upregulated during aging in wildtype mice are onlymildly
affected or even downregulated in transgenic mice and vice versa for downregulated genes in
wildtype mice.
Taken together, data from young mice (see section 4.2, p.59ff.) and differential gene expression
during aging suggest that transgenic mice lose plasticity in neuronal functioning related gene
expression, which might partially cause the cognitive decline in those mice.
4.5 Induction of immune response in APP/PS1 mice
Data fromdifferential gene expression revealed that themajor effects seen in APP/PS1 transgenic
mice can be related to immune response. Immune response in the CNS is mainly driven by
microglia and astrocytes. To rule out that differential gene expression seen in transgenic mice
is only the effect of a gliosis, I evaluated the ratio between neuronal and non-neuronal cells in
the given set of mice and performed confocal imaging using neuronal, microglial and astrocytic
marker. As it is shown in figure 4.21A (see p.82), the ratio of neuronal:non-neuronal cells is not
changing significantly between transgenic andwildtype mice. Confocal imaging further indicate
that the significant changes observed in APP/PS1mice is rather a result from glial activation than
an induction of cell number as no obvious differences could be observed between wildtype and
transgenic mice, as it is exemplary shown for 4 months old mice in figure 4.22B (see p.82).
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Figure 4.21 – Neural cell counts from transgenic and wildtype mice:
Ratio of neuronal over non-neuronal cells FACS-sorted for epigenetic analysis. No significant differences
between wildtype (green) and transgenic (yellow) mice can be observed at the given sample size (n=2-5,



















Figure 4.22 – Confocal imaging of the dentate gyrus from 4 months old mice:
Confocal imaging of amyloid plaques (left), microglia (center) and astrocytes (right) in brain slices from
wildtype (top) and transgenic (bottom) mice using a magnification of 20x. Plaques, astrocytes (GFAP) and
microglia (IBA1) are labeled in green, neurons (NeuN) in red and DAPI-stained nuclei are labeled in blue.
Error bars resemble standard deviation.
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4.6 Transcription factor analysis in APPPS1 mice
One potential mechanism that might cause a deregulation of gene expression is a modification of
TF activity. To identify potential TFs that might act as drivers for differential gene expression or
that could be targeted to reinstate a healthy gene expression, I performed a TF binding site pre-
diction analysis on the previously described RNAseq dataset using Pscan (Zambelli et al., 2009).
A list of differentially expressed genes is parsed into Pscan which then screens the promoters
for each gene and tries to align those to an implemented set of 263 TF binding sites, or motifs. A
score is computed for eachmotif:promoter-pair and a p-value is given for each motif. For amore
solid analysis, p-values were transformed into adjusted p-values. Transcription factors with an
adjusted p-value ≤ 0.05 and a motif length ≥ 8 were considered as significant and scores ≥ 0.95
were considered as likely true positive motif:promoter-pairs.
Due to the large overlap of differentially expressed genes in 4 and 8 months old transgenic mice,
themajority of significant TFs found by Pscan is shared between the age groups (see figure 4.23A,
p.84). A substantial number of highly significant TFs can be related to immune response, i.e.
STAT1, SPI1, IRF1, or NFκB1 (see table 4.2, p.86). Thus, results from Pscan do nicely match data
from functional pathway analysis. Figure 4.23B and C (see p.84) shows the coverage of differ-
entially expressed genes targeted by significant TFs. A core-set of TFs was defined covering TF
families known to function in neuronal plasticity and neural immune response, namely ETS,
GATA, IRF, KLF, NFκB and STAT. A detailed list of TFs covered by Pscan and included in the core-
set can be seen in table 7.17 (see p.136). 74-80% of all differentially genes significant in 4 months
old mice are likely to be regulated by at least one of the TFs included in the core-set consistently
for all brain regions. The coverage only marginally changes in 8 months old transgenic mice.
Only approximately 6 to 12% of genes expressed in either age group or brain region can not be
linked to one of the TFs included in Pscan.
In the ACC and CA1, most of the genes that carried a motif belonging to the core-set of TFs were
likely targeted bymembers of the ETS or KLF family. Only a very small fraction of genes might be
regulated by proteins from the GATA family. The ETS is regulating a larger fraction of differen-
tially expressed genes in the DG. Inside that TF family, the most significant hit is SPI1. Members
from the KLF family covered by Pscan were restricted to KLF1, KLF4, and KLF5. Thus, some
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genes targeted by this family of TFs might not be identified by the described analysis yet.
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Figure 4.23 – Overrepresented transcription factors in APP/PS1 transgenic mice:
A) Overrepresented TFs in 1.5 (yellow), 4 (red), and 8 (blue) months old APP/PS1 transgenic mice compared
to wildtype mice identified by Pscan. The top 20 significant motifs identified for 8 months old mice were
chosen for plotting. Dotted lines resemble the threshold for significance (=0.05).
B/C) Pie-chart: Percentage of differentially expressed genes for 4 (top) and 8 (bottom) months old mice with
motifs for either one of the core-set TFs, non-core-set TFs and those genes that do not carry any of the motifs
included in the analysis (unassigned). Bar charts next to each pie chart resemble the relative coverage of
target genes for each respective TF family included in the core-set.
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The activity of TFs depends on different parameters. Some TFs might form complexes with other
proteins, some need to undergo post-translational modifications to become active. Another im-
portant parameter is the pure abundance of a respective TF which is mainly driven by gene
expression itself. Thus, I checked for the level of gene expression from the core-set TFs in AP-
P/PS1 transgenic mice. As shown in figure 4.24, only a small fraction of genes coding for core-set
TFs is differentially expressed or mildly deregulated (|log2foldchange| ≤ 0.5). Gene expression
per se is stronger affected in 8 months old mice compared to 4 months old mice as previously
shown in figure 4.5B (see p.63) and core-set TF coding genes are also following that pattern as
the number of significant genes is higher in 8 months old mice. The core-set TFs affected in their
gene expression are largely shared among the brain regions and included Irf1, Spi1 and Stat1
(all regions), Elf1, Fli1, Nfκb1, RelA, Stat3 and Stat6 (ACC and CA1), Klf4, and Stat4 (both exclusive
for the ACC). The only significantly downregulated transcription factor in the given datasets is
Stat4. All differentially expressed core-set TFs can be related with immune response. Addition-
ally, NfκB and Stat3 were also implicated with neuronal signaling. Altogether, upregulation of
the identified core-set TFs further induces immune response observed in APP/PS1 mice.




























Figure 4.24 – Differentially expressed transcription factors in APP/PS1mice:
Numbers of differentially expressed and mildly deregulated genes corresponding to core-set TFs in 4 (red,
top) and 8 (blue, bottom) months old APP/PS1 mice. Transcription factor coding genes not affected in their
gene expression are shown in grey.
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Table 4.2 – Biological function of deregulated Transcription factors
TF effect reference
Elf1 induction of immune response Sharrocks (2001); Wang et al.
(1993a)
FLI1 TGF-β signaling; tumor suppression Hahm et al. (1999); Sharrocks
(2001)
IRF1 activation of immune response, tumor suppression Miyamoto et al. (1988); Xie et al.
(2003)
KLF4 induction of apoptosis, tumor suppression (El-Karim et al., 2013; Rowland
et al., 2005)
NFκB proliferation, cell survival, neuronal plasticity, induction
of immune response
Brantley et al. (2001); Hayden
et al. (2006); Mattson and Caman-
dola (2001)
RELA NFκB subunit p65 see NFκB
SPI1 differentiation of microglia Sharrocks (2001); Suzuki et al.
(2003)
STAT1 induction of immune response and apoptosis Frank et al. (1999); Takagi et al.
(2002)
STAT3 neuronal signaling, immune suppression Chiba et al. (2009); Yu et al. (2007)
STAT4 induction of immune response (Deng et al., 2004; Wurster et al.,
2000)
STAT6 induction of immune response (Goenka and Kaplan, 2011;
Wurster et al., 2000)
4.7 Differential splicing in APPPS1 transgenic mice
Differential gene expression analysis and corresponding transcriptin factor binding site predic-
tion indicate severe changes on the transcription machinery following amyloidosis. This dis-
ruption might not only resemble changes in transcription frequency but also differential exon
usage. Thus, I studied alternate splicing based on RNAseq datasets from 1.5, 4, and 8 months old
mice using the R package DEXSeq (Anders et al., 2012). DEXSeq is able to detect relatively mild
changes in exon usage, thus a log2foldchange cutoff of ± 0.15 (≈ 10%) was used for the whole
analysis.
Figure 4.25A (see p.87) shows volcano plots for significance and fold change of differentially
expressed exons. Only few exons were differentially expressed in all three brain regions and
age groups with the exception of the ACC of 1.5 months old mice, where a significant number
86 Michael Gertig
4.7. DIFFERENTIAL SPLICING IN APPPS1 TRANSGENIC MICE 4. RESULTS
1.5 months 4 months 8 months
ACC CA1 DG
A




























































































Figure 4.25 – Differiental splicing in APP/PS1 transgenic mice:
A) Volcano plots for exons detected by the DEXSeq analysis for 1.5 (yellow), 4 (red) and 8 (blue) months
old transgenic mice. Only exons with an adjusted p-value ≤ 0.1 are plotted for technical reasons. Dashed
lines resemble the threshold for significance of 0.1 (horizontal) and the cutoffs for log2foldchange of ± 0.15
made for analysis.
B) Number of differentially spliced exons and corresponding number of differentially spliced genes. Note
the different scaling for y-axis in the ACC.
C) Venn diagrams showing the number of differentially spliced genes common or exclusive for the three
age groups.
of exons was upregulated in transgenic mice compared to wildtype littermates. The number of
differentially spliced genes in each respective brain region and age group is shown in figure 4.25
(B). Approximately 1.4 exons per differentially spliced gene were significant in the ACC of 1.5
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months old mice. Except for the ACC of young mice, the differential expression profile of exons
is similar to gene expression, as the number of differentially spliced genes is increasing during
aging. However, the number of deregulated exons is onlymarginal compared to those from gene
expression (see figure 4.5, p.63). Only few genes are differentially spliced in all age groups and
tested brain regions (see figure 4.25C, p.87). These genes include APP cleaving enzymes like PS1
and CTSD, the APP recognizing enzyme TREM2 and APP itself.
Table 4.3 – Overrepresented KEGG-pathways for differential splicing in young APP/PS1 mice
KEGG pathway Represented genes p-value adjusted p-value
Long-term potentiation 25 2.16E-07 3.80E-05
Huntington’s disease 42 7.01E-06 6.17E-04
Lysosome 31 1.09E-05 6.40E-04
Alzheimer’s disease 39 7.98E-05 3.50E-03
Regulation of actin cytoskeleton 44 9.94E-05 3.49E-03
Parkinson’s disease 31 1.05E-04 3.09E-03
Neurotrophin signaling pathway 30 1.68E-04 4.23E-03
Citrate cycle (TCA cycle) 12 3.17E-04 6.95E-03
MAPK signaling pathway 49 3.82E-04 7.45E-03
Oxidative phosphorylation 29 4.03E-04 7.07E-03
Oocyte meiosis 26 7.03E-04 1.12E-02
Endocytosis 39 7.33E-04 1.07E-02
GnRH signaling pathway 23 7.95E-04 1.07E-02
Calcium signaling pathway 37 9.68E-04 1.21E-02
Spliceosome 27 9.83E-04 1.15E-02
Fc gamma R-mediated phagocytosis 22 2.22E-03 2.41E-02
Glioma 16 3.75E-03 3.82E-02
Ubiquitin mediated proteolysis 27 3.88E-03 3.73E-02
Alanine, aspartate and glutamate metabolism 10 4.16E-03 3.79E-02
Since the quality of RNAseq was validated for each sample and data from differential gene ex-
pression, the exceptional differential splicing in the ACC of 1.5 months old mice is unlikely to be
an artifact of sequencing or an unspecific output from DEXSeq. To get further insight into these
data, I screened the differentially spliced genes for overrepresented functional pathways (KEGG
pathways). Nineteen significant KEGG pathways with an adjusted p-value≤ 0.05 were identified
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that can mainly be categorized in neuronal plasticity (”Long-term Potentiation”, ”Calcium Sig-
naling Pathway”), neurodegenerative diseases (”Alzheimer’s Disease”, ”Parkinson’s disease”) or
metabolism (”Citrate Cycle”, ”Oxidative Phosphorylation”), whereby a large proportion of genes
is shared among pathways of a similar category (see table 4.3, p.88).
4.8 Differential splicing during aging
4.8.1 Differential splicing in healthy aging
The relatively low abundance of differential splicing upon amyloidosis was unexpected an led to
the question if splicing is also just marginally affected during aging. I thus performed a similar
analysis on aging wildtype and transgenic mice. Figure 4.26A (see p.90) shows the adjusted p-
value and log2foldchange of exons for each age comparison in wildtype mice’s ACC, CA1 and DG.
For computational and visual purposes, exons with an adjusted p-value below 0.1 are not shown
and the y-dimension of each plot is designed to show the bottom 99.9% of significant data. The
majority of significantly differentially transcribed exons is only mildly affected (<10%). While
the changes in splicing seem to be negligible in the CA1, a number of differentially transcribed
exons can be found in the other two regions. The most differences do hereby occur when com-
paring 4 and 8 months old mice. Gene expression in healthy wildtype mice revealed a mild ten-
dency towards downregulation in the ACC and a rather neutral ratio in the DG (see figure 4.10,
p.70). In contrast, the majority of exons in the ACC of both aging comparisons is upregulated
suggesting a trend towards inclusion of exons, while a slight tendency towards exon exclusion
can be observed in the DG of 4 vs 8 months old mice.
Aminimum of 590 exons corresponding to 414 genes (DG in early-life aging) are found to change
with age regarding the ACC and DG. The most significant differences can though be found in
the ACC of 4 vs 8 months old mice (15,891 exons from 4699) (see figure 4.26B, p.90). While
approximately 3.4 exons per genewere significantly differentially transcribed in the ACC of mid-
life agingmice, the majority of genes in the other comparisons contained only a single significant
exon (x̂: 1.2 - 1.4). In the ACC, 524 out of all 689 differentially spliced genes in early-life aging
were also significant in the mid-life aging. 78% of the commonly significant exons change in
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Figure 4.26 – Differiental splicing in aging wildtype mice:
A) Volcano plots for exons detected by the DEXSeq analysis for 1.5 vs 4 (green) and 4 vs 8 (purple) months
old transgenic mice. Only exons with an adjusted p-value ≤ 0.1 are plotted for technical reasons. Dashed
lines resemble the threshold for significance of 0.1 (horizontal) and the cutoffs for log2foldchange of ± 0.15
made for analysis.
B) Number of differentially spliced exons and corresponding number of differentially spliced genes. Note
the different scaling for y-axis.
C) Venn diagrams showing the number of differentially spliced genes common or exclusive for the three
age groups.
the same direction throughout aging. In contrast, from all 71 common exons in the DG, 23 are
developing in opposite directions throughout aging.
To check whether differential splicing affects certain functional pathways in aging mice, I
screened for overrepresented KEGG pathways. Only a single significant pathway (adjusted p-
value ≤ 0.05) was found for the ACC and DG of 1.5 vs 4 months old mice, namely ”Spliceosome”
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and ”Tight Junction” respectively (see table 4.4, p.92). The ”Spliceosome”-pathway is also signif-
icantly represented in 4 vs 8 months old mice (both ACC and DG). Due to the high number of
differentially spliced genes, the most significant pathways appear in the ACC of 4 vs 8 months
old mice and those pathways cover a broad range of biological functions mainly involved in
neuronal signaling (”Axonal guidance”, ”Long-Term Potentiation”), general signal transduction
(”Phosphatidylinositol signaling system”) and gene expression (”Aminoacyl-rRNA biosynthesis”,
”Spliceosome”) (see table 4.4, p.92). No significant pathways were found for differentially spliced
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Figure 4.27 – Comparison of differential gene expression and splicing analysis:
A linear regression for each comparison is displayed in red and the R2 value for each correlation analysis
is written ontop of each plot.
A) Comparison of the log2foldchanges from each respective analysis. Horizontal lines resemble the cutoff
for gene expression analysis and vertical lines cutoff for differential splicing. Note that in the given exam-
ple differential gene expression and splicing are almost mutually exclusive. No correlation can be found
between the foldchanges.
B) Normalized mean counts from gene expression analysis versus absolute log2foldchange for splicing. No
correlation can be found between the two given parameters. Differential splicing seems to be less likely in
highest expressed genes.
C) Log2foldchange from gene expression plotted against the adjusted p-value from splicing analysis (with
padj ≤ 0.05). No correlation can be found here as well.
D) Comparison of the normalized read counts from gene expression and the adjusted p-value from splicing
analysis. Only values for significant exons were plotted. Significance of differentially transcribed exons
appears independent from read count of the corresponding gene.
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Due to the high number of significant exons and the resulting broad range of functional path-
ways, I investigated whether the data is contaminated with too many false positives. Since qual-
ity control of the RNAseq data confirmed a high quality, I hypothesized that any significant frac-
tion of false positives could either derive from a very high basal gene expression or differential
gene expression. I thus checked whether one can correlate either read counts or foldchanges
from differential gene expression analysis with the exon foldchange and adjusted p-value (see
figure 4.27, p.91). As shown in 4.27A (see p.91), differential gene expression and alternative
splicing seem to be mutually exclusive in the given example (DG of 1.5 vs 4 months old wildtype
mice). Only exons from genes that had an absolute log2foldchange below 0.5 were significant
in splicing analysis, as it is also shown in 4.27C (see p.91). Also, no correlation could be found
between the exons’ foldchanges and basal gene expression of corresponding genes which is de-
scribed by the normalized read count from gene expression analysis. However, it seems that the
highest expressed genes aremore unlikely to be differentially spliced. Taken together, these data
indicate that there is no correlation between gene expression and differential splicing. Any po-
tential artificial effects that might cause a high number of false positive values are thus unlikely
a result from the data or the chosen cutoffs for analysis but rather a limitation of the utilized
DEXSeq package.
Table 4.4 – Overrepresented KEGG pathways for differential splicing in aging wildtype mice
1.5 vs 4 months: ACC KEGG
pathway
adj. p-value genes
Spliceosome 0.0023 PRPF31, RBM25, DDX5, SRSF5, DDX46, HNRNPK,
PRPF40B, TCERG1, SF3B2, SF3B1, PRPF38B, WBP11,
U2AF2, SRSF2, HNRNPU
1.5 vs 4 months: DG KEGG
pathway
adj. p-value genes
Tight junction 0.0427 AKT2, CDK4, ACTN1, AKT3, SPTBN1, SYMPK,
EPB4.1L3, MPDZ, CTTN, PRKCB, ACTN4, MLLT4
4 vs 8months: DG KEGGpath-
way
adj. p-value genes
Spliceosome 0.0022 DDX23, SRSF6, SRSF1, XAB2, DDX5, PRPF8, THOC1,
SF3B1, SRSF2, DHX38, SART1, AQR, CHERP, HNRNPM
Ubiquitin mediated proteolysis 0.0124 UBA1, PPIL2, NEDD4L, HUWE1, TRIP12, PIAS3,
HERC3, NEDD4, UBE2Q2, UBA7, CDC16, HERC1,
UBE3C, GM20661
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Table 4.5 – KEGG pathways for differential splicing in wildtype ACC: 4 vs 8 months (1)
KEGG pathway genes ad. p-value
Axon guidance 65 3.01E-08
Long-term potentiation 42 2.75E-08
Endocytosis 88 2.34E-08
Ubiquitin mediated proteolysis 66 1.77E-08
ErbB signaling pathway 47 9.43E-08
Phosphatidylinositol signaling system 42 1.60E-07
Spliceosome 59 2.50E-07
mTOR signaling pathway 33 4.28E-07
Regulation of actin cytoskeleton 86 2.66E-06
Insulin signaling pathway 61 2.68E-06
MAPK signaling pathway 99 6.24E-06
Focal adhesion 78 1.11E-05
Neurotrophin signaling pathway 54 1.15E-04
Glioma 32 1.50E-04
Aminoacyl-tRNA biosynthesis 24 1.50E-04
Renal cell carcinoma 34 1.43E-04
Fc gamma R-mediated phagocytosis 43 1.82E-04
Inositol phosphate metabolism 28 2.07E-04
Lysine degradation 23 2.81E-04
Lysosome 49 2.78E-04
Progesterone-mediated oocyte maturation 38 3.08E-04
Adherens junction 35 3.06E-04
Circadian rhythm 11 5.84E-04
GnRH signaling pathway 41 5.88E-04
Chronic myeloid leukemia 34 7.21E-04
Adipocytokine signaling pathway 31 7.22E-04
Glycerophospholipid metabolism 31 7.22E-04
Prostate cancer 38 1.04E-03
RNA degradation 28 1.33E-03
Pathways in cancer 104 1.80E-03
Endometrial cancer 25 1.74E-03
Wnt signaling pathway 55 1.75E-03
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Table 4.6 – KEGG pathways for differential splicing in wildtype ACC: 4 vs 8 months (2)
KEGG pathway genes ad. p-value
Colorectal cancer 35 3.79E-03
Cardiac muscle contraction 32 5.64E-03
Pancreatic cancer 30 6.14E-03
Arrhythmogenic right ventricular cardiomy-
opathy (ARVC)
30 1.25E-02
Acute myeloid leukemia 24 1.77E-02
Non-small cell lung cancer 23 1.82E-02
Calcium signaling pathway 62 2.22E-02
Long-term depression 28 2.55E-02
Valine, leucine and isoleucine degradation 20 2.58E-02
Tight junction 46 2.65E-02
Oocyte meiosis 40 3.18E-02
SNARE interactions in vesicular transport 17 3.67E-02
Dilated cardiomyopathy 33 3.96E-02
Fc epsilon RI signaling pathway 30 4.17E-02
Gap junction 31 4.49E-02
T cell receptor signaling pathway 40 4.50E-02
Limonene and pinene degradation 9 4.56E-02
VEGF signaling pathway 28 4.54E-02
Type II diabetes mellitus 20 4.48E-02
4.8.2 Differential splicing in aging transgenic mice
The differences found between wildtype and transgenic mice regarding splicing were relatively
little, except fromdifferences in the ACC of 1.5months oldmice (see figure 4.25A, p.87). However,
quite some differences were found throughout aging in wildtype mice. To confirm the data from
wildtype-vs-transgenic comparisons and to shed some light on splicing in aging transgenic mice,
I did a similar analysis as described above for transgenic mice. By comparing the volcano plots
fromwildtype aging (see figure 4.26A, p.90) and transgenic aging (see figure 4.28A, p.95), one can
identify certain similarities between the two sets of data. As it was observed for wildtype mice, a
strong effect of mid-life aging on splicing can be found in the ACC, while the effect on the CA1 in
both aging comparisons is rather negligible. Different from wildtype mice, there are only very
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Figure 4.28 – Differiental splicing in aging transgenic mice:
A) Volcano plots for exons detected by the DEXSeq analysis for 1.5 vs 4 (green) and 4 vs 8 (purple) months
old transgenic mice. Only exons with an adjusted p-value ≤ 0.1 are plotted for technical reasons. Dashed
lines resemble the threshold for significance of 0.1 (horizontal) and the cutoffs for log2foldchange of ± 0.15
made for analysis.
B) Number of differentially spliced exons and corresponding number of differentially spliced genes. Note
the different scaling for y-axis.
C) Venn diagrams showing the number of differentially expressed exons common and age exclusive for the
three age groups.
few exons differentially transcribed in the ACC of 1.5 vs 4 months old and the DG of 4 vs 8months
old transgenic mice. 4845 genes were differentially spliced in the ACC during mid-life aging and
each gene showed in average 3 affected exons (see figure 4.28B). In the DG of 1.5 vs 4 months old
mice where 1791 genes were differentially expressed, each gene resembles in average 2 exons.
From the few genes differentially spliced in the ACC during early-life aging, the majority is also
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significant later on (see figure 4.28C, p.95).
Pathway analysis from alternative splicing in wildtype mice revealed a broad spectrumwith par-
ticular enrichment of neuronal function related pathways and signal transduction. Themajority
of pathways identified for the ACC of mid-life aging transgenic mice was found to be similar
in comparison to wildtype mice (see table 4.8, p.97). Notably, one of the 8 pathways unique
for transgenic mice is ”Alzheimer’s Disease”. With only one exception, all pathways overrepre-
sented in the DG of early-life aging transgenic mice are also significant in the ACC during mid
life aging. The pathway ”Alzheimer’s Disease”, however, is not among the significant ones in
the DG. Though some differential splicing can be linked with amyloid pathology, these data from
wildtype and transgenic mice suggest that differential splicing is a crucial mechanism for aging
and is only mildly affected by the transgenic induction of APP and PS1.
Table 4.7 – Overrepresented KEGG pathways for differential splicing in early-life aging transgenic mice:
DG
KEGG pathway genes ad. p-value
Ubiquitin mediated proteolysis 35 8.97E-06
Phosphatidylinositol signaling system 24 1.30E-05
Spliceosome 31 3.97E-05
MAPK signaling pathway 47 8.80E-04
Endocytosis 37 3.25E-03
GnRH signaling pathway 22 5.25E-03
Gap junction 20 6.85E-03
Inositol phosphate metabolism 15 6.66E-03
Focal adhesion 33 2.53E-02
Insulin signaling pathway 25 3.25E-02
ErbB signaling pathway 18 3.73E-02
RNA degradation 14 4.20E-02
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Table 4.8 – KEGG pathways for differential splicing in mid-life aging transgenic mice: ACC (1)
KEGG pathway genes ad. p-value
Phosphatidylinositol signaling system 45 3.19E-08
Insulin signaling pathway 67 9.45E-08
ErbB signaling pathway 48 1.16E-07
Renal cell carcinoma 41 1.60E-07
Axon guidance 63 2.06E-07
mTOR signaling pathway 34 2.52E-07
Glioma 38 2.31E-07
Endocytosis 86 2.55E-07
Focal adhesion 83 9.81E-07
Long-term potentiation 38 3.96E-06
Lysosome 55 5.24E-06
MAPK signaling pathway 101 6.34E-06
Regulation of actin cytoskeleton 86 7.25E-06
Neurotrophin signaling pathway 58 8.00E-06
Ubiquitin mediated proteolysis 59 1.81E-05
Spliceosome 55 1.80E-05
Colorectal cancer 40 1.52E-04
Endometrial cancer 28 1.51E-04
Alanine, aspartate and glutamate metabolism 19 3.08E-04
Inositol phosphate metabolism 28 3.29E-04
Fc gamma R-mediated phagocytosis 43 3.16E-04
RNA degradation 30 3.49E-04
Prostate cancer 40 4.04E-04
Progesterone-mediated oocyte maturation 38 5.34E-04
Adherens junction 35 5.14E-04
Lysine degradation 22 1.21E-03
Chronic myeloid leukemia 34 1.23E-03
Non-small cell lung cancer 26 2.16E-03
Acute myeloid leukemia 27 2.14E-03
Pancreatic cancer 32 2.07E-03
Pathways in cancer 106 2.13E-03
Calcium signaling pathway 66 7.55E-03
GnRH signaling pathway 38 8.64E-03
ABC transporters 21 1.28E-02
Michael Gertig 97
4. RESULTS 4.9. DNA METHYLATION IN APP/PS1 MICE
Table 4.9 – KEGG pathways for differential splicing in mid-life aging transgenic mice: ACC (2)
KEGG pathway genes ad. p-value
Gap junction 34 1.28E-02
Adipocytokine signaling pathway 28 1.33E-02
T cell receptor signaling pathway 43 1.79E-02
Fatty acid elongation in mitochondria 7 1.76E-02
Alzheimer’s disease 61 2.12E-02
Circadian rhythm 9 2.15E-02
B cell receptor signaling pathway 31 2.48E-02
Tight junction 47 2.69E-02
Oocyte meiosis 41 2.97E-02
Mismatch repair 12 3.29E-02
Huntington’s disease 60 3.33E-02
Arginine and proline metabolism 22 3.73E-02
VEGF signaling pathway 29 3.70E-02
Wnt signaling pathway 50 3.88E-02
Limonene and pinene degradation 9 5.39E-02
Aldosterone-regulated sodium reabsorption 18 5.35E-02
Aminoacyl-tRNA biosynthesis 18 5.35E-02
4.9 DNA methylation in APP/PS1 mice
So far, I demonstrated an increased deregulation of gene expression in APP/PS1 mice which is
mostly related to immune response. In order to explore the possible mechanisms driving these
gene expression changes, I analyzed DNA methylation. DNA methylation is known to influence
gene expression in several ways, however, has not yet been significantly explored in the context
of AD. To gain some more insight into the molecular processes underlying gene expression in
APP/PS1 mice, I performed MeDIP-sequencing on neuronal and non-neuronal cells to analyze
DNA methylation along the genome in 1.5, 4, and 8 months old APP/PS1 transgenic mice.
Figure 4.29A (see p.99) shows the averagemethylation profile of genes in the murine genome for
low, mid and high expressed genes based on gene expression data. The number of methylated
sites is reduced for all gene fractions around the TSS and methylation in general is reduced in
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the gene bodies of highly expressed genes. This is in line with the general consensus on DNA
methylation as a marker for silenced genes. The differences between high and low expressed
genes are stable across brain regions and cell types. Approximately 50% of all sequenced sites
of methylation can be mapped to intergenic regions of the genome and 30% to intronic regions
(see figure 4.29B), confirming the function of DNA methylation as a repressive mark of gene
expression.
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Figure 4.29 – NGS plots for DNA methylation along gene bodies:
A)Number of normalizedmapped reads along the gene body averaged for the entire genome for 1.5months
old APP/PS1 mice’s ACC, CA1 and DG. The three profiles resemble low (purple), mid- (orange) and high
(green) expressed genes in each respective brain region. Note the reduced bulk level of DNA methylation
in highly expressed genes, resembling their active state.
B) Proportion of each respective genomic methylation site in neuronal and non-neuronal cells. Note that
the overall distribution is rather similar but non-neuronal cells had less methylated DNA in intergenic
regions.
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A DNA methylation: 1.5 months 4 months 8 months








































Figure 4.30 – DNA methylation in APP/PS1 transgenic mice:
A) Number of hypo- and hypermethylated 700bp bins (adjusted p-value ≤ 0.2) in neuronal and non-
neuronal cells from the ACC, CA1 and DG of APP/PS1 mice and corresponding changes in gene expression
(light colors). Values above the x-axis depict downregulation of DNA methylation but upregulation of gene
expression and vice versa.
B) Exact numbers of differentially methylated DNA regions in neuronal and non-neuronal cells.
C) Common and region exclusive differentially methylated genes in neuronal cells from the CA1 and DG of
4 month old transgenic mice. Note that the number of genes is only a fraction of the number of significant
bins since some genes contain more than one significant methylation site.
Gene expression in 1.5 months old mice was not strongly affected in APP/PS1 mice and thus, one
would not expect massive changes in the DNAmethylation of those youngmice. In fact, only few
genomic sites were significantly differentially methylated in the ACC, CA1 and DG of 1.5 months
old transgenic mice compared to wildtype littermates (see figure 4.30A and B). Figure 4.30 (A)
also shows the number of differentially methylated DNA sites compared to the number of differ-
entially expressed genes in the respective age group and brain region. Surprisingly, the overlap
between upregulation of gene expression and DNA hypomethylation is marginal and changes
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in gene expression are clearly exceeding differential DNA methylation. From 246 genes with
deregulated DNA methylation sites in the ACC of old mice, only 8 were also differentially ex-
pressed in the same age group and brain region (see figure 4.31A, p.102). Similar findings were
made for the CA1 and DG. Interestingly, the number of differentially methylated sites increases
inconsistently throughout aging in the two cellular fractions while gene expression is disrupted
gradually. While there were 296 differentially methylated sites in non-neuronal cells from the
ACC of 8 months oldmice, differential DNAmethylation in neuronal cells or the other age groups
is onlymarginal. An opposite effect can be found in the hippocampal regions CA1 and DG, where
most of the differential methylation was found in neuronal cells from 4 months old wildtype vs
transgenic mice. Only a smaller fraction of genes that are differentially methylated in either of
the regions at 4 months of age is also significant in the respective other hippocampal region (see
figure 4.30C, p.100). These findings might indicate differential mechanisms how DNA methyla-
tion affects gene expression in distinct cell-types and even brain regions.
Due to the surprisingly low coverage of differential gene expression and DNA methylation, I an-
alyzed the DNAmethylation profile of expressed genes in more detail and tried to correlate gene
expression with DNA methylation specifically in promoter regions, exons and introns. Figure
4.31B (see p.102) exemplarily shows the results for neurons from the DG of 4 months old mice.
No correlation could be found in regard to introns and exons and only a mild correlation can be
observed in promoter regions. However, this weak correlation might be artificial due to the re-
dundancy from significant genes as a result from multiple methylation sites within. Apart from
a direct impact of DNA methylation on gene expression which could not be confirmed here, it
might also function as a priming mechanism for gene expression, thus in a rather long-term pat-
tern. To test this hypothesis, I compared DNA methylation from 4 months old mice with data
from RNA sequencing from 8months old mice and again found no decent correlation (see figure
4.31C, p.102). Furthermore, genes with differentially methylated DNA sites can not be assign to
common functional pathways, supporting the previous findings of an absent or only mild direct
connection between DNA methylation and differential gene expression.
These results indicate, that DNA methylation is not affected in those genes differentially ex-
pressed in APP/PS1 transgenic mice and that the effect of DNA methylation on gene expression
in APP/PS1 mice might not primarily depend on intragenic mechanisms.
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Figure 4.31 – Independence of differential gene expression and DNA methylation in APP/PS1 mice:
A) Overlap of deregulated gene expression and differentially methylated DNA sites (padj ≤ 0.2) annotated
to genes in non-neuronal cells from the ACC of 8 months old mice and neuronal cells from the CA1 and DG
of 4 months old mice.
B) Absent correlation between the foldchanges fromMeDIP- and RNA-seq data analysis for promoter (left),
exonic (center) and intronic (right) regions. Dashed lines resemble a linear regression of data. The R2-value
for each correlation is depicted on top of each plot. Example data shown represent neuronal tissue in the
DG of 4 months old transgenic mice compared to wildtype littermates.
C) Similar correlation analysis regarding the same MeDIP data as shown in B and RNAseq data from 8
months old mice’s DG.
The absent correlation of DNA methylation and differential gene expression indicate, that DNA
methylationmight be rather globally affected and not specific to certain genes. When comparing
the genome-wide average read count along the gene body, the profiles in cells from the different
brain regions and cell-types are rather diverse. Though a considerable amount of DNA sites were
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Figure 4.32 – Differential distribution of DNA methylation in APP/PS1 mice:
A) Number of normalized mapped reads along the gene body averaged for the entire genome for samples
with the highest number of differentially methylated DNA sites respectively for the ACC, CA1, and DG of
APP/PS1 wildtype (green) and transgenic (yellow ) mice. The profiles resemble the range of means for the
respective replicates.
B) Distribution of differentially methylated DNA sites along the genome. Note that the overall profile is
rather similar to the baseline distribution with the exception of non-neuronal cells in the ACC.
deregulated in non-neuronal cells from the ACC of old mice, no difference between wildtype and
transgenic mice can be detected on a genome-wide scale (see figure 4.32A). Interestingly, DNA
methylation is globally upregulated in CA1-neurons from transgenic mice while an opposing
effect can be observed in the DG. These findings emphasize the differential linkage between
DNA methylation and gene expression in different cellular states and environments.
Compared to the global distribution of DNA methylation in either neuronal or non-neuronal
cells (see figure 4.29B, p.99), differentially methylated sites in non-neuronal cells from the ACC
of 8 months old mice are enriched inside of the gene body, predominantly within promoters,
exons, and 5’ and 3’ untranslated regions (see figure 4.32C). Methylation within introns, in con-
trast, remains relatively stable. This enrichment is absent in neuronal cells from the CA1 and
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DG, where the distribution of significant methylation sites is rather similar to the global distri-
bution of DNA methylation with the majority of significant sites mapping to intergenic regions.
These data suggest a partially gene-directed effect in glial cells and a rather global disruption
of DNA methylation in neuronal cells which might explain the absence of significant functional
pathways represented by the differentially methylated genes.
ACC CA1
non-neuronal, 8 months neuronal, 4 months




























































































































Figure 4.33 – Long distance interactions between genes and sites of DNA methylation:
Genes identified via RNA sequencing from the ACC of 8 months old mice and CA1 of 4 months old mice plot-
ted for defined regions of chromosome MMU4 and MMU7. Significantly differentially expressed genes are
labeled blue, non-significant ones in gray. Hypo- (blue) and hypermethylated (red) DNA sites are depicted
as rectangles below each graph. Previously described long distance interaction domains (LDID) were added
to identify correlations between gene expression changes and distant DNA methylation.
Due to the high proportion of significant intronic and intergenic methylation sites, I hypothe-
sized that the effect of the transgene on DNA methylation is not specifically directed towards
significantly deregulated genes identified by RNA sequencing but rather functioning on distant
interactions. Therefore, I aimed to identify deregulated genes and DNA methylation sites within
previously described long distance interaction domains (Dixon et al., 2012). In those groups
showing a strong deregulation of DNAmethylation, 68.1% to 75.5% of all deregulated genes were
found in domains containing differentially methylated DNA sites. Figure 4.33 shows defined re-
gions of the murine chromosomes 4 and 7 and the respective results from non-neuronal cells
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from the ACC and CA1-neurons. Notably, though one can identify common domains of deregu-
lated genes andmethylation sites, the number of affected genes per domain is rather little. I thus
screened for gene expression hot-spots, defined as long distance interaction domains in which at
least 20% of the expressed genes are differential in APP/PS1 mice. Notably, only 7 hot-spots were
identified in the ACC and CA1 of old mice and 2 in the CA1 of 4 months old mice (see table 7.18,
p.136). DNA methylation changes in these regions was only sparse as it is exemplarily shown in
figure 4.34.
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Figure 4.34 – Gene expression hot-spots and sites of DNA methylation:
Hot-spots within the murine chromosome 7 and 17 in the ACC and CA1 of 8 and 4 months old mice respec-
tively. Long distance interaction domains with at least 20% of the genes within deregulated in APP/PS1mice
are here defined as hot-spots (light red). Significantly deregulated genes are labeled blue and hypo- (blue)
and hypermethylated (red) DNA sites are depicted as rectangles underneath the plot as well as the LDIDs
within the given area of the chromosome.
Taken together, data from MeDIP sequencing suggest that DNA methylation changes in APP/PS1
mice are not directly affecting gene expression via intragenic nor intrachromosomal interac-
tions. These findings, however, oppose the general consensus that a high DNA methylation state
is directly linked to a low gene expression rate and vice versa. I thus speculated, that DNAmethy-
lation per se is rather defining a basal gene expression - i.e. that defining cell fate - than acting on
gene expression upon endogenous stimuli. To test this hypothesis, I compared the DNA methy-
lation profiles of neuronal and non-neuronal cells in 1.5 months old mice to avoid any effect of
aging or amyloid pathology. The observed differences between neuronal and non-neuronal cells
are massive and range from approximately 10,000 in the DG to more than 30,000 differentially
methylated sites in the CA1 and ACC of 1.5 months old mice. This further supports the described
findings and indicates the importance for DNA methylation in determining cell fate.
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4.10 H3K4me3 in APP/PS1 mice
The strong induction in gene expression of APP/PS1 transgenic mice regarding immune response
might be encoded by a downregulation of gene repressive marks and an upregulation of active
marks. One histone modification that is in general associated with active genes in H3K4me3.
Thus, I performed a ChIPseq analysis on H3K4me3 to reveal changes in this particular epigenetic
marker and to find a potential correlation to gene expression. Due to the previously discovered
diverse cell type specific effect of amyloid deposits on DNA methylation regarding the ACC and
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Figure 4.35 – Genome wide distribution of H3K4me3:
A) Relative occurrence of H3K4me3 peaks within the gene body and in distal intergenic regions. Data
shown are for the DG of 4 months old mice and exemplary for all age groups, cell types and brain regions.
B) Number of normalized mapped reads along the gene body averaged for the entire genome. The three
profiles shown resemble low(purple), mid (orange), and high (green) expressed genes.
C) Occurence from all significant H3K4me3 peaks (adjusted p-value ≤ 0.2) in non-neuronal cells from the
DG of 4 months old mice. Note an enrichment of signals within the 5’-untranslated region and first exon.
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Strikingly, only a single gene with differentially tri-methylated H3K4 was found in neurons from
aged mice in the ACC and the DG considering an adjusted p-value ≤ 0.2, namely Thy1. Surpris-
ingly, a higher number of significant sites (737) was found in non-neuronal cells from the DG of
4 months old mice, corresponding to 501 individual genes. H3K4me3 is a well accepted mark
for active promoters and was thus expected to change concordantly to the induction of immune
response related gene expression. Figure 4.35A (see p.106) shows the genome wide distribution
of peaks which were most abundant within promoter and intronic regions. Also in line with the
previous assumptions is the induction of H3K4me3 in proximity to the TSS of highly expressed
genes (see figure 4.35B, p.106). Interestingly, the significant differences concerning H3K4me3 in
the DG of 4months oldmice showed a strong enrichment of signal in the 5’UTR and first exons in-
dicating an effect on initiating transcription and presumably driving changes in gene expression















































































Figure 4.36 – Independence of identified H3K4me3 peaks and differential gene expression in APP/PS1
mice:
A) Absent correlation between H3K4me3 and differential gene expression in non-neuronal DG-cells from 4
months old APP/PS1 mice concerning promoter regions, exons and introns.
B) Venn diagram for overlaps between RNAsequencing from 4 and 8 months old mice and H3K4me3
ChIPseq from 4months oldmice. Note that not a single gene differentially express inmid-agedmice showed
a significantly differential H3K4me3 signal.
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The changes observed in H3K4me3, however, only reflect downregulation of histone methyla-
tion and are independent from differential gene expression, indicating an artificial effect within
the data which might partially result from the relatively low sample size (see figure 4.36, p.107).
Taken together, data fromH3K4me3-ChIPseq in general could confirm the common assumptions
on that particular histone mark functioning in transcription initiation. However, the low sam-
ple size and relatively high variancewithin samples preclude a thorough analysis on amyloidosis
driven effects on histone methylation.
4.11 Drug screening for novel therapeutic strategies in AD
As I was able to show, the transcription machinery is strongly disrupted in APP/PS1 mice coin-
ciding with amyloid pathology. This diruption might be partially driven by deregulated TFs and
epigenetic modification that might act directly on the respective genes or via long-distance inter-
actions. Thus, the data from APP/PS1 mice do partially match data from human AD patients and
might thus serve as a valid model to predict novel therapeutic strategies. To do so, I performed
a drug screening using the DrugPairSeeker. Since no significant pathology-related changes were
found for alternative splicing and, in addition, the effect of DNA methylation remains unclear,
the drug screening was based on gene expression data.
The DrugPairSeeker is a Java-based tool developed and published by Zhong et al. (2013). It com-
pares a given set of up- and downregulated genes with a differential gene expression database
retrieved for several cancer cell lines treated with more than 1300 individual drugs. It computes
the overlay of genes upregulated in the context of a certain phenotype and those downregulated
in the database and vice versa. The difference between matches and mismatches is taken as a
score for each respective drug. Thereby, the DrugPairSeeker tries to predict the most efficient
pair of drugs which might attenuate the observed deregulation of gene expression. For identify-
ing novel drugs, I ran the DrugPairSeeker with all genes from the respective comparisons with
the given thresholds for significance and foldchange. Since amyloid pathology is acting on all
three tested brain regions, affecting both hippocampal and cortical dependent cognition, the top
10 ranked drug pairs for each comparison (Wildtype vs transgenic and aging in transgenic mice)
were collected. Drugs were then ranked according to their frequency in the given comparisons
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and were filtered to remove non-promising drugs. Drugs were filtered to exclude those that
show adverse site effects, are unlikely to cross the blood brain barrier, were withdrawn by the
World Health Organisation, or were already unsuccessfully tested in regard to AD.
The resulting top 10 drugs are listed in table 4.10. Even though the DrugPairSeeker’s database
was built on different cancer cell lines and not in regard to neuropathologies, part of these highly
ranked drugs do actually seem promising for the treatment of AD. Three of the top 10 compounds
are acting as HDAC inhibitors. HDAC inhibitors like vorinostat (SAHA) were already considered
as promising therapeutic drugs for Alzheimer’s disease and successfully tested by our group
in the past in regard to AD and age-related cognitive decline (Benito et al., 2015; Peleg et al.,
2010; Stilling et al., 2014). The drug screening was based on the differential gene expression
and results do thus mainly cover changes in immune response observed in APP/PS1 mice. Con-
cordantly, other highly ranked drugs were shown to act in the suppression of NFκB signaling
(Acacetin and Parthenolide) or in maintaining homeostasis (i.e. Kaempferol). Another drug that
was discovered by the DrugPairSeeker though not among the top10 is Memantine, a NDMA re-
ceptor antagonist currently used for the treatment of progressed AD. As an antagonist for NMDA
receptors, it is mainly functioning in neuronal signaling and plasticity.
Table 4.10 – Top 10 drugs identified by screening with DrugPairSeeker after filtering
Drug chemical family source mode of action
Vorinostat (SAHA) hydroxamid acid synthetic HDAC inhibitor
Trichostatin A benzendoid natural (i.e. Strepto-
myces platensis)
HDAC inhibitor
Acacetin flavone natural (i.e. Robinia
pseudoacacia)
NFκB suppression
Parthenolide lactone natural (i.e. Tanace-
tum parthenium)
NFκB suppression
Pirinixid acid pyrimidine derivate synthetic PPARα antagonist
Piperlongumine pyridin derivate natural (i.e. Piper
longum)
reactive oxygen species induction
Lovastatin lactone natural (i.e. As-
pergillus terreus)
HMG-CoA-reductase inhibitor
Sirolimus macroldie natural (i.e. Strepto-
myces hygroscopicus)
mTOR inhibitor
Valproic acid fatty acyl synthetic HDAC inhibitor
Kaempferol flavone natural (i.e. Aloe vera) antioxidant
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4.12 Combinatory treatment with SAHA and memantine
For identifying a novel therapeutic approach to counteract AD, I aimed for a targeting both the
strong immune response and the mild deregulation of plasticity related genes found in APP/PS1
transgenic mice. Thus, I hypothesized that a combination therapy of the two individually well
described drugs Memantine and Vorinostat might augment their respective effect on cognition
and amyloid pathology. Dosages were chosen where the full therapeutic potential of each indi-
vidual drug is not reached to enable the identification of mild enhancements of a combinatory
treatment. Transgenic mice of 4-5 months of age were treated with the drug-combination for 4
weeks before behavioral experiments started. The age group of 4-5 months was chosen to model
a stage of the disease in human patients, where it can be diagnosed and thus a therapy can be
initiated. Mice underwent the open field test, elevated plus maze, Morris water maze and fear
































































































Figure 4.37 – Explorative behavior and basal anxiety levels in drug treated APP/PS1 transgenic mice:
A) Overall distance traveled inside the open field arena. A reduction in that value would indicate a reduc-
tion in exploratory behavior. No difference could be observed between the groups (ANOVA: p = 0.082)
B) The distance traveled inside the center area (10cm distance from the walls) as a read-out for basal anx-
iety. None of the groups showed a significant increase compared to the vehicle group, though Memantine-
treated mice spent more time in the center area than mice from the Combi-group (Tukey’s test: p=0.036).
C) Time spent inside the center area. Mice treated with memantine (Mem) showed a significant increase
compared to mice treated with vehicle (p = 0.036) and combinatory treatment (p = 0.014) indicating a re-
duced basal anxiety.
The open field test is a behavioral experiment to quantify locomotive, exploratory and basal
anxiety related behavior in mice. Mice treated either with SAHA, memantine or a combination
of both are not affected in their locomotion, as mice from all groups traveled approximately the
same distance within the open field area (see figure 4.37A). The time spent and distance traveled
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within the center area of the open field are indicators for basal anxiety levels. Mice treated with
memantine spent significantly more time in the center area than mice treated with vehicle (p =
0.0359) or the combinatory treatment (p = 0.0140) and traveled a longer distance in the center
area than mice that received the combinatory treatment (p = 0.0362) while no significant effect
was found after treatment with SAHA, neither alone nor in combination with memantine.
A second test for studying anxiety-like behavior in mice is the elevated plus maze. A tendency
of mice to stay in the closed arms of the plus maze is an indicator for an increased anxiety.
However, none of the groups showed a significant effect in the elevated plus maze compared
to mice treated with vehicle, neither regarding the time mice spent in open or closed arms nor
the latency to enter either of the arms the first time (p > 0.05) (see figure 4.38). Thus, the mild
anxiolytic effect that was found for memantine when given exclusively in the open field test





























































































Figure 4.38 – Evaluation of anxiety-like behavior in treated APP/PS1 transgenic mice:
A & B) Total time the mice spent inside the closed arms (A) and on the open arms (B). A tendency towards
open arms would indicate an anxiolytic effect of the respective medications, though no significant differ-
ences were found between the groups (ANOVA: pA = 0.85, pB = 0.98).
C) Latency for the first exploration of either arm. A significant difference could mask results from the ratio
of time spent in open and closed arms. No significant differences were detected among the tested mice
(ANOVA: p = 0.43).
To study spatial memory, mice were tested in the Morris water maze. Figure 4.39A (see p.112)
shows the learning curve based on the time the mice needed on each consecutive day to find
the platform. The strongest learning effect can be seen during the first 3 days of training and
mice performed significantly better in finding the platform after 10 days (p < 0.0001). The only
significant difference in learning compared to mice treated with vehicle was observed at day 3,
when SAHA mice performed substantially worse (p = 0.0167), and on day 7 when mice treated
with memantine showed a reduced escape latency and thus a better learning (p = 0.0163). A first
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Figure 4.39 – Spatial memory in treated APP/PS1 mice tested in the Morris Water Maze:
A) Average time needed to enter the target platform on each consecutive training day. Learning effect was
confirmed by 2-way ANOVA (p< 0.0001). Significant difference towards vehicle were found in the SAHA
group at day 3 (p = 0.0167) and in the memantine group at day 7 (p = 0.0163).
B) Percentage of time mice spent in the target quadrant (TQ) and off-target quadrants (OT) during the first
probe test at day 6. Chance level of 25% is resembled by the dashed line.
C) Latency to cross the target platform area during the second probe test at day 11. No significant differ-
ences were found among the groups (ANOVA: p = 0.62).
D) Percentage of time mice spent in the target quadrant (TQ) and off-target quadrants (OT) during the sec-
ond probe test at day 11. Chance level of 25% is resembled by the dashed line.
E) Average time needed to enter the target platform on each consecutive training day during reversal learn-
ing. No significant improvements were observed for the 4 days of reversal training (2-way ANOVA: pdays =
0.64).
F) Escape latency during the probe test after reversal learning. No significant differences were observed
among the groups (ANOVA: p = 0.86).
G) Percentage of time spent in the target quadrant (TQ) and off-target quadrant (OT) during reversal probe
test. Chance level of 25% is resembled by the dashed line.
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None of the groups showed a significant preference for the target quadrant and, interestingly,
similar findings were made even five days later when performing a second probe test (see fig-
ure 4.39B-D, p.112). This indicates that all mice showed severe memory impairments, though
they have improved in performing the task initially. Since no significant enhancement could be
detected regarding spatial memory retrieval, reversal learning test was performed to test for a
potential effect on cognitive plasticity. Therefore, the platform was placed in the opposite quad-
rant and mice were trained for another 4 days. As it is shown in figure 4.39E (see p.112), mice
have already learned the new platform position at the first day as the escape latency did not
differ from the last day of initial training. No further significant improvement of the latency
was discovered for any of the groups (2-way ANOVA: pdays = 0.64). The probe test after reversal
learning revealed again no difference between drug treated mice and those treated with vehicle
(ANOVA: p = 0.86). Also, even though all groups did reach the chance level of 25%, none of the
groups showed a significant preference towards the novel target quadrant (two-tailed t-test: p
> 0.7). Memantine or SAHA when given alone or in combination were thus at the given dosage
not suitable to reduce the cognitive impairment in APP/PS1 mice regarding the acquisition and




















































Figure 4.40 – Contextual fear conditioning in APP/PS1 mice after drug treatment:
A) Percentage of time mice spent with freezing behavior during conditioning prior to the electric foot shock.
No significant differences were observed (ANOVA: p = 0.80).
B) Percentage of time mice spent with freezing behavior 24 hours after conditioning. No differences can be
found between the groups (ANOVA: p = 0.39).
Finally, I tested the mice in the contextual fear conditioning to quantify a potential effect of either
drug on the formation and/or retrieval of contextual aversive memory. During the conditioning
trial and, thus, prior to the test, none of the groups showed any difference regarding the overall
motility compared to vehicle mice (see figure 4.40A), matching the findings from open field (see
figure 4.37A, p.110). All mice have learned the foot shock and were showing a considerable
amount of freezing behavior 24 hours after the test when being reintroduced to the conditioning
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chamber (see figure 4.40B, p.113), however no significant differences could be observed (ANOVA:
p = 0.39).
Taken together, though memantine showed a mild anxiolytic effect in the open filed test, none
of the medications was able to augment cognitive performance in APP/PS1 mice when given
at low dosages either alone or in combination. Experiments were conducted in two batches
including both genders. Consistency of data was confirmed by two-way ANOVA as no significant
differences could be observed between mice from different batches or gender.
114 Michael Gertig
5. Discussion
5.1 Interregional differences outweigh age and disease
In this study I aimed to predict and validate a novel therapeutic strategy based on a longitudinal
transcriptional and epigenetic characterization of a mouse model for Alzheimer’s disease. The
APP/PS1 mouse model B6-Tg(Thy1-APPswe; Thy1-PS1 L166P) (Radde et al., 2006) is frequently
used in current science for studying the cognitive decline as well as the immune response upon
amyloid deposition (Bittner et al., 2012; Jay et al., 2015). The hippocampus and isocortex are
brain areas strikingly affected by amyloid deposition both in human AD patients at severe stages
and in the given AD mouse model (Braak and Braak, 1991; Radde et al., 2006). While the neu-
ropathology in APP/PS1 mice emerges from the hippocampus, isocortical regions like the ACC
are only affected in progressed disease stages.
Due to the time-dependent spread of amyloid deposition and the resulting effect on neurodegen-
eration, it is important to specifically study distinct brain regions. Even though the hippocampal
sub-regions aremost likely affected by the transgene at roughly the same time and severity in AP-
P/PS1mice, their functions in cognition are quite diverse (Kandel, 2013; Radde et al., 2006). I thus
speculated that their transcriptional profiles themselves are diverse as well. Using Illumina RNA
sequencing, I was in fact able to show that the transcriptional profiles of the two anatomically
neighboring hippocampal areas DG and CA1 are as distinct as either one of those is compared to
the ACC and that approximately 20 to 30% of the entire transcriptome is differential in distinct
brain regions. Furthermore, I found that these differences completely outweigh any effects of
the transgene or aging in those mice as the only observed clusters could be related to brain re-
gions. As a general phenomenon throughout the different approaches of data analysis, the DG
always seemed to be the most variable brain region and, interestingly, was only mildly affected
at an age of 4 months compared to the ACC or CA1. Notably, the DG is one of the few sites in
the adult murine brain were neurogenesis happens throughout maturity (Cameron et al., 1993).
Adult neurogenesis does not only play a physiological role in cognitive processes like pattern
recognition, it is also likely to be an important compensatory mechanism for neurodegeneration
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and was even shown to be elevated in some mouse models for AD (Deng et al., 2009; Winner
et al., 2011). This might explain the increased variability and the relatively mild progression of
the pathology in the DG of APP/PS1 transgenic mice.
In addition to the region-specific transcriptomic diversity, data on DNA methylation revealed
striking differences between cell types as well compared to only mild differences between the
genotypes. This is in line with findings from Zeisel et al. (2015) who was even able to split sub-
cell-types in cortical and hippocampal tissue simply based on their transcription profiles. Taken
together, these data clearly indicate the need for brain region-specific but also cell type-specific
molecular approaches whenever applicable.
5.2 Compensatory effects in young APP/PS1 mice temporarily
delay cognitive decline
Preliminary data from our lab revealed that juvenile APP/PS1 mice show no cognitive impair-
ment yet. Here, I showed that these findings on mice behavior do very nicely coincide with
transcriptomic data, as the differences in gene expression found between 1.5 months old wild-
type and transgenic mice were only marginal. Interestingly, pathway analysis revealed neu-
ronal plasticity related functions when considering mildly deregulated genes, i.e. ”Axon guid-
ance” and ”Calcium Signaling”. Furthermore, the genes involved in those pathways were mainly
regulated in a gain-of-function manner in transgenic mice, indicated by an upregulation of the
NMDA-receptor domains GRIN1 and GRIN2D, MAPK3, and UNC5A or a downregulation of CD38.
This might indicate a compensatory effect of gene expression in transgenic mice counteracting
the incipient amyloid pathology. For instance, a reduction of CD38 was shown to drive NGF-
induced neuronal differentiation and neurite outgrowth, thereby promoting survival of new-
born neurons, while UNC5Awas shown to promote axon guidance acting as a receptor for netrin-
1 (Hedgecock et al., 1990; Serafini et al., 1996; Yue et al., 2009).
Radde et al. described the APP/PS1 mouse model in 2006 and showed that though the mice did
not show any amyloid plaques yet at 1 months of age, quite a substantial number of plaques
were formed at an age of 2 month. The chosen age of 1.5 months is thus nicely reflecting a
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stage where the mice are cognitively fine but neurodegeneration is just starting to occur and
thus compensatory effects are likely to still maintain homeostasis at least partially. Another
example of these compensatory effects besides the promotion of neuronal differentiation is the
clearance of amyloid deposits bymicroglia. Whilemicroglia are in principle able to scavenge the
brain from neurotoxic amyloid, they become dysfunctional with progressing disease, loosing
their phagocytotic ability and even promoting neurodegeneration (Jones et al., 2014; Khoury
et al., 1996; Meda et al., 1995). This dysfunction of microglia, however, is just one of the immune
response related effects that are dominating the entire gene expression profiles in APP/PS1 mice
at later time points.
5.3 Cognitive decline in APP/PS1 mice is accompanied by a
progressive induction of immune response
In early 2015, Gjoneska et al. published a similar approach for characterizing AD in another
mouse model for the disease, the CK-p25 mice. They found a two-directional effect of the pathol-
ogy on gene expression: A downregulation of genes that can be linked to cognitive decline and
a broad upregulation of immune response related gene expression. However, they did not con-
sider the fold change of differential gene expression for their analysis. In the present study, I
analyzed gene expression profiles of APP/PS1 transgenic mice in a longitudinal approach dif-
ferentially for mildly and severely affected genes. I was able to confirm the findings made for
CK-p25 mice in APP/PS1 mice as well. Furthermore, I found that downregulation of gene ex-
pression linked to cognitive decline is rather mild and that the gene expression profile per se is
masked by a strong induction of immune response related genes. Notably, most of the changes in
gene expression upon early amyloid pathology worsen during age progression. The induction of
immune response could be linked to a well defined core-set of TFs including proteins belonging
to the ETS, GATA, IRF, KLF, NfKB and STAT families.
Interestingly, TFs were previously shown to interact quite frequently with each other thereby
modulating their regulatory effect. One of the main TFs of the ETS family not only responsible
for deregulated gene expression but also deregulated in its expression itself is SPI1. In central
nervous tissue, SPI1 is specific for microglia and a TF essential for cell viability and phagocytotic
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activity (Smith et al., 2013). Along with other core-set TFs like IRF8, it is crucial for the synthesis
of new microglia from erythromyeloid precursor cells (Kierdorf et al., 2013). IRF8 also func-
tions in the regulation of neuronal cell death, as reinstatement of IRF8 expression in neurons
can prevent apoptosis upon ischemia, and interacts with TFs of the STAT family (Xiang et al.,
2014). Even though STAT activity is often linked with immune response, apoptosis and cancer
pathways, knowledge on its role in healthy cognition is increasing in the recent years (Thomas
et al., 2015). STAT signaling is not only crucial for the synthesis of new astrocytes, activation
of the JAK/STAT-pathway upon interleukin-6 and interleukin-15 signaling was shown to be in-
volved in adult neurogenesis as well (Bauer, 2009; Bonni et al., 1997; Gómez-Nicola et al., 2011).
Opposing effects of the different STAT proteins were reported on neuronal functioning. While
STAT3 activity was implicated in NMDA-receptor dependent long-term depression, spatial mem-
ory formation is negatively regulated by STAT1 (Hsu et al., 2013; Nicolas et al., 2012). STAT3 was
also shown to interact with NFκB, whose activation is partially driving cell death in the CNS (Liu
et al., 2011; Zhang et al., 2005). GATA proteins like GATA2 and GATA3 are highly implicated in the
synthesis of new blood cells (Ku et al., 2012; Rodrigues et al., 2012). Interestingly, they were also
shown to trigger pre- and post-natal neurogenesis and do thus function in neural development
and cognition (Nardelli et al., 1999; Zhao et al., 2008). Altogether, the identified core-set TFs do
not only drive the immune response in APP/PS1 mice, they are also a link between the induced
immune response and an impaired neuronal functioning.
Only a fraction of the described core-set TFs was also found to be differentially expressed them-
selves, however, the activity of all described TFs is tightly regulated by posttranslational mecha-
nisms, for instance acetylation and phosphorylation (Cowley and Graves, 2000; Lamonica et al.,
2006; Zhuang, 2013). Interestingly, these posttranslational modifications are often regulated by
proteins involved in epigenetic modifications and TFs were shown to form complexes with these
proteins, including histone acetyltransferases and HDACs (Feng et al., 2010; Icardi et al., 2012;
Ray et al., 2013; Suzuki et al., 2003). Though the majority of these proteins were not affected in
their gene expression in APP/PS1 mice, histone acetylation is affected in those mice and other
mouse models for AD and targeting histone acetylation is considered a promising therapeutic
approach for counteracting the disease (Benito et al., 2015; Francis et al., 2009; Xu et al., 2011).
The frequently described beneficial effect of different HDAC-inhibitors on preventing cognitive
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decline or reinstating memory function is thus likely not solely dependent on epigenetic modifi-
cations but also based on the interaction between HDACs and TFs (Gaub et al., 2010; Peleg et al.,
2010; Ricobaraza et al., 2009). In summary, the core-set TFs do not only act in immune response
but also in neuronal functioning and homeostasis. This might indicate a role in compensatory
mechanisms, trying to reinstate a healthy cellular environment and coping with neurodegener-
ation, driven by amyloid deposits. Furthermore, reinstating a healthy regulation of gene expres-
sion via these TFs might be a promising approach to ameliorate the AD pathology and could be
achieved by directly targeting the TFs or enzymes involved in posttranslational modifications.
5.4 Alternative splicing of only few genes in APP/PS1 mice
might facilitate amyloid deposition and cognitive decline
The two major neuropathologies in AD patients are the amyloid plaques and tau NFT. The for-
mation of these plaques and tangles does not only depend on the frequency of posttranslational
processing, i.e. cleavage of APP resulting into Aβ42, but also on differential composition of APP
and tau themselves resulting fromdifferential splicing (Belyaev et al., 2010; Kar et al., 2005; Rock-
enstein et al., 1995). Here, I analyzed alternate splicing in APP/PS1 mice to discover other genes
whose splice variants might contribute to the progression of the disease and to study the effect of
amyloidosis on the splicosome. Interestingly, the analysis on amyloidosis driven changes in al-
ternative splicing showed that the splicosome is not dramatically effected by amyloid deposition.
Notably, the splicosome within the ACC of young mice was severely affected by the transgene.
However, this effect is unlikely caused by amyloid deposits as the ACC is not affected by amyloi-
dosis at that stage (Radde et al., 2006). These findings again highlight the need for region specific
analysis and suggest that alternative splicing is rather functioning in neuronal development and
aging than neurodegeneration.
Even though, the effect of amyloidosis on alternative splicing was mild, I was able to iden-
tify some significant splice variants of APP processing and recognizing enzymes like PS1, Ctsd
(Cathepsin D) and Trem2 (Triggering Receptor Expressed on Myeloid cells 2) as well as APP itself
in the tested brain areas of 4 and 8 months old mice. Notably, tau was not found to be differen-
tially spliced, indicating the specific effect of alternate splicing triggered by the transgenic APP
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and PS1. Differential exon usage in the PS1-gene was already described in 1997, though not
much is known about potential differences in the activity of PS1 splice variants (Rogaev et al.,
1997). An intronic mutation of PS1 can lead to an insertion of a single codon resulting in an
induction of Aβ42 synthesis suggesting a similar effect of differential splicing as well (De Jonghe
et al., 1999). CTSD can cleave APP at its γ-cleavage site, thereby generating the neurotoxic Aβ42
(Sadik et al., 1999). However, nothing is known so far about differential splicing of Ctsd and its
consequences.
TREM2 forms a transmembrane complex with TYROBP (TYRO protein tyrosine kinase Binding
Protein) and was proposed to function in the recognition of amyloid and subsequent activation
of microglial phagocytosis (Frank et al., 2008; Hickman and El Khoury, 2014). Mutations in the
Trem2 gene were shown to drastically increase the risk for AD (Guerreiro et al., 2013; Jonsson
et al., 2013). Furthermore, different protein variants of TREM2 were identified that function as
risk factors for AD as well, though it remained unknown whether these variants are the result
of alternate splicing or posttranslational modifications (Jin et al., 2014). One of these variants
lacks a transmembrane domain, forming a soluble isoform that might inhibit the function of the
membrane-bound TREM2 (Piccio et al., 2008; Schmid et al., 2002). Interestingly, this soluble form
of TREM2 was found to be increased in the cerebrospinal fluid of patients suffering from central
nervous diseases like multiple sclerosis but also AD, though its actual role in promoting diseases
remains unknown (Heslegrave et al., 2016).
Two more genes were identified to be differentially spliced throughout disease progression in-
volved in neuronal functioning rather than amyloid processing, namely Ntrk2 (Neurotrophic
Tyrosine Kinase, receptor type 2) and Thy1 (Thymocyte differentiation antigen 1). Ntrk2, also
known as tyrosine receptor kinase B, recognizes BDNF (Brain Derived Neurotrophic Factor) and
as such is involved in promoting differentiation and survival of newborn neurons (Bartkowska
et al., 2007; Bergami et al., 2009). In regard to AD, Ntrk2 was shown to be indirectly influenced
by Aβ through calpain leading to cleavage of the receptor and thus impairment of BDNF signal-
ing (Jerónimo-Santos et al., 2015). Furthermore, different splice variants of Ntrk2 were shown to
influence APP-intracellular domain levels and might thus also influence the production of neu-
rotoxic Aβ species (Ansaloni et al., 2011). Thy1, also known as CD90 (Cluster of Differentiation
90), was first described in 1964 and found to be highly expressed in T-cells and nervous tissue
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(Reif and Allen, 1964). Due to its high expression in neuronal tissue, the Thy1 promoter is widely
used for generating transgenic mice (Dana et al., 2014; Feng et al., 2000; Radde et al., 2006). The
APP/PS1mouse line used in the presented study is only one example for these mouse models. De-
spite the high expression of Thy1 in nervous tissue and its effect on long-term potentiation in the
DG and axon regeneration, knowledge about its role in central nervous diseases is quite sparse
(Deininger et al., 2003; Nosten-Bertrand et al., 1996). Even though no splice variants of Thy1 are
described yet, data from differential splicing might indicate splice variants of Thy1 which might
then contribute to the cognitive decline or promote compensatory mechanisms in APP/PS1 mice.
Taken together, I was able to highlight a specific effect of the APP/PS1 transgene on differential
splicing of genes with isoforms and splice variants that were already previously linked to cog-
nitive decline or immune response in regard to neurodegenerative diseases. Furthermore, the
presented data imply the need for further studies on splice variants of Thy1 and Ctsd in regard
to AD.
A stronger effect on differential exon usage was, however, identified during aging in both wild-
type and transgenic mice. In fact, previously published data from our lab already suggested
a striking effect of aging on alternate splicing linked to cognitive decline rather than neuro-
inflammation (Stilling et al., 2014). I was thus again able to validate the previously described
linkage between aging and differential splicing in a different experimental approach (Mazin
et al., 2014; Tollervey et al., 2011). Taken together these data indicate a naturally occurring dif-
ferential exon usage in neuronal development following endogenous requirements on splice
variants that is specifically impacted by amyloid deposition in a small number of genes. This
disruption of differential splicing might then additionally promote neurodegeneration and thus
cognitive decline in APP/PS1 mice.
5.5 DNAmethylation acts via long-distance interactions in AP-
P/PS1 mice
Data from RNAseq revealed a strong effect of the transgene on gene expression. Changes in gene
expression can result from different molecular processes. These processes include the binding
of TFs and subsequent initiation of gene expression as well as epigenetic mechanisms. These
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epigenetic mechanisms include DNA methylation and histone modification. Here, I analyzed
DNA methylation profiles in an approach similar to differential gene expression analysis with
MeDIPseq and identified some significant changes in all three tested brain regions upon amyloid
pathology. Interestingly, no consistent effect could be detected throughout aging. DNA methy-
lation is in general associated with gene silencing and in fact I found levels of DNA methylation
decreased in genes with high gene expression (Newell-Price et al., 2000). Furthermore, the ma-
jority of sequenced bins was found in distal intergenic regions, thus regions were transcription
should not occur. Interestingly however, quite a substantial fraction of significant differences
was detected in those distal intergenic regions as well, indicating a rather unspecific effect of
the transgene on DNA methylation. Concordantly, no functional pathways were significantly
overrepresented by genes where DNA methylation was shown to be deregulated. These find-
ings match data on human AD patients, where DNA methylation changes in the frontal cortex
were shown to cover a broad variety of cellular processes rather than specific pathways (Bakul-
ski et al., 2012). This unspecific effect on the genome might resemble a global deterioration of
transcriptional regulation and might facilitate disease progression.
Other labs have already investigated the effect of Aβ on DNA methylation levels in different AD
mousemodels or cell culture (Isaacs et al., 2013; Sanchez-Mut et al., 2013) and found a correlation
between DNA methylation and gene expression only in a small set of genes. Here, I show on a
genome-wide scale that, even though a small number of genes shows a reduced gene expression
and an increase in DNA methylation or vice versa, DNA methylation and gene expression can
not be correlated on a larger scale. Additionally, I presented the first data ever showing cell-type
specific DNA methylation in an AD mouse model giving a better understanding on the differen-
tial effect of amyloid pathology on neuronal and non-neuronal cells. Notably, Isaacs et al. (2013)
found a link between DNA methylation and gene expression mainly in genes involved in cell-
fate determination. This is in line with my findings, indicating that DNA methylation is rather
involved in differentiating cell-types and only plays a secondary role in responding to endoge-
nous or exogenous stimuli. These stimuli might be disturbances in homeostasis, for instance
caused by amyloid plaques, but also external stimuli causing neuronal activity. Recent data
from our lab showed the effect of fear conditioning on DNA methylation in the hippocampus
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and ACC (Halder et al., 2015). During memory acquisition, the number of differentially methy-
lated genes was comparable to that found in APP/PS1 mice and did not reach the dimension of
cell-type related differences. Furthermore, Halder et al. also showed that the majority of differ-
ential DNA methylation does not occur within genes but in intergenic regions, rather suggesting
long distance interactions between CpG sites and genes presumably regulated through the tran-
scriptional repressor CTCF (Wang et al., 2012).
Notably, CTCF was shown to mediate interactions between chromatin and the nuclear lamina
and thereby chromatin architecture (Handoko et al., 2011). Mutations in CTCF can lead to dis-
turbances in higher order chromatin structures and were found to cause cognitive dysfunctions
(Watson et al., 2014). Additionally, gene expression of APP is regulated via CTCF related path-
ways as well (Burton et al., 2002). The chromatin-lamina interactions are also regulated by the
chromatin state giving a link between disruptions in the epigenetic machinery and subsequent
changes of gene expression in distal chromosomal regions or even different chromosomes (Harr
et al., 2015). Here I showed that potential impact of DNA methylation on gene expression upon
amyloidosis are rather in the dimensions of interchromosomal interactions than those within
defined interaction domains of up to 10 million base pairs and do thus depend on changes of the
chromosomal architecture (Dixon et al., 2012). Additionally, I claim that direct effects of DNA
methylation on gene expression are rather involved in determining cell fate and suggest further
studies on the cell type specific mediation of chromatin organization, also mediated via CTCF as
it was only insignificantly studied yet (Hou et al., 2010).
5.6 The impact of amyloidosis on H3K4me3 remains elusive
Apart from the rather global and cellular function-independent primary effect of DNA methyla-
tion, it can still be considered a mark for gene silencing and I was able to find DNA methylation
reduced in active genes. To further identify the epigenetic mechanisms underlying the massive
changes in gene expression, I also aimed to investigate an active epigenetic mark. Trimethy-
lation of H3K4 is in general implicated with transcriptionally active genes (Ruthenburg et al.,
2007). Via ChIP-sequencing on H3K4me3, I could confirm the previously described correlation
between high levels of H3K4me3 and a high rate of gene expression previously. Surprisingly
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though, the only significantly differential H3K4me3 peaks were found within the Thy1 gene for
most age groups in both the ACC and DG of transgenic mice. The only exception were non-
neuronal cells from the DG in 4 month old mice. Interestingly, this very age group and brain
region revealed only few changes in gene expression, primarily upregulated while H3K4me3
was globally downregulated. In regard to AD, Aβ was previously shown to increase the level of
H3K4me3 in two hormone-genes specifically (CORT and SST) (Rubio et al., 2012). These changes
were not identified in this study. Furthermore, studies on the Ck-p25 AD mouse model revealed
massive changes of H3K4me3 (Gjoneska et al., 2015). The data from the described ChIPseq ex-
periments are thus partially contradictory to previously described data on H3K4me3 in regard
to AD. Even though a decent quality of ChIP-sequencing was validated for each sample individu-
ally and the general linkage between active gene expression and H3K4me3 could be confirmed,
I can not rule out an artificially introduced bias and absence of significant difference between
wildtype and transgenic mice resulting from the small technical sample size (n=2) and relatively
high variance, thus weak statistical power.
5.7 Drug screening and treatment of APP/PS1 mice
Compared to gene expression, changes in splicing and DNA methylation were rather unrelated
to cellular functions and inconsistent throughout disease progression. I thus decided to base the
screening for novel therapeutic drugs for AD on gene expression data. Rather than interfering
with the activity of some differentially expressed genes, I claim that it is more promising to tar-
get core modulators of gene expression. These core modulators include TFs and thus I screened
for overrepresented TFs and defined a core-set of these responsible for a large fraction of differ-
entially expressed genes. Targeting these proteins might normalize gene expression of a larger
portion of deregulated genes. In fact, a variety of the defined core-set TFs is involved in amyloid
deposit induced signaling and some of them were already studied in regard of AD themselves.
Phosphorylation of STAT3, for instance, is reduced in AD patients and different mousemodels for
ADupon amyloid deposition (Chiba et al., 2009). Healthy levels of phosphorylated STAT3 could be
reinstated using the PI-3K inhibitor LY294002, though was not yet thoroughly studied in regard
to AD (Fang et al., 2006). STAT1 was shown to mediate the memory-impairing effect of Aβ and
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can be inhibited by fludarabine, a therapeutic drug for treating different types of cancer (Frank
et al., 1999; Hsu et al., 2013). Some phytoestrogens are able to suppress both phospho-STAT1
and IRF mediated inflammation and might serve as potential drugs for AD as well (Jantaratnotai
et al., 2013).
After identifying those promising drug targets, I additionally performed a goal-directed drug
screening based on all the differentially expressed genes and identified a variety of drug candi-
dates that might reinstate a healthy gene expression. The most abundantly identified drugs in-
cluded SAHA, trichostatin A, acacetin, parthenolide, pirinixid acid, piperlongumine, lovastatin,
sirolimus, valproic acid and kaempferol. Notably, even though not among the top 10 drugs,
memantine was identified by the drug pair seeker as well and is a commonly used drug in AD
patients. Some of these top 10 drugs can be linked to AD due to their mode of action or were even
tested already in mouse models for AD. For instance, the flavone-derivate acacetin was shown to
suppress neuroinflammation through NFκB and NO signaling andmight thus be suitable for tar-
geting the inflammatory response in AD (Ha et al., 2012; Nathan et al., 2005). Parthenolide was
shown to prevent the formation of amyloid-like fibers and also shows anti-inflammatory func-
tions but was like acacetin not tested in regard to AD yet (Mathema et al., 2012; Romero et al.,
2013). In contrast, sirolimus was already successfully tested in a mouse model for AD, leading
to a reduction of Aβ and tau pathology (Caccamo et al., 2010). Interestingly, three of the top10
identified drugs (SAHA, trichostatin A and valproic acid) are widely used HDAC-inhibitors that
were recently tested in regard to AD (Benito et al., 2015; Kazantsev and Thompson, 2008; Noh and
Seo, 2014; Wang et al., 2012). SAHAwas found to elevate cognitive performance in aged wildtype
mice by reinstating histone acetylation and a subsequent pre-clinical study in our lab confirmed
a beneficial effect of this particular HDAC-inhibitor on cognition in APP/PS1 mice, linked with
a reduction in neuro-inflammation (Benito et al., 2015; Peleg et al., 2010). A clinical study on
vorinostat in AD patients is most likely going to follow, confirming the procedure described in
this work as promising and valid for discovering novel therapeutic approaches.
Since SAHA was recently confirmed as a promising treatment for AD, I hypothesized that a com-
binatory treatment of APP/PS1 mice using SAHA along with a second drug might reduce the
necessary dosage of both drugs and widen their therapeutic effects. As SAHA is supposedly
mainly acting on reinstating gene expression through histone acetylation andwas shown to have
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anti-inflammatory potential (Benito et al., 2015), I chose memantine for the combinatory treat-
ment of APP/PS1 transgenic mice. Memantine is commonly used in AD patients and facilitates
synaptic plasticity and thus cognitive function by antagonizing NMDA receptors and reinstating
glutamatergic signaling (Barnes et al., 1996). Unfortunately, I was not able to identify any ben-
eficial effect of the combinatory treatment in regard to anxiety-like and exploratory behavior
or spatial and contextual memory acquisition and retrieval. The dosages of the chosen drugs
were designed to represent a reduced dosage analogue to those used for human patients and
compared to the standard dosages used in mice to enable identification of an augmented effect.
Corresponding dosages for memantine were previously shown not do bear the full therapeu-
tic potential though a similar dosage was able to reinstate memory functions in another mouse
model for AD (Liu et al., 2014; Minkeviciene et al., 2004; Saab et al., 2011). Since both drugs were
previously successfully studied in APP/PS1 transgenic mice, it is likely that they were not able to
augment the therapeutic potential of the respective other drug simply due to the intentionally
chosen reduced dosage and the relatively mild expressed cognitive decline at the given age of 5
to 6 months. Further experiments are needed to shed some more light on a potential advantage
of combinatory treatments of SAHA and memantine.
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Alzheimer’s disease is characterized by a progressive cognitive decline coinciding with the for-
mation of amyloid plaques and tau fibrils in the human brain. It is the most common form of de-
mentia and the number of people suffering from dementia worldwide was recently estimated to
46.8 million people, our knowledge on the molecular basics of AD and its development is rather
little. Even though many different therapeutic drugs were tested in pre-clinical trials and some
drugs are commonly used for treating AD patients, no cure is available yet. Unfortunately, the
possibilities to study the disease in human patients is limited and mainly rely on post-mortem
tissue. Thus, mouse models specifically reflecting different aspects of the disease were generated
during the recent years.
In this study, I used an APP/PS1 transgenic mouse line to study the specific effect of amyloid
pathology on gene expression, DNA methylation and histone methylation, thereby identifying
core modulators of disease progression and new potential therapeutic strategies for counteract-
ing AD. I was able to show that amyloid deposits on gene expression are independent from the
respective brain region, though the transcription profiles of these brain regions are strikingly di-
verse. This global deregulation of gene expression can be linked to a small set of TFs that might
serve as target proteins for therapeutic drugs. Gene expression is mainly driven by immune
response related processes while deregulation of genes that function in neuronal processes is
rather mild. Interestingly though, the identified significant TFs bridge the induction of immune
response upon amyloid deposition with a loss of neuronal function leading to cognitive decline.
The deregulation of genes and corresponding functional pathways becomes more severe with
increasing age and thus follows the progressive cognitive decline observed in APP/PS1 mice.
The wildtype-like cognitive performance of young transgenic mice can be explained by compen-
satory mechanisms counteracting the effect of neurotoxic Aβ. These compensatory mechanisms
become overwhelmed while Aβ plaques spread, leading to pathological aging.
In contrast to the strong effect of the immune response on gene expression, splicing does al-
most exclusively affect neuronal functioning and is rather affected by aging than amyloidosis.
Nonetheless, I was able to detect differentially spliced genes with splice variants previously
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shown to promote the disease and identified two genes where alternative splicing was not yet
related to neurodegenerative diseases, namely Thy1 and Ctsd. The deregulation of gene expres-
sion observed in APP/PS1 mice might partially be driven my a global disruption of the epigenetic
landscape concerning DNA methylation. This disruption, is likely to cause a deterioration in
higher order chromatin structures and might thereby impact gene expression rather indirectly.
In contrast, I claim that gene-directed effects of DNAmethylation leading to the silencing of genes
is primarily involved in encoding cell-fate.
By using the DrugPairSeeker on RNAseq data, I identified a number of drugs potentially able
to reinstate healthy gene expression in APP/PS1 transgenic mice through diverse mechanisms.
Some of these drugs were already successfully tested in animal models for AD and our group
recently confirmed a beneficial effect of the HDAC-inhibitor SAHA on cognition and neuro-
inflammation in regard to AD. Here, I studied the therapeutic potential of a combinatory treat-
ment of SAHA along with the NMDA-receptor antagonist memantine, a commonly used drug for
AD patients. I hypothesized, that a combinatory treatment might broaden the medications’ effi-
cacy and enables the use of mild dosages of the individual drugs thereby limiting adverse side
effects. Unfortunately, a beneficial effect on memory functioning of either drug individually or
in combination was not confirmed for APP/PS1 mice, presumably due to the reduced dosages
and mild cognitive impairment observed in mice of the chosen age.
Altogether, I identified a set of core-modulators of differential gene expression and novel alter-
native splicing in the Thy1 and Ctsd genes that might drive disease progression. Furthermore, I
hypothesize that the severe disruptions of gene expression are at least partially driven by dete-
rioration of the chromatin architecture resulting from deregulated epigenetic mechanisms. Fur-
ther experiments on DNA-DNA interactions via ”chromosome confirmation capture” approaches
andDNA-protein interactions, i.e. regarding CTCF, are necessary to test this hypothesis. Based on
RNAseq data, I predicted a set of therapeutic drugs able to counteract amyloidosis in AD patients
and illustrated the need for further studies concerning the combinatory usage of these drugs for
enhancing the treatment of human patients. Based on previous studies regarding the identified
drugs, I conclude that the applied procedure in this work is a suitable and valid approach for
discovering novel therapeutic drugs for counteracting AD and other human diseases.
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Figure 7.1 – Detailed dendrogram for eucledian distances of RNA samples:
Detailed view on the dendrogram and sample IDs shown above and below the distance heatmap depicted































Table 7.1 – KEGG pathways enriched by interregional differences common in different age groups
ACC vs CA1 ACC vs DG CA vs DG
Arrhythmogenic right ventricular cardiomyopathy Adherens junction Arrhythmogenic right ventricular cardiomyopathy
Axon guidance Arrhythmogenic right ventricular cardiomyopathy Axon guidance
Basal cell carcinoma Axon guidance Basal cell carcinoma
Calcium signaling pathway Calcium signaling pathway Calcium signaling pathway
Dilated cardiomyopathy Colorectal cancer Dilated cardiomyopathy
ECM-receptor interaction Dilated cardiomyopathy ECM-receptor interaction
Focal adhesion ECM-receptor interaction ErbB signaling pathway
Hypertrophic cardiomyopathy (HCM) ErbB signaling pathway Focal adhesion
MAPK signaling pathway Fc gamma R-mediated phagocytosis Gap junction
Melanogenesis Focal adhesion GnRH signaling pathway
Neuroactive ligand-receptor interaction Gap junction Hedgehog signaling pathway
Pathways in cancer GnRH signaling pathway Heparan sulfate biosynthesis
Ribosome Hypertrophic cardiomyopathy (HCM) Hypertrophic cardiomyopathy (HCM)
Wnt signaling pathway Inositol phosphate metabolism Long-term potentiation
MAPK signaling pathway MAPK signaling pathway
Neuroactive ligand-receptor interaction Melanogenesis
p53 signaling pathway Neuroactive ligand-receptor interaction
Pathways in cancer p53 signaling pathway
Phosphatidylinositol signaling system Pathways in cancer
Regulation of actin cytoskeleton Phosphatidylinositol signaling system
Renal cell carcinoma Regulation of actin cytoskeleton
Ribosome TGF-beta signaling pathway
Type II diabetes mellitus Vascular smooth muscle contraction
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Table 7.2 – Canonical pathways for upregulated genes in 1.5 months old APP/PS1 mice: ACC
Pathway -lg(pvalue)
TR/RXR Activation 3.01
Germ Cell-Sertoli Cell Junction Signaling 2.85
Ephrin Receptor Signaling 2.62
Unfolded protein response 2.23
Superpathway of Cholesterol Biosynthesis 2.22
Table 7.3 – Top 10 canonical pathways for upregulated genes in 4 months old APP/PS1 mice: ACC
Pathway -lg(pvalue)
TREM1 Signaling 16.9
Dendritic Cell Maturation 15.5
Superpathway of Cholesterol Biosynthesis 14.8
Antigen Presentation Pathway 14.1
T Helper Cell Differentiation 13.8
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses 12.7
phagosome formation 12.1
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 12
Granulocyte Adhesion and Diapedesis 10.4
Leukocyte Extravasation Signaling 10.1
Table 7.4 – Top 10 canonical pathways for upregulated genes in 8 months old APP/PS1 mice: ACC
Pathway -lg(pvalue)
TREM1 Signaling 18
Dendritic Cell Maturation 14.2
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses 14.1
EIF2 Signaling 14.1
Superpathway of Cholesterol Biosynthesis 13.9
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 13.7
T Helper Cell Differentiation 13
phagosome formation 11.6
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 11.4
Antigen Presentation Pathway 11
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Table 7.5 – Canonical pathways for downregulated genes in 1.5 months old APP/PS1 mice: ACC
Pathway -lg(pvalue)
Glycine Degradation (Creatine Biosynthesis) 2.28
eNOS Signaling 2.21
Table 7.6 – Top 10 canonical pathways for downregulated genes in 4 months old APP/PS1 mice: ACC
Pathway -lg(pvalue)
Superpathway of Inositol Phosphate Compounds 3.94
Integrin Signaling 3.83
Axonal Guidance Signaling 3.65
G-Protein Coupled Receptor Signaling 3.6
Ephrin A Signaling 3.6
Semaphorin Signaling in Neurons 3.39
CCR3 Signaling in Eosinophils 3.31
ErbB Signaling 3.26
D-myo-inositol (1,4,5)-trisphosphate Degradation 2.93
Neuropathic Pain Signaling In Dorsal Horn Neurons 2.91
Table 7.7 – Top 10 canonical pathways for downregulated genes in 8 months old APP/PS1 mice: ACC
Pathway -lg(pvalue)
G-Protein Coupled Receptor Signaling 10.9
Synaptic Long Term Potentiation 8.82
cAMP-mediated signaling 8.79
Dopamine-DARPP32 Feedback in cAMP Signaling 8.73
Neuropathic Pain Signaling In Dorsal Horn Neurons 8.14
CREB Signaling in Neurons 7.97
Axonal Guidance Signaling 7.59
Breast Cancer Regulation by Stathmin1 7.14
Molecular Mechanisms of Cancer 6.78
GNRH Signaling 6.77
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Regulation of Cellular Mechanics by Calpain Protease 2.66
FAK Signaling 2.3
Apoptosis Signaling 2.28
Tryptophan Degradation to 2-amino-3-carboxymuconate Semialdehyde 2.01
Table 7.9 – Top 10 canonical pathways for upregulated genes in 4 months old APP/PS1 mice: CA1
Pathway -lg(pvalue)
Superpathway of Cholesterol Biosynthesis 12.2
Antigen Presentation Pathway 12.1
Dendritic Cell Maturation 11.3
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 10.5
Communication between Innate and Adaptive Immune Cells 10.4
TREM1 Signaling 10.4
T Helper Cell Differentiation 9.57
Complement System 9.26
Cholesterol Biosynthesis I 7.37
Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) 7.37
Table 7.10 – Top 10 canonical pathways for upregulated genes in 8 months old APP/PS1 mice: CA1
Pathway -lg(pvalue)
TREM1 Signaling 20.3
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses 19.1
Dendritic Cell Maturation 18.6
Superpathway of Cholesterol Biosynthesis 16.7
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 15.7
phagosome formation 15.4
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 13.9
T Helper Cell Differentiation 13.8
Type I Diabetes Mellitus Signaling 12.7
Antigen Presentation Pathway 12.3
Michael Gertig 133
7. SUPPLEMENTAL FIGURES AND TABLES
Table 7.11 – Top 10 canonical pathways for downregulated genes in 8 months old APP/PS1 mice: CA1
Pathway -lg(pvalue)
Dopamine-DARPP32 Feedback in cAMP Signaling 11.2
Breast Cancer Regulation by Stathmin1 10.5
Role of NFAT in Cardiac Hypertrophy 8.66
GABA Receptor Signaling 7.92
Axonal Guidance Signaling 6.73
Melatonin Signaling 6.03
nNOS Signaling in Neurons 5.8
Thrombin Signaling 5.77
Protein Kinase A Signaling 5.73
HIPPO signaling 5.53




Uracil Degradation II (Reductive) 2.51
Thymine Degradation 2.51
FXR/RXR Activation 2.37
Acute Phase Response Signaling 2.12
Granulocyte Adhesion and Diapedesis 2.09
Table 7.13 – Top 10 canonical pathways for upregulated genes in 4 months old APP/PS1 mice: DG
Pathway -lg(pvalue)
Granulocyte Adhesion and Diapedesis 6.83
Dendritic Cell Maturation 5.52
TREM1 Signaling 4.58
Agranulocyte Adhesion and Diapedesis 4.15
Complement System 4.08
phagosome formation 3.95
Caveolar-mediated Endocytosis Signaling 3.24
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 3.12
Communication between Innate and Adaptive Immune Cells 2.95
Coagulation System 2.54
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Table 7.14 – Top 10 canonical pathways for upregulated genes in 8 months old APP/PS1 mice: DG
Pathway -lg(pvalue)
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 14.4
Dendritic Cell Maturation 14
TREM1 Signaling 12.4
Communication between Innate and Adaptive Immune Cells 12.1
Antigen Presentation Pathway 11.5
phagosome formation 11.4
T Helper Cell Differentiation 10.7
CD28 Signaling in T Helper Cells 9.84
Complement System 8.92
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 8.82
Table 7.15 – Canonical pathways for downregulated genes in 1.5 months old APP/PS1 mice: DG
Pathway -lg(pvalue)
Parkinson’s Signaling 2
Table 7.16 – Top 10 canonical pathways for downregulated genes in 8 months old APP/PS1 mice: DG
Pathway -lg(pvalue)
Axonal Guidance Signaling 6.12
Glutamate Dependent Acid Resistance 3.52
G-Protein Coupled Receptor Signaling 3.22
TR/RXR Activation 3.14
Xenobiotic Metabolism Signaling 2.99
GABA Receptor Signaling 2.96
p70S6K Signaling 2.93
Nitric Oxide Signaling in the Cardiovascular System 2.73
GNRH Signaling 2.71
Breast Cancer Regulation by Stathmin1 2.7
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Table 7.17 – Core-set of transcription factors including ETS, GATA, IRF, KLF, NFκB and STAT







































Table 7.18 – Hot-spots of gene expression in APP/PS1 mice
4mo ACC
domain chrom. start stop
chr17-16 17 33943055 34503055
8mo DG
domain chrom. start stop
chr1-100 1 170869869 172349869
chr4-60 4 136044085 137644085
chr17-16 17 33943055 34503055
8mo ACC
domain chrom. start stop
chr1-100 1 170869869 172349869
chr7-50 7 102451486 105851486
chr7-66 7 127976486 128736486
chr7-74 7 141494101 143814095
chr11-21 11 46426498 49586498
chr13-10 13 21588131 23748131
chr17-16 17 33943055 34503055
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ACC anterior cingulate cortex
AD Alzheimer’s disease
APP amyloid precursor protein
BACE1 β-site APP cleaving enzyme 1
CA cornu ammonis
ChIP Chromatin immunoprecipitation




FACS fluorescence-activated cell sorting
HDAC histone deacetylases
KEGG Kyoto Enzyclopedia of Genes and Genomes
LTM long-term memory
me methylation
MeDIP Methylated DNA immunoprecipitation
NFT neurofibrillary tangles
NGS Next-generation sequencing
PAM partition around medoid
PCA Principal component analysis
PS/PSEN presenilin
RT room temperature
SAHA suberoylanilide hydroxamic acid
STM short-term memory
TFs transcription factors
Thy1 Thymocyte differentiation antigen 1
Trem2 Triggering Receptor Expressed on Myeloid cells 2
TYROBP TYRO protein tyrosine kinase Binding Protein
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Maechler, M., Rousseeuw, P., Struyf, A., Hubert, M., Hornik, K., 2015. cluster: Cluster Analysis Basics and
Extensions. R package version 2.0.3 — For new features, see the ’Changelog’ file (in the package source).
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., Kivipelto, M., 2010. Alzheimer’s disease: clinical
trials and drug development. The Lancet Neurology 9 (7), 702–716.
156 Michael Gertig
9. BIBLIOGRAPHY
Marioni, J. C., Mason, C. E., Mane, S. M., Stephens, M., Gilad, Y., Jul. 2008. RNA-seq: An assessment of
technical reproducibility and comparison with gene expression arrays. Genome Research 18 (9), 1509–
1517.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., Beyreuther, K., Jun. 1985. Amyloid
plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of
Sciences of the United States of America 82 (12), 4245–4249.
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cessing of decision-making and social threat in patients with history of suicidal attempt: A neuroimaging
replication study. Psychiatry Research: Neuroimaging 234 (3), 369–377.
on Aging, N. I., Jun. 2015. Alzheimer’s Disease Medications: Fact sheet. Tech. Rep. 15-3431, National Insti-
tutes for Health.
Ott, A., Slooter, A. J. C., Hofman, A., van Harskamp, F., Witteman, J. C. M., Van Broeckhoven, C., Van Duijn,
C. M., Breteler, M. M. B., 1998. Smoking and risk of dementia and Alzheimer’s disease in a population-
based cohort study: the Rotterdam Study. The Lancet 351 (9119), 1840–1843.
Pages, H., 2016. BSgenome: Infrastructure for Biostrings-based genome data packages and support for effi-
cient SNP representation. R package version 1.38.0.
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